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SUMMARY
Thrombosis is the pathological formation of platelet aggregates that cause
stroke and heart attack—the leading causes of death in developed nations. Deter-
mining effective dosages for platelet therapies (e.g. aspirin, Integrilin, and Plavix)
to prevent thrombosis is a persistent medical challenge (studies estimate up to 45%
of patients exhibit insufficient responses to these drugs) and recent studies have im-
plicated pathological flow conditions of high shear rates and stenosis morphology as
primary factors. However, there are currently no diagnostic instruments able to reca-
pitulate a range of such pathological flow conditions for evaluating thrombosis with
and without these drugs.
In this work, a microfluidic device and associated optical system were designed and
fabricated for simultaneous measurement of platelet aggregation at multiple initial
wall shear rates within multiple stenotic channels in label-free whole blood and used
to characterize thrombosis at varying dosages of two platelet therapies: acetyl-salicylic
acid (aspirin) and eptifibatide (Integrilin).
Results from our studies show the effects of pathologically high shear rates on
enhancing platelet thrombosis and demonstrate the widely varied, shear-dependent
efficacy of each therapy. This study lays the foundation for the future development
of a medical diagnostic for optimizing the type and dosage of patient platelet therapy




Thrombosis is the pathological formation of platelet aggregates that occlude blood
flow causing stroke and heart attack —the leading causes of death in developed na-
tions. Heart attacks, also known as myocardial infarction, are caused when platelet
aggregates, or thrombi, are formed within the coronary arteries to occlude flow.
Stroke, or cerebrovascular accident, are often caused when thrombi migrate to the
small vessels of the brain and occlude flow.
Each of these thrombosis-induced conditions presents a dramatic burden to mor-
tality, morbidity, and health care costs. In mortality, recent reports have estimated
that in 2007 alone 785,000 Americans experienced a new coronary attack, 470,000
experienced recurring attacks, and an additional 195,000 may have experienced silent
attacks. The same report estimates morbidity from 610,000 new, 185,000 recurring,
and 195,000 silent stroke cases in the same year. While not all of these heart attacks
and strokes were fatal, they still accounted for an estimated 1 in every 3 deaths in
the United States, approximately 813,804 [7].
Resultant costs of prevention and care for stroke, heart attack, and related car-
diovascular conditions for affected Americans was estimated at $286 billion for the
same year of 2007, a figure which includes direct cost of medical care and indirect
costs due to lost productivity. This figure far exceeds its closest competitor, cancers
and benign neoplasms, whose direct and indirect costs are estimated at $228 billion
[7].
With such costs, improved instrumentation for diagnosing and treating patholog-
ical platelet aggregation has the potential for major clinical impact. Currently, the
1
mainstay for thrombosis prevention without other treatable causes or risk factors is
therapy including aspirin and/or an additional anti-platelet agent (e.g. eptifibatide,
clopidogrel), a choice that balances the patient’s risk of severe thrombotic events
against the risk of GI discomfort and bleeding. This choice is often made empirically
and without measurement of dosing or efficacy (i.e. appropriate platelet inhibition).
Patients are determined to have failed therapy if they have a vascular event while
being treated; then either increased dosing or combination therapy is initiated.
Thus this section of the thesis will review the structure and function of platelets
and key receptors targeted in anti-platelet therapies. It will then provide a survey of
the current methods for measuring and understanding platelet behavior, and finally
it will outline the goals that we aim to achieve in this study.
1.1 Platelets
Although platelets compose only 1% or less of blood (by volume), they are vital to
wound healing, during which they adhere to the site of injury and participate in
the complex cascade of events involved in blood clotting. Under normal conditions,
circulating platelets are discoid, anuclear cells 2-3 µm in diameter and are present
in concentrations on the order of of 200,0000—400,000 cells per milliliter of blood.
Platelets originate from megakaryocyte cells within bone marrow, each of which can
produce thousands of platelets that will remain in circulation for approximately ten
days. Key features of the platelet’s structure and function include a variety of exter-
nally presented surface receptors as well as internally stored clotting factors. External
surface receptors such as GPIb and GPIIb/IIIa allow platelets to rapidly adhere to
sites of injury and to one-another, respectively. Specifically, adhesion is primarily
mediated by the bond between GPIb and von Willebrand Factor (“vWF”, located
suspended in blood serum and released from other platelets) and collagen (a common
structural protein in blood vessels and extra-cellular matrix). In contrast, GPIIb/IIIa
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is thought to primarily bind to fibrinogen and vWF, both found in other platelets as
well as suspended in blood serum. In addition to these surface receptors, platelets also
internally store and release clotting factors in alpha- and dense- type vesicles (also
known as granules for their appearance under electron microscopy) each of which
store different types of factors. Alpha granules predominantly store fibrinogen, cy-
tokines, growth factors, and von Willebrand Factor (vWF) while dense granules store
adenosine diphosphate (ADP), serotonin, and calcium. Release of these factors from
the interior of the platelets induces other nearby platelets to release their granules
in a positive feedback wave. The contents of these granules has been observed to
induce shape changes in platelets from their normally smooth and discoid shapes, to
activated states in which they flatten and form pseudopod spines [8].
Platelets can stop the flow of blood by two different methods: coagulation and
thrombosis. Coagulation occurs primarily under conditions of low fluid shear (below
1500 s−1) and requires the activity of a number of clotting factors found in blood
serum to form nets of fibrin which entrain platelets and red blood cells, in a red
clot. In contrast, thrombosis generally occurs at higher shear rates (exceeding 1500
s−1), and is mediated primarily by platelets in a white clot. Under these high shear
conditions, this process has been shown to occur in three phases: (I) initial adhesion
of platelets to a substrate, (II) the rapid accumulation of platelets binding to other
platelets and (III) the final stabilization and contraction of the platelets into a solid
mass that occludes flow [9, 10]. Thus it is clear that a deeper understanding of
how flow affects these different methods of platelet activity is necessary to optimize
therapy and prevention.
1.2 Platelets in flow
Blood is a complex fluid with some novel hemodynamic properties based on its par-
ticulate nature. First, the viscosity of blood varies with local shear rate, and as flow
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rate and shear rate increase, the viscosity of the blood will decrease. Additionally,
blood can separate into two phases, one particle-rich layer filled with cells, and the
other a relatively acellular plasma layer near the vascular wall [11].
This layer is not completely acellular, however, and is sometimes populated with
platelets and leukocytes which have been displaced from centerline flow by red blood
cells, whose deformability allows them to centrally migrate. This process of “margina-
tion” enhances platelet adhesion to the walls of the vessel and to other platelets. While
many researchers are aware of this phenomenon, it remains difficult to account for in
experimental assays. In this study, we assume constant viscosity (Newtonian fluid),
and acknowledge the under-estimation errors associated with the assumption.
Under this Newtonian assumption, we can calculate a parameter frequently used





Where V indicates local velocity and x indicates distance from the wall. Previ-
ous work has described three specific shear flow regimes within the body and their
associated binding mechanisms. The lowest range, from 100 to 1500 s−1 found in
unobstructed veins and arteries, is primarily governed by fibrinogen, coagulation fac-
tors, and the GPIIb/IIIa (also known as integrin αIIbβ3). Next, from 1500 to 4000
s−1 found in arterioles, primarily governed by GPIb, GPIIb/IIIa, and soluble agonists
such as ADP. And the final regime describing higher pathologic shear found in stenotic
or obstructed arteries with shear rates above 4000 s−1 and above, primarily governed
vWF and GPIb [12, 4, 13]. Such conditions are found in constricted arteries, such as
those commonly observed in clinical cases of coronary artery disease and atheroscle-
rosis, conditions which affect more than 17 million Americans [10, 9, 14, 15, 16].
High shear rates are thought to affect thrombosis in the following ways. First, it
regulates how many platelets, soluble coagulation factors, and fibrinogen molecules
pass near the adhesive surface of the vessel wall over a period of time. Second, high
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Figure 1: Normal, physiologic flow conditions in healthy, non-constricted arteries
exhibit lower shear rates compared with pathological flow conditions induced by local
constrictions commonly caused by coronary artery disease and atherosclerosis. Shear
rate can be expressed by the change in velocity, v, over the change in radius, x, shown
in the diagram.
shear rates have been found to enhance the adhesive behavior of specific proteins such
as the GPIb receptor and von Willebrand Factor [17, 18, 19]. Next, it determines the
residence time during which reactive soluble factors and related species can affect one
another. Finally, increased shear rates and increased shear forces can detach platelets
from eachother or from surfaces such as the vessel wall, creating an embolus.
1.3 Platelet therapy
A number of different types of therapeutics have been developed for the treatment of
thrombosis according to the previously discussed flow regimes. Platelet drug thera-
pies have been developed to disable specific targets of each of these aforementioned
three mechanisms including: GPIIb/IIIa inhibitors (eptifibatide, abciximab), solu-
ble agonist inhibitors (clopidogrel, acetylsalicylic acid), and anti-coagulants (heparin,
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citrate) [4]. A multi-shear approach to screening anti-platelet efficacy could thus pro-
vide salient information on shear-dependence to guide clinicians to choose appropriate
drugs and dosages for patients with potential arterial pathologies, or to aid in the
process of industrial drug candidate screenings [4].
Thus local shear conditions and flow patterns can enhance or diminish specific
mechanisms affected by anti-platelet therapies. Investigations in this area can lead
to enhanced knowledge of both platelet behavior and to pre-clinical drug efficacy
screenings.
These drugs have provided invaluable rapid therapy, but they have a major flaw:
patient responses vary widely, leading to potentially severe consequences. Under-
and over- dosing of these medications can result in ineffective treatment, excessive
bleeding, severe gastric discomfort, or death. Despite these dangers, clinicians are
unable to determine how effective a medication is and thus employ a generic solution
when prescribing these drugs.
As a result, out of the current 68 million Americans taking anti-platelet drugs,
more than 15 million are misdiagnosed with the dosage or the wrong drug and consti-
tute one of the four top drug types causing hospitalization in senior citizens [7, 20, 21].
Thus what is needed is a method to quantify platelet function to measure the effi-
cacy of these drugs and their varying dosages. Currently a number of companies are
attempting to commercialize such diagnostic methods, discussed in detail in the next
section . While their efforts have tested poorly in clinical trials, they have demon-
strated a market size of $3 billion for anti-platelet diagnostics [2, 11, 22, 23].
A rapid, inexpensive, clinical test for efficacy of anti-platelet therapies would be
desirable for a variety of reasons. First, a test of efficacy may allow improved dosing
of these agents, since dosing of these agents is done in fixed amounts that are not
dependent on blood volume or platelet activity. Second, such a test would help to
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identify patients that do not respond to anti-platelet therapy. Although this pop-
ulation has been identified in the literature, the mechanism of unresponsiveness is
unclear—whether due to under dosing, misuse (or non-compliance) of medication, or
underlying physiologic differences.
1.4 Platelet function testing
As outlined by the previous sections, platelets not only play a crucial role in wound
healing and primary hemostasis, but are also a key part of a growing public health bur-
den presented by thrombosis [7]. Thus methods for measuring and assessing platelet
function are an area of significant interest. To this end, a wide variety of platelet
function tests exist, although none have been developed.
The goal of this section is to provide a description of each method, identify the
strengths and weaknesses of each, and to provide a brief history on its clinical successes
and failures.
1.4.1 Flow cytometry
Flow cytometry is a popular method for measuring platelet function since the whole
blood cytometer can be used for such a wide variety of standardized clinical laboratory
measurements. This technique is often used for targeted cell or receptor counts after
the administration of fluorescently labelled monoclonal antibodies. The method works
by flowing a thin, focused stream of single cells through a laser beam, which evaluates
cell types through forward scattering, which provides information on the shape of each
passing cell. Additional fluorescence detectors can provide information on additional
targets of interest.
The platelet function assays using flow cytometry and antibody labelling include
the popular VASP kit (BioCytex, Marseilles, France) which can provide absolute
quantification of the number of receptors and the ability of therapeutic drugs to bind
them using only a small amount of blood (less than 1 mL) for each test [24]. The
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VASP (vasodilator–stimulated phosphoprotein) phosphorylation assay, which is used
to test whether therapeutic drugs can bind the P2Y12 receptor, the main target
of clopidogrel (Plavix) through the conversion of the vasodilator-stimulated phos-
phoprotein phosphorylation (VASP) protein to its phosphorylated form (VASP–P),
determined using an antibody for the latter and measuring the resultant fluorescence
[20]. Recent studies have demonstrated PRI cutoff values of 48-53% as prognostic
indicators for stent thrombosis following coronary percutaneous interventions, and
others have reported that clopidogrel loading doses adjusted according to PRI values
< 50% decreased the rate of major adverse cardiovascular events after PCI [25]. How-
ever, results from the VASP kit tests have shown poor correlations with results from
other popular testing methods (i.e. the VerifyNow, and light transmission aggregom-
etry), suggesting that the definition of “clopidogrel resistance”is very test dependent.
Thus a more clinical testing and tracking of patient outcomes may be required for
future development and validation of this method [26].
Unlike other methods, flow cytometry allows for integrated measurements of other
important elements of blood including vWF titers, levels of coagulation factors in the
blood, platelet count, mean platelet volume, mean corpuscular volume, red blood cell
count, hemoglobin concentration, white blood cell count, etc. The machine enables
the acquisition of a wide variety of platelet metrics for a very complete set of clinical
data.
The disadvantages of method are its lack of clinical correlates for patient outcomes,
or for correlates with similar platelet function analysis methods. In addition, flow
cytometry faces additional challenges from its requirements for trained personnel,
and from time–consuming and labor–intensive sample preparation. [24].
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1.4.2 Bleeding time
Bleeding time is one of the oldest assays for platelet function, and is performed
completely in-vivo. A small blade (often spring loaded or otherwise mechanically
enabled to make standardized cut sizes), makes a small incision into the skin and
blood pressure at the wound site is monitored to indicate when bleeding ceases due
to platelet activity. The output of the test is the time needed for the wound to stop
bleeding, and is typically performed in triplicate.
Clinically, the BT assay has shown poor sensitivity to platelet therapies and is
not often recommended for use in most clinical settings due to its aforementioned
variability. However it has shown great clinical utility for the diagnosis of vascular
disorders such as Ehlers Danlos (a condition which affects collagen production), as
well as low platelet count or hematocrit [27].
Advantages of the method are its simplicity and low associated costs. Its in–vivo
application makes it one of the only test methods able to reflect the interactions of the
vessel wall with a subject’s platelets and results are thus very physiologically relevant
[28, 20].
Disadvantages of the method are thus its low responsiveness to platelet therapies,
poor reproducibility, invasiveness, and the numerous sources of variability including
skin temperature, skin thickness, consistency of wound depth, and subjective mea-
surement of bleeding cessation [29].
1.4.3 Light transmission aggregometry
Light transmission aggregometry (LTA) was first developed in the 1960s by Born,
who noted visible turbidometric changes in a solution of PRP (platelet rich plasma)
after the addition of the agonist adenosine diphosphate (ADP).
The method requires a sample of platelet rich plasma (PRP), which is prepared
by centrifuging a sample of whole blood. The resultant platelet rich plasma is placed
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in a clear, heated (37◦C) cuvette with a small stir bar atop a magnetic stirring plate.
Platelets are activated through the addition of an agonist (e.g. ADP, ristocetin,
botrocetin, collagen, arachidonic acid, thrombin, epinephrine), after which the stir
plate begins to rotate the stir bar to generate shear forces and to mix the contents of
the cuvette. Platelets first change shape, causing a small increase in sample turbidity,
and then begin to aggregate and precipitate out of solution, reducing the turbidity
of the solution. These platelet-platelet bonds underlying aggregate formation are
thought to be due primarily to the activation of the GPIIb/IIIa receptors [20].
Currently the oldest and most tested method of platelet function testing, and
is a general comparison standard against which results from all other methods are
compared [24, 20, 4]. Advantages of this method are the preponderance of clinical
data describing its clinical efficacy, the ability to make dynamic measurements in real-
time, and the ability to discern multiple important binding events (platelet cohesion
and platelet shape change). The advanced age of this method has allowed long term
studies to document statistically significant, nearly threefold increases in endpoint
risks of major adverse effects associated with aspirin resistance as diagnosed using
LTA with ADP and arachidonic acid agonists [30]. Additional studies have shown
the utility of the LTA method to diagnose platelet disorders and generalized ”bleeding
disorders” [31].
Disadvantages of the method are primarily due to the need for PRP instead of
whole blood–a process which is time consuming, labor intensive, potentially detri-
mental to the sample, non-physiological use of small enclosed cuvette volumes, poorly
reproducible, requires large sample volumes, and results lack standardization for stir
speed, size of stir bar, size of cuvette, etc. Furthermore, the stirring activity creates
variable shear rates within the cuvette which may skew results ∼ 300s−1 [20, 25, 4, 32]
These disadvantages have led to more user-friendly devices aimed at point-of-
care applications including the VerifyNow, and the impedance-based Whole Blood
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Analyzer, both of which are discussed in greater detail below.
1.4.4 VerifyNow
To date, Accumetric’s VerifyNow is perhaps the most commercially successful point-
of-care platelet diagnostic. Founded in 1996, the product has been successfully mar-
keted as a point-of-care diagnostic for small clinics and hospitals. The device is a
modified form of the LTA assay which addresses some of the LTA’s greatest weak-
nesses with the ability to use whole blood samples, and does not require additional
pipetting due to its use of enclosed cartridges pretreated with reagents and able to
perform automated aspiration steps.
Like the LTA method, the VerifyNow depends on the platelet-platelet cohesion.
Unlike LTA, whole blood is able to be used in this device due to the addition of fibrino-
gen coated glass or latex particles whose wavelength is measured over time to indicate
aggregation. Thus when platelets bind to the fibrinogen coated beads, they begin to
precipitate the beads out of solution and transmission increases. Testing only requires
the addition of a small volume of blood (<1 mL) anticoagulated using citrate and a
cartridge loaded into the machine to begin. Blood is automatically aspirated up into
the machine, and a magnetic bead stirs the blood with the cartridge-specific agonist
and coated beads, and light transmission readings begin. Results are available within
only 2-5 minutes. Outputs of the test are “platelet reactive units” (PRU) which use
cutoff values for a binary detection of “high on” or “normal”. Currently, the test sells
three different types of cartridges for the detection of GPIIb/IIIa antagonists (using
thrombin-receptor-activated protein (TRAP)), aspirin (using Arachidonic Acid), and
clopidogrel (using ADP/PGE1). In addition, the test has shown some utility for
detection of [25, 20].
The VerifyNow has an extensive background of clinical studies to back up its in-
vitro results for GPIIb/IIIa, aspirin/ASA, and clopidogrel. Its GPIIb/IIIa assay kit,
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the first of its cartridges on the market, has shown results with excellent agreement to
other methods including LTA and flow cytometry, and good consistency in its results
from site to site [33, 34]. The GOLD center study, a large scale clinical trials of over
500 human subjects, showed a high correlation between adverse patient outcomes
and low response values from the VerifyNow using the GPIIb/IIIa test kit with long-
term patient major adverse cardiac events (MACE’s: composite of death, myocardial
infarction, and urgent target vessel revascularization), implying that the assay might
be useful for diagnosing resistance to GPIIb/IIIa drugs [35].
The VerifyNow aspirin assay uses arachidonic acid as agonist and to detect resis-
tance to acetyl salicylic acid (ASA) effects. The test has been shown correlates well
with AA-induced LTA [36] and is associated with an increased risk of adverse clinical
outcomes in stable patients with coronary artery disease [37].
The VerifyNow clopidogrel assay is a two channel cartridge which measures P2Y12
platelet activity using the agonists ADP and prostaglandin–1 (PGE1) in one cartridge
channel, and measures global platelet activity using TRAP (thrombin receptor ac-
tivating peptide) and PAR4-AP (PAR4 activating peptide) in a second cartridge
channel.
In prospective study the PRU values on clopidogrel (12 h post-loading of 600 mg)
of 380 patient undergoing PCI were used to derive a optimal cut-off value of ≥ 235
PRU for post-treatment reactivity in predicting six month out-of-hospital cardiovas-
cular (CV) death, non-fatal MI, or stent thrombosis [38]. Using the clinical cut-off,
patients with high post-treatment reactivity had significantly higher rates of CV
death, stent thrombosis, and the combined endpoint. These results were confirmed
by a study in 683 patients with acute coronary syndrome undergoing dual-antiplatelet
therapy during a percutaneous coronary intervention [39]. With the optimal cutoff
value of ≥ 240 PRU could be used to predict significantly higher rates of cardiovascu-
lar death, stent thrombosis, or non-fatal myocardial infarction during a twelve month
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post-treatment observation period [39].
Despite these success, other trials have not been as positive. The GRAVITAS
clinical trial examined over 1100 human subjects over a six month period after sur-
gical intervention and subsequent treatment with Plavix. The VerifyNow was used
to determine whether it could successfully predict an optimal patient dosage (high or
standard concentration treatment). Results showed that there was no significant dif-
ference in patient outcomes between VerifyNow’s predicted optimal treatment and the
standard concentration treatments. This was a disappointing development both for
platelet function analyzers, for whom the VerifyNow has been the strongest demon-
stration of potential capabilities, and for the manufacturers of Plavix, who had hoped
to demonstrate enhanced product efficacy [38, 40].
In summary, the advantages of the method are its small sample volumes, user-
friendly interface, and easy to interpret results. Standardization of results is also
much improved from LTA due to its extra automation and minimal sample handling.
Clinically, it has shown some predictive ability for adverse MACE’s in some patients
using ASA, GPIIb/IIIa inhibitors, and clopidogrel. However, it has not shown the
ability to adjust patient dosages to optimal amounts to avoid these adverse events.
There are a number of disadvantages to the test as well. First, the method itself
does little to recapitulate the pathological conditions that it attempt to diagnose.
Like the LTA, the device is only able to measure low– or no– shear flow conditions
due to its enclosed cartridges. This means that it ignores several key bonding evens
including vWF to GPIb, one of the primary mediators of high shear thrombosis [4].
The test also requires the use of non-physiological agonist agents, which may confound
or distort correlations with clinical results. Additional disadvantages of the method
are its high per–test cost (∼ $ 40-60 per single cartridge) likely due to its user-friendly
features including the enclosed, automation-friendly, reagent storage and specialized
bead manufacture, especially in comparison to the cost of a single cuvette and stir
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bar required for similar results from an LTA assay. Similar to other tests, the test is
also limited to a specific defined range of hematocrit and platelet count [20].
1.4.5 PFA-100
With these concerns over flow integration into the assay in mind, we address the
platelet function analyzer for the high shear regime, the Platelet Function Analyzer
(PFA–100), developed by Siemens Healthcare Diagnostics.
The PFA–100 tests platelet function under high shear rates (∼4000-6000 s−1)
within different disposable cartridges, and is intended for a laboratory/research envi-
ronment. The machine consist of a number of integrated parts including a capillary,
a sample reservoir and a porous membrane. During a test, 800 µL of whole blood
with 0.109 or 0.129 mol/l buffered sodium citrate is aspirated at a constant pressure
from the sample reservoir through a capillary (∼ 500 µm) blocked by a the disposable
biochemically active porous cellulose membrane with a central aperture of 100 µm
(P2Y) or 150 µm (Col/ADP, Col/EPI). Part dimensions are defined by information
provided by the company [41], but further information on tolerances for dimensions
are not available. A variety of different disposable biochemically active membranes
are available, including: collagen and ADP (Col/ADP), collagen and Epinephrine
(Col/EPI), and ADP, prostaglandin, and calcium chloride (P2Y).
At the beginning of each test, trigger solution is dispensed on the membrane to
dissolve the reagents. The blood sample is then aspirated up through the capillary and
through the aperture and the membrane. As the sample passes through the aperture,
platelets will begin to adhere to the coated cellulose surface. Due to the interaction
with the membrane and the dissolved reagents, platelets become activated, release
their granule contents, and start to aggregate. Over the duration of the test (300
seconds, or 5 minutes), platelets will continue to form a plug until occlusion of flow.
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These activators and cartridge conditions cause platelet adhesion to the mem-
brane, activation of the platelets and aggregation, followed by a platelet plug forma-
tion in the area of the aperture. Thus, the test end point is the time to aperture
occlusion and the resulting cessation of blood flow, closure time (CT), or non-closure
(NCT) when CT is greater than 300 seconds.
The PFA–100 allows a simple and standardized test performance. However, dif-
ferent concentrations of anticoagulants, sample collection, transportation, conditions
and time window between sampling and testing may influence CT [42]. Thus, estab-
lishing individual reference values has been recommended.
Moreover, CT values inversely correlate with a decreasing hematocrit less than
30% and a decreasing number of circulating platelets of less than 100×109 . There-
fore, knowledge of the actual platelet count and hematocrit are essential for the inter-
pretation of the CT results . Furthermore, it is important to realize that CT values
increase with decreased vWF activity. Apart from any disease entity, this may be
related to the effect of the ABO-blood group system on vWF activity (lowest activity
can be observed in patients with blood group O) [39].
The PFA-100 is one of the most widely used and studied platelet function tests
with more than 600 publications in peer review journals. It offers tests for diag-
nosing the following: clopidogrel (using the agonist adenosine diphospate —ADP),
ASA (using the agonist arachidonic acid), GPIIb/IIIa antagonists (using the agonist
Thrombin Receptor Agonist Peptide—TRAP), general thrombosis disorders (using
collagen), and von Willebrand’s disease (using the agonist ristocetin) [25].
Due to the low cost and accessibility of aspirin, it has been a primary target of
numerous studies with this instrument [43, 44]. Although aspirin does show increases
in average CT values [45] it is still far less specific than other marketed devices at de-
tecting “aspirin resistance”. In fact, the prolongation effects observed may be closer
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related to patients taking other types of anti-inflammatory drugs, and not to specifi-
cally anti-platelet effects [30]. This deficiency has been a high hurdle for acceptance
of this instrument in the healthcare community, especially given the relative successes
of other methods such as the previously discussed LTA, VerifyNow, and WBA units.
Notably, the use of epinephrine in the C-EPI cartridge for the detection of aspirin
uncommon in contrast to the use of arachidonic acid assays, the agonist which is used
in the aforementioned competitors’ assays. Some studies have shown that arachidonic
acid is ineffective as an agonist in their assay, supporting the theory that inhibitors of
soluble factors have little effect at high shear rates such as those within their device
[46]. The company has embarked on a number of large scale clinical studies on thou-
sands of subjects [47, 48] attempting to find correlations of their test with aspirin
sensitivity, but to date has not been very successful. They have, however, identi-
fied what they believe to be various independent factors influencing non-response as
defined by C-EPI, specifically old age, an acute vascular event, chronic ASA usage,
the ASA dosage, diabetes mellitus, the concentration of buffered sodium citrate, and
cut-off time used to determine abnormal CT.
The second most popular target is clopidogrel (Plavix). The detection of platelet
inhibition by clopidogrel has not been shown to be reliable for both the C-EPI and
the C-ADP activation, but a new cartridge for the assessment of the anti —P2Y12
effect will be available for broad clinical applications [49]. However, the PFA-100 may
help to monitor therapy with GP IIb/IIIa antagonists [50].
Although the PFA-100 has not been able to match current competitors on the
detection of aspirin and clopidogrel, it has been successful in detection of von Wille-
brand disease (vWD), with an estimated 90% sensitivity [51] Additionally, very
short or shortened Col/ADP CT has also been identified as a potential marker for
platelet hyperreactivity or hyperfunction, which is present in patients suffering from
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an acute myocardial infarction, an acute coronary syndrome or stable angina, sta-
ble cardiovascular disease patients with increased risk of major adverse events, ASA
non-responders or patients with genetic polymorphisms associated with a heightened
platelet reactivity.
Close monitoring of the successes and failures of the high-shear PFA–100 are
especially valuable to this project, which seeks to characterize shear-induced effects
on anti-platelet efficacy. Combined with information on low- or zero- shear devices
like the LTA and VerifyNow, their studies often span large populations of subjects
which are often inaccessible to academic researchers, thus their efforts have to the
potential to advise directions for our work.
1.4.6 Impedance aggregometry
Impedance aggregometers measure changes in electrical impedance due to the buildup
of platelets on the surface of two noble metal electrodes after the administration of
select platelet agonists. Currently, the most popular commercial impedance aggre-
gometers are the Whole Blood Analyzer (Chronolog, Haverton PA) and the Multi-
plate system (Dynabyte, Munich, Germany). Each unit is available in a multichannel
format (1-4 channels from Chronolog, 1-5 channels from Dynabyte). The process of
testing is the same as LTA, although measurements are electrical instead of optical.
The Whole Blood Aggregometer is composed of a pair of electrodes, a stirring ele-
ment, and a heating element. A 500 µL blood sample is added to an equal amount of
saline, an electrode, and a small stir bar in a cuvette, and warmed for approximately
five minutes at 37◦C. The sample is then ready to be placed in the testing chamber,
which has a rotating magnet that will spin the stir bar in the cuvette. The test will be
able to begin when the electrode has been able to establish a consistent baseline. At
that point, a chosen agonist is added to the cuvette, and the stir bar both distributes
the agonist throughout the sample, and also provides a local shearing force on the
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blood. Activated platelets then adhere to the electrode, and the impedance will rise
in accordance with the coverage of the electrode by platelets in the sample. The ma-
chine has three primary outputs used to describe its measurements of impedance due
to platelet adhesion over time: Lag Time (the time period before impedance passes
2 Ohms), Amplitude (the maximum change in impedance over the timecourse of the
trial), and Area Under the Curve (the integral of the impedance over time) also called
the ”AUC”. The Multiplate system shares the basic characteristics and limitations
with the whole-blood laboratory-based aggregometer systems. This system is nearly
identical to the Whole Blood Analyzer, except that it does not require washing of the
electrodes and also adds computerized electronic pipetting of the activators and adds
duplicate measurements to enhance reproducibility.
A primary advantage of the device is able to use whole blood instead of the PRP
required for LTA, thus avoiding additional sample handling and potential activation
of the platelets and improves method standardization. Second, the multichannel for-
mats offered provide exceptional experimental throughput. The method also provides
outputs on the dynamics of aggregation, unlike the VerifyNow or PFA–100 which
simplifies its measurements to a single number. Finally, many of these methods of-
fer affordable base unit costs (∼$4000-7000) and similarly affordable per-test costs
($0.03− $5.24).
Disadvantages of the method are its poor ability to assess surface binding, its
closed volumes, and its non-physiological flow conditions. Additionally, each test re-
quires some cleaning of electrodes, and electrodes which have been improperly cleaned
can lead to errors in results (see Chapter 5), although this problem has been reme-
died in the Multiplate through the use of disposable ready-to-use test cells with two
independent sensor units consisting of two silver-coated copper electrodes.
Despite these disadvantages, the WBA has been quite successful in detecting con-
genital and acquired platelet disorders and in monitoring the familiar anti-platelet
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targets of aspirin and clopidogrel. In a study including 182 patients after PCI those
identified as dual non-responders to acetylsalicylic acid and clopidogrel by WBA in-
duced by ADP and collagen were at higher risk (relative risk 2.57; 95% CI 1.185.61;
log-rank p= 0.03) to suffer from a combined primary endpoint of myocardial in-
farction, target vessel revascularization, late stent thrombosis, or cardiac death. A
number of tests are available including: clopidogrel (ADPtest and ADPtest HS),
acetylsalicylic (arachidonic acid), GPIIb/IIIa antagonists (TRAPtest), general activ-
ity tests using collagen (COLtest), and von Willebrand’s disease (vDWD) [25].
1.4.7 Perfusion chambers
Unlike the methods discussed thus far, perfusion chambers attempt to incorporate
biomimetic flow conditions into their assays. Generally they can be categorized as
cylindrical tubes or rectangular channels. The former were popularized by H. R.
Baumgartner’s ex-vivo studies with human blood taken from the antecubital vein,
or in-vivo in rabbits [52]. In contrast to simple collagen coatings of glass surfaces,
perfusion chambers often use biological substrates such as subendothelium of rabbit
aorta, human renal arteries, or human umbilical arteries. Popular end-point mea-
surements are radiometry of deposited radio-labelled platelets on thrombus forming
surfaces while continuous tests often monitor pressure drop over a segment of interest
in testing for thrombus formation [18]. More recently, this principle has been applied
to the Badimon chamber, a flow channel lined with porcine vascular tissue which is
examined by microscopy and/or post-testing histology for platelet accumulation [53].
In rectangular cross-section flow channels, the parallel plate chamber is a popular
tool for characterizing shear induced behaviors. The first parallel-plate perfusion sys-
tem was developed in the early 1980s by K. S. Sakariassen and colleagues [18], and
remains a popular method for drug efficacy screenings in the early development stage
[54]. This device has been employed in many studies with human and animal in vitro
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anti-coagulated blood, in ex vivo studies in man and in in vivo studies in dogs. A rect-
angular flow slit with different heights, allows studies at different wall shear rates at a
constant flow rate, thus analogous to the annular chamber. During the mid-1990s, R.
M. Barstad and colleagues introduced various eccentric stenoses into the flow chan-
nel of the chamber [55]. This results in rapidly increasing wall shear rates from 420
up to 32,000 s−1. A variation to be mentioned is the so called Hele-Shaw perfusion
chamber developed by S. Usami and colleagues [56] which allows studies at contin-
uous shear variation from virtually 0 to 20,000 s−1 in one perfusion run. Common
measurements using this instrument are radiometry of radio-labelled platelets, en-face
morphometry, confocal microscopy, standard morphometry, computer-assisted mor-
phometry and immunologic quantification of deposited fibrin and platelets following
plasmin digestion of the thrombotic deposits. A variety of biomarkers released by ac-
tivated platelets, protease cleaved activation peptides from coagulation factors, FPA,
and TAT complexes are usually sampled downstream to the thrombus forming area
during the individual perfusion runs. Also, activated platelet GPIIb-IIIa, platelet
pro-coagulant activity (annexin V binding) and platelet microparticle formation are
assessed downstream to the site of thrombus formation [16].
However, one of the greatest drawbacks of the perfusion chamber is its general lack
of flexibility to achieve specific channel morphologies. Additionally, their large sizes
tend to use up unecessarily large volumes of samples. Thus, customizable, microscale
versions of these flow chambers have become the obvious next evolution of platelet
analysis.
1.4.8 Microfluidic platelet assays
The field of microfluidics has provided high throughput, low volume methods well
suited for the development of tools to study platelet function in the research com-
munity. Low volumes enable not only high throughput from regular sample volumes,
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but also allows screening of small samples volumes from mouse models, which may be
used to study protein knockouts. Microfluidics also allows the selective manipulation
and observation of cellular-level interactions between platelets and their surround-
ings, or even to study single platelet behavior. It has also allowed the construction of
highly customized flow channels to aid in our understanding of how the biomechanics
of flow influence thrombosis. Finally, it allows systematic studies of large numbers
of parameters, a key element in the study of the closely intertwined events of the
coagulation pathway. This section will review some of the standout contributions of
microfluidics to the field of platelet research.
A demonstration of the application of microfluidics to both murine thrombosis
models and to microfluidic channel design comes from the Jackson group, who along
with Ruggeri have presented significant research in the area of shear induced platelet
activity [17, 12]. In one of their more recent works, they showed the development
of a mouse injury model for observing thrombosis in-vivo uses a mild crush injury
of the wall of the mesenteric artery of a mouse under DIC microscopy to observe
platelet aggregate formation. The induction of this local stenosis creates a rapid
local increase in downstream platelet accumulation, which forms cycles of aggregation
and disaggregation [57]. Microfluidic fabrication allowed the group to attempt to
recapitulate this aggregation behavior in a microchannel to investigate the effects of
the shear gradient on thrombus formation with and without the influence of anti-
platelet drugs. The designed microchannels were approximately 20 µm in height,
very close to the size of a single platelet (1-2 µm), and induced peak shear rates of
(20000 s −1). Results showed that thrombi formed specifically in the area downstream
of the constriction in ”discoid aggregates” within a deceleration zone. The stability
and formation of these aggregates was highly receptor specific, with GPIb providing
a vital link to allow the formation of stable thrombi. In contrast, the effects of soluble
agonists such as ADP, TXA2, and thrombin proved ineffective at preventing formation
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of aggregates at these high shear rates, but was successful at reducing the stability
of formed thrombi. The researchers attribute this to the formation of ”membrane
tethers” formed with the help of extracellular calcium addition. This work, headed
by the Jackson research group, provides a thorough experimental demonstration of
their previous theories and techniques on the different adhesive mechanisms at play
using in-vivo and in-vitro demonstrations.
Effects of channel morphology on thrombosis have been further characterized us-
ing microfluidic models by Tovar-Lopez [58], who measured thrombus formation in
multiple configurations of stenosis from a step-like constriction to a straight channel.
His work concluded that the step configuration was most effective at creating sta-
ble thrombi, while the straight channel was unable to form stable thrombi even at
shear rates twice as high as the constricted channel, a finding supported by the work
of others [59, 57]. However, it is notable that thrombi within his channels formed
strictly downstream of the step-like stenosis, not within the constriction itself in the
same manner noted by others [59]. Also, although both Nesbitt and Tovar-Lopez
investigate the effects of channel morphologies on platelet activation, their studies do
not compare activity differences due to changing shear rate while keeping morphology
constant.
Another work that took advantage of the small volume requirements of microflu-
idics to study murine platelet behavior came from Gutierrez in 2008 [60]. This work
compared thrombosis in two different strains of knockout mice–one completely lacking
the αIIbβ3 receptor, and the other with a domain mutation. Device channels were
straight (i.e. non-constricted) 24 x 200 µm in height x width over its cross-section
and examined shear rates from 13 to 1300 s−1. Due to the small size of the channels,
small sample volume, and the researchers’ desire to keep shear constant, they exam-
ined only the adhesion step alone in 40 µL over a 10 minute period, quantified by
the number of fluorescently labelled stationary platelets on the device’s inner surface.
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Results showed that even at this lower shear regime, platelets with no αIIbβ3 recep-
tor were unable to form aggregates. The work validated the utility of microfluidics
for phenotyping genetic knockouts and provided new information on the structure
and function of a key protein in the process of thrombosis. Similar to Gutierrez,
the Diamond research group has also employed microfluidics for phenotypic knock-
out mice. In 2008, they showed the role of the αIIbβ3 receptor protein in binding
collagen by comparing the platelet adhesion in receptor knockout mice to controls.
Like the Gutierrez group, they used non-constricted channels with focal regions of
patterned collagen at low shear rates (400, 1000 s−1). Thrombosis was quantified by
the measured intensity of fluorescence from the labelled platelets. While both of these
approaches have proven effective for research oriented evaluations of small blood vol-
umes, this volume constraint has prevented them from more in-depth investigations
of the effects of high shear rates on platelet activity seen in human pathologies.
Microfluidics have also been useful for creating controlled environments for cel-
lular level studies, such as the Lam group’s studies on single platelet spreading over
micropatterned collagen regions (simulating focal vessel injuries) [61], or platelets
adhering to microchannels seeded with endothelial cells (simulating intact, healthy
vasculature) [62]. They applied this approach to study the synergistic effects of en-
dothelial inflammatory signaling, platelet adhesion, and sickle cell flow mechanics on
vascular occlusion in these engineered microvascular environments.
Recently, a company called Bioflux has begun attempts to bring microfluidic
platelet assays to the commercial world with the BioFlux Live Cell imaging sys-
tem. The system consists of a PDMS flow chamber integrated with a well plate and
microscopy system for examinations of cells under various flow conditions. The group
has focused on applying the system to platelets and vascular cells, although it also
advertises applications with stem cells and immune cells. The testing apparatus uses
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fluorescent platelet labelling and microscopy to perform adhesion screenings, simi-
lar to the devices and techniques of Gutierrez [60] and Neeves [63] discussed above,
but with greater throughput and higher equipment reliability/repeatability. While
the system does offer similar capabilities to the aforementioned researchers, the cost
of each study unit is near $80,000 (personal correspondence) due to the cost of the
associated microscopy and cell culture equipment. Recently Bioflux has released a
Journal of Visualized Experiments (JOVE) video detailing the applications of their
system to screening GPIIb/IIIa drug efficacy on a platelet sample [3].
1.4.9 Conclusions on current platelet function tests
The preceding section has provided a survey on the current state of the art in platelet
function measurement and analysis and identified some of the strongest competitors
and their defining features, strengths, and weaknesses. Key failings of current meth-
ods are inconsistencies in results due to sample handling requirements, inconsistencies
between testing methods, and (most importantly) lack of consistent clinical evidence
that such diagnostics are able to predict major adverse clinical outcomes (MACE)
and/or reduce these adverse effects through optimized treatment. As stated by others
in the field, there is distinct need in the field for an easy bedside assay with consistent
and clinically validated metrics which can be used to monitor patients during disease
and therapy [4].
These points are echoed in an overview report put forth in a 2006 report by the
International Society on Thrombosis and Hemostasis, the head oversight committee
for the science and engineering of this area of medical technology. Their report
summarizes many the key design features for an optimal commercial platelet function
diagnostic, the main points of which are summarized in the list below. [11].
The diagnostic should incorporate dynamic flow to simulate vascular conditions in
order to address the different bonding mechanisms observed under flow [17, 9, 10, 15].
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This perfusion region should have an eccentric stenosis to simulate pathological flow
conditions that have been shown to stimulate specific thrombus growth patterns
[57, 58]. Next, flow conditions should be able to reach both pathological high shear
rates, and physiological low shear rates to recapitulate the range of flow conditions
which may be present in a patient [17, 9, 10, 15]. Additionally, it should also be sensi-
tive to the addition of a variety of anti-platelet drugs, such as the GPIIb/IIIa, P2Y12,
and aspirin tests currently on the market. The device should also be able to detect
clinically relevant events of thrombus detachment, or embolism, for enhanced clinical
relvance. The report also acknowledges that antibody or fluorescence labelling and
microscopy are very effective for measuring platelet thrombosis, their high cost and
size makes them difficult to use in point-of-care diagnostics. Finally, the diagnostic
should provide continuous, real-time monitoring on the kinetics of thrombus forma-
tion. Currently there is no commercial device able to address all of these criteria.
Most commercialized methods for platelet function analysis are only able to perform
testing on single samples at a single shear rate under flow conditions—including high
speed bead mixing, forced flow through a membrane, cone-and-plate flow that are
not relevant to biological flow through blood vessels.
For comparison, this design criteria has been charted against representatives from
the previous section (Fig. 2): the VerifyNow for point-of-care, user-friendly develop-
ment of some of the most well-studied methods in the field from light transmission
aggregometry (LTA); the PFA-100, the first high shear platelet analysis device which
has been aggressively marketed to medical laboratories but seen mixed success; and
the Bioflux system whose specialty in cell-level assays using high end research equip-
ment represents much of the microfluidics community. Since there is not yet a device
able to satisfy the listed categories, a multi-faceted approach combining their infor-
mation is required, and recommended by some [4, 20].
Recent advances in platelet research have added additional concerns to methods
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Figure 2: Comparison of current commercial platelet function analysis methods [2]
(*) and [3] (+) based on criteria from the International Society on Thrombosis and
Hemostasis (ISTH) 2006 oversight report [4]. These three entries represent the cur-
rent state of the art in the field. The VerifyNow leverages its technology from Light
Transmission Aggregometry, one of the oldest platelet analysis methods, in a more
user-friendly package aimed at the point of care market. The PFA-100 is the first
high shear platelet analysis device which has been aggressively marketed to medical
laboratories and despite going through extensive clinical tests has seen mixed diag-
nostic efficacy. Finally, the Bioflux company specializes in custom miniaturized flow
assays and vasculature cell assays using high-end research equipment, and represents
the commercial side of the microfluidics community.
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for platelet function testing, including measurement methods for platelet aggregation.
As discussed previously, the formation of a thrombus occurs in three phases: (I) initial
adhesion of platelets to a substrate, (II) the rapid accumulation of platelets binding
to other platelets and (III) the final stabilization and contraction of the platelets into
a solid mass that occludes flow [9, 10]. However, most studies to date have been
conducted only on the initial adhesion phase [14, 15], using fluorescence microscopy
and are not well suited to volumetric measurements in real time. Microscopy methods
are limited by small measurement areas, poor depth measurement, the need for image
post-processing, and often require sample pre-treatment.
The field of microfluidics has provided high throughput, low volume methods well
suited for the development of tools to study platelet function in the research com-
munity. Recently, Gutierrez et al. [60] showed the importance of platelet receptor
integrin αIIβ3 in genetically modified mice platelets adherence to collagen (thrombo-
sis phase I) at low shear rates 50-1410 s−1 in a multichannel microfluidic device. While
this device was able to address multiple shear rates in multiple channels simultane-
ously, these tests did not include pathologically relevant high shear behavior or the
later stage of rapid platelet-platelet bonding known as ”rapid platelet accumulation”
(thrombosis phase II). Other recent work by Tovar-Lopez et al. [58] has shown the
importance of stenotic geometry to high-shear platelet aggregation using microscale
devices. While this study and device thoroughly analyzed changes in platelet aggre-
gation downstream of the stenosis, it did not examine aggregation within the stenoses
nor explore aggregation at varying shear rates in identical stenoses.
Thus current methods have been limited by one or more of the following pa-
rameters: limited relevance to physiological flow [41, 20], need for external cell
labeling,[60, 64] platelet fractionation and washing for imaging and analysis [65, 31]
non-pathologically relevant low shear rates [66, 14, 10], small measurement area lim-
ited by microscopy [67, 10, 14], channel sizes insufficient to observe rapid platelet
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accumulation, and large volumes of blood [68]. Additionally, many in vitro mod-
els have not attempted to address aspects of specific clinical pathologies relevant to
thrombosis including high shear rates and stenotic morphology [69, 9, 14, 10].
There is presently no instrumentation able to simultaneously examine individ-
ual trials of a wide range of fluid shear rates including those exceeding 10000 s−1,
with simultaneous platelet aggregation to occlusion measurement, which is impor-
tant given the time dependent effects of clotting and anticoagulants. The creation
and application of such high throughput instruments could enable essential, large
scale, comprehensive studies which would inform research on cardiovascular patholo-
gies and their appropriate anti-platelet therapies. The field could benefit from a low
volume, high throughput, short analysis time, and low cost system while minimizing
sample handling.
Finally, and perhaps most importantly, the greatest failing of most of these meth-
ods is in their inability to consistently predict clinical outcomes and to effectively
guide improvements in therapy. Without such clinical evidence, these devices are
unlikely to succeed in commercialization, and may instead be best suited as tools for
research and development for the next design iteration [4, 20, 70].
1.5 Thesis outline
This work has three primary aims:
• Aim 1: Design, fabricate, and test a microfluidic device capable of inducing
shear rates ranging from 500-20000 s−1 in stenotic channels.
• Aim 2: Development of an optical sensor for label-free, non-contact, multi-
channel, high temporal resolution measurement of platelet-based thrombus for-
mation.
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• Aim 3: Apply the integrated system to measure platelet aggregation as a func-
tion of shear rates dosed with platelet therapies
This thesis outlines the design, fabrication, testing, and application of a microflu-
idic device and associated optical system for simultaneous measurement of platelet
aggregation at multiple initial shear rates within four stenotic channels in label-free




This chapter describes the design, fabrication, and testing of a microfluidic device for
measurement of in-vitro platelet aggregation for a wide range of different shear rates.
2.1 Design and modelling
The design for an optically-clear, multichannel, microfluidic device was developed
to induce a spectrum of shear rates while permitting direct optical measurement of
formation of occlusive blood clot formation in porcine blood. Specifically, we desired
to address shear rates of 500, 1500, 4000, 7000, 10000, and 13000 s−1 within the
channels high-shear stenotic regions. These shear rates were chosen to represent the
physiological conditions in veins and arterioles (500-1500 s−1), pathological shear rates
(4000 s−1), and high pathological shear rates (10000 s−1 and above), as discussed in
the preceding Chapter.
As a design consideration, while other work [57, 60] has limited the minimum
channel dimension to 20-50 µm, we chose a minimum dimension of 250 µm to enable
observation of aggregates on the order of millions of platelets (100s of microns) dur-
ing rapid platelet accumulation, for comparison with prior work [59]. Rapid platelet
accumulation is also significant because it presents a potentially unique set of bind-
ing events which are not present during the formation of smaller aggregates on the
order of hundreds of platelets (e.g. the platelet adhesion and early platelet aggrega-
tion events) [59, 5]. Another consideration was the design of the stenosis to reflect
pathologically relevant geometry. Thus we designed the diameter reduction from the
channel region to the stenosis region to be 53%, near to the 50% reduction often
used as an indicator for surgical intervention in the left main coronary artery [71]. In
30
the channels upstream and downstream of the high-shear stenotic regions, we require
that the maximum shear rates not exceed 1500 s−1, the upper bound of physiological
shear rates. In our initial designs, we tested thrombosis in channels with dimensions
of 250, 500, 750, and 1000 µm, and empirically determined that the 750 µm wide
channel was the widest channel able to induce thrombotic occlusion using less than
10 mL of porcine blood. This wider channel was preferable to the narrower channels,
which would often be occluded by artefact debris or preformed aggregates common
in unfiltered porcine blood used in early experiments.
Early chip designs used different stenosis geometries and a common inlet and out-
let to increase the range of shear rates obtainable from one channel (Fig. 6). This
design was changed in later experiments to four identical stenosis geometries with in-
dependent outlets. The use of identical stenoses removed the potentially confounding
effects of comparing occlusion in channels with very different surface area to volume
ratios and overall cross-sectional areas. Separate outlets were used to prevent ”cross
talk” between channels as occlusion events change local pressure drops. An en–face
view of the final chip design is shown in Fig. 3.
In order to obtain a wide range of initial wall shear rates in multiple identical mi-
crochannels sharing a single flow input, we passively controlled channel flow resistance
downstream of the stenotic region through the use of 50SHL Tygon tubing (Saint Gob-
ain, Valley Forge, PA), a formulation rated for blood handling which exhibits low cell
adhesion. Thus determination of shear rates within the stenosis required fluid mod-
elling efforts combined the effects of the channel and tubing resistances. While other
groups have used on-chip resistive channels for controlling flow rates [60], this off-chip
resistive tubing design enables simple shear rate control over two orders of magnitude
from an array of identical microchannels, simplifies fabrication, and interfaces easily
with weighing scales for flow rate measurement
In this work, we calculated initial estimates for resistance tubing dimensions using
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Figure 3: Schematic showing top view of the design of the microfluidic device for
inducing platelet aggregation at four distinct initial wall shear rates in whole blood
within the high shear stenosis regions. An off-chip suspended syringe (not shown)
connected to the sample inlet provides a pressure driven flow through the channel
regions (750 µm wide by 750 µm high) and through the locally constricted stenosis
regions (750 µm wide by 250 µm high) then back into channel regions of the same
dimensions prior to egress from four separate outlets and their respective resistance
tubing. Dimensions of the four stenoses were identical to one-another, the use of
varying downstream tubing lengths and dimensions (not shown) enables the study of
a wide range of initial wall shear rates.
an analytical method, then refined the estimates using a computational method.
These methods are discussed in the following sections.
2.1.1 Analytical modelling
Analytical modelling was used for initial estimates of resistance tubing dimensions
based on target wall shear rates. First, wall shear rate values and pressure drops
were chosen, and used to determine the target overall resistance within each flow
path (defined from fluid reservoir inlet to flow outlet). Then, using a circuit model
assuming Poiseuillar laminar flow, the requisite length for each outlet tubing section
was determined.





Where Q is the volumetric flow rate, dh is the hydraulic diameter of the channel
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(in the case of a channel with rectangular cross-section) [10]. Hydraulic diameter of
a channel with a cross section of width w and height h is defined as dh = 2hw/(h +
w) × f(Re), where f(Re) is an adjustment factor based on the aspect ratio and the
Reynolds number describing flow within the channel [72]. Having set the dimensions
of the stenosis at h = 250 µm and w = 750 µm as discussed in the previous section,
the resultant hydraulic diameter of the stenosis with adjustment factor for aspect
ratio is dh = 351 µm. This specific hydraulic diameter was desirable for its similarity
to previous work examining platelet-platelet aggregation [73, 59]. We may then input
desired values for γ to solve for the target volumetric flow rate Q.
Next, this Q value is used to solve for the target length of resistance tubing. In
general, the overall flow rate and resistance within a flow path from flow inlet to flow
outlet can be defined as:
∆P = RtotalQ (3)
Where Rtotal is the total resistance in the flow path. Using a circuit model, resis-
















Where µ = 0.00385 Pa × s is the average dynamic viscosity of blood [75], Lin
is the length of the inlet tubing, Lch is the length of the channel, Lt is the length
of the outlet resistance tubing, Lst is the length of the stenosis, din is the diameter
of the inlet tubing dch hydraulic diameter of the channel, dt is the diameter of the
tubing, and dh is the hydraulic diameter of the stenosis. We set all of these values
except the Lt and dt based on our materials and previously discussed dimensions
(Lin=150 mm, Lch = 15 mm, Lst = 300 µm, din = 1.75 mm, dch = 750 µm, dh =
351 µm). Commercial vendors of the preferred tubing formulation, Tygon S50HL,
provide tubing with inner diameters dt of 0.79, 1.27, 1.58, and 2.38 mm, from which
we could calculate preferred values of Lt which were convenient for interfacing with
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downstream flow measurement using weighing scales, whose use is further discussed
later in this Chapter.
This method was used for initial estimations only. Researchers in this field have
noted that wall shear estimates using such analytical equations may have significant
inaccuracies due to particle margination-based local changes in viscosity [10]. Further
efforts were pursued for refinement of tubing length calculations based on computa-
tional models, discussed in the following section.
2.1.2 Computational modelling
Measurements of shear rate γ in the remaining body of this work were determined
finite volume fluid modelling using ANSYS (ANSYS Inc., Canonsburg, PA).
Simulations of flow in the model used the following settings. Blood viscosity, µ,
and density, ρ, were assumed constant (valid for shear rate <6 s−1 [75]) at 0.00385
Pa·s and 1.080 g/mL, respectively [75]. Particulate fluid effects were not considered
due to the relative dimensions of the channel in relation to cell size (approximately
50 to 150 times). However, findings on platelet margination effects due to particulate
flow indicated that such models have potential value [76], and is an area for future
investigations. Boundary conditions were for pressure P=0 at all outlet faces, and all
no-slip walls on all other surfaces. The boundary to the inlet was consdered as having
a set pressure of 1400 Pa, determined by ρgh. Flow was assumed to be laminar, and
solutions convergence was set at 1e−6 or 500 iterations. Mesh elements used minimum
side lengths of 2 µm within the stenosis region to approximate the boundary layer
region in which a platelet (2-20 µm diameter) binds. Optimal meshing conditions
were achieved by modeling long resistance tubing sections by smaller tube formations






We applied this model to select resistive tubing lengths ranging from L=60 cm, d=
0.79 mm to L=30 cm, d=2.38 mm (for experiments where input ∆P was set at 1400
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Figure 4: Six shear rate profiles were computed and were obtained experimentally
by varying outlet tubing geometry connected to a uniform channel geometry (a).
The maximum shear rate outside of the stenoses regions is within physiological range
<1500 s−1, while maximum shear rate within the stenoses were designed for a variety
of physiological and pathological shear rates (500-13000 s−1) (b).
Pa). Modeled wall shear stress measurements were extracted from the solved simu-
lation and imported into Matlab, where the values were averaged over the perimeter
to obtain the local shear rate γ at discrete points over the length of the channel to
produce the data shown below in Fig. 4.
Notably the shear rate peaks at the borders of the stenosis region, a region where
initial aggregates appeared in microscopy studies. Others in the field have examined
the effects of adjusting stenosis angles, and such adjustments to mitigate the local
peaks may be of interest. However, the dimensions of vascular occlusions vary widely
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over patients, and in this work we have adhered to the primary criteria of percent
occlusion by area >50%, eccentric formation, and hydraulic diameter of 350 µm.
Having calculated the initial wall shear rate, we were interested in the changes in
wall shear rate over the time course of occlusion. We conducted simulations of channel
occlusion using a solid model created in SolidWorks, and analyzed corresponding
changes in initial wall shear rate using an ANSYS finite volume fluid model. In these
simulations, we assumed thrombus growth was uniformly distributed over the entire
inner surface of the stenosis and thus modelled channel occlusion by thrombus growth
as a localized reduction in the height and width of the stenosis cross section.
Stenosis% = 100 ∗ d0 − di
d0
(5)
These simulations were analyzed in ANSYS with the same settings described
earlier in this section. In order to reflect clinical concerns, local stenosis dimensions
are shown here by stenosis %, which is defined by Equation 5, where d0 is the initial
diameter, and di is the constricted diameter. Flow rate results were as expected from
2, with an exponential relationship of Q ∼ d−4h . Results showed that as stenosis %
increased, shear rate increased to a maximum of nearly 4-fold (19260 s−1) its initial
amount for increases from 66 to 90 stenosis % until falling precipitously as flow rates
approach zero. Notably shear rate increases most rapidly between 80-90 stenosis %,
which may be instrumental in the ”rapid platelet accumulation” phase observed in
later stage thrombosis. Other experimental methods have used constant flow models
and shown increases in shear rate of approximately 21-fold for a similar increase
in stenosis % (80 to 93%) [5]. In contrast, the model developed in this work uses
constant pressure, and thus increases in shear are much more modest, but perhaps
more physiologically relevant since the heart is not able to provide infinite pressure
required to produce a constant flow condition.
Thus with the desired dimensions determined, we next describe the methods used
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Figure 5: Simulations of channel occlusion using a solid model of the channel with
initial shear rate 4000 s−1 in our device. The model was created in SolidWorks, and
analyzed corresponding changes in wall shear rate using an ANSYS finite volume
fluid model. shear rate increased to a maximum of nearly 4-fold (19260 s−1) its initial
amount for increases from 66 to 90 stenosis % until falling precipitously as flow rates
approach zero. Notably shear rate increases most rapidly between 80-90 stenosis %,
which may be instrumental in the ”rapid platelet accumulation” phase observed in
later stage thrombosis. Other experimental methods have used constant flow models
and shown increases in shear rate of approximately 21-fold for a similar increase in
stenosis % (80 to 93%) [5].
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to fabricate these devices.
2.2 Device fabrication
The desired dimensions described above presented distinct challenges. First, the
requisite device feature sizes ranged from 250 to 1000 µm, an atypical size range
for traditional semiconductor methods used for soft-lithography microfluidic devices.
Second, the device was designed with three-dimensional curved surfaces at the edges
of the stenosis (designed to blunt the sudden increases seen in Fig. 4) and the fil-
lets on the upper border of the non-stenotic channel regions (implemented to help
prevent areas of stagnant flow which might entrain passing soluble factors and thus
skew results). While these regions were curved, the stenosis region itself retained a
rectangular cross section in order to prevent optical measurement errors.
Traditional semiconductor fabrication methods of photolithography on silicon are
commonly limited to hydraulic diameters of 5-200 µm and relatively large effort is
necessary to obtain curved, three-dimensional topographies. Thus, in order to fabri-
cate a microfluidic device with the requisite change in hydraulic diameters (300-1000
µm) as well as the gradual transition to the stenosis from the non-stenotic channel
region, we utilized an unconventional microfabrication technique. We first created
a mold in aluminum 6013 using a vertical milling machine (Haas, OM-1a, Oxnard,
CA). The milling process used square endmills with diameters D=0.25-1.57 mm and
a ball endmill with D=125 µm operated at a spindle speed of 30000 rpm (See Fig.
7). For all tools, feed rates were 50.8 mm/min; depths of cut were D/3. Unattended
mold machining time was approximately 30 hr, attended user- operation time was
approximately 2 hours. Mold surface average roughness, Ra, measured by white light
interferometry (Zygo, NewView 200, Middlefield, CT), was approximately 150 nm,
less than the 2 µm platelet diameter, and so was deemed sufficient. Absolute di-
mensions of our device were measured using high resolution (0.762 µm) 3D digital
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Figure 6: An early version of the device mold was constructed using a customized
Sherline mini milling machine (a). The mold geometry was milled using square end-
mills ranging from 150-1000 µm in diameter (a, inset) at spindle speeds of 80000 rpm.
The completed mold is shown on the bottom left (b), and the molded PDMS device
layer on the bottom right (b, inset).
microscopy (Keyence VHX-600) as 250 µm in height and 750 µm in width at the
stenosis region, and 751 µm at peak height at the channel regions
While this method was used to create devices with some curved features but
rectangular cross-section stenoses, we questioned what the effects of changing the
shape of the stenosis had on subsequent platelet aggregation. In order to answer
this question, we needed to develop a fabrication method for creating stenosis cross
sections of widely varied shapes and sizes.
39
Figure 7: Fabrication of the final device mold was achieved in 6013 Aluminum using
an vertical milling machine with square endmills with diameters D=0.25-1.57 mm at
a spindle speed of 30000 rpm.
2.2.1 Circular cross-section channels
Recent intravascular angiographic clinical studies of human coronary arteries affected
by atherosclerosis have shown that affected vessels exhibit localized constricted cross
sections with predominantly eccentric elliptical or circular cross sections. Overall area
reductions in cases of patients characterized as extremely high risk for thrombosis
from myocardial infarct were reported in the range from 50-84% [77, 78]. Thus there
is great interest in designing instruments to better understand how and why these
conditions of altered artery shapes impact patients risk for thrombosis.
The ability to accurately, inexpensively, quickly and repeatably fabricate sub-
millimeter scale features has made soft-lithography based microfluidics a vital tool for
the biomedical research and lab-on-a-chip assays. However, traditional methods used
in this field, such as photolithography, deposition, and etching are generally limited to
creating features with rectangular cross-sections, low aspect ratios, and feature heights
below 200 µm [79]. These limitations cause several problems in the application of
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microfluidics to biological assays. Specifically, rectangular cross sections induce non-
physiological gradients in fluid shear rate, velocity, and pressure in contrast with the
rounded cross-sections found in most natural physiological systems, such as blood
vessels and airways. Further, fabrication of features with multiple heights is complex
and costly. Finally, casting and releasing around complex features can be problematic.
Thus the development of methods for fabricating a wide range of heights and cross-
sections within the same device would provide a valuable complement or replacement
to standard microfabrication techniques.
Although previous groups have formulated methods for obtaining rounded chan-
nels such as reflow of photoresist during photolithography of the device mold, molding
through the use of small wires, or by using additional coating hexanes within square
channels, all of these methods have shown poor control over the resultant geometries
and are unable to vary shapes and aspect ratios [79, 80]. In contrast, micromilling
channel molds is an option which can address a wide range of features and dimensions.
We next present a technique for the fabrication of an array of micro-scale channels
of varying cross-sectional shape and areas with dimensions from 100 – 750 µm. In
addition, we demonstrate the utility of these channels for investigating effects of
varying local flow conditions on thrombosis.
To study the effects of vessel shape, we designed an array of microchannels to
study clot formation within four constricted regions with distinct cross-sectional ar-
eas: circular, square, semicircular, and eccentric (elliptical). Square and semicircular
cross sections were chosen to represent the dynamics of traditionally fabricated mi-
crochannels, while the circular and eccentric channels were chosen to represent the
clinical conditions described previously.
Square and circular cross sections had equal hydraulic diameters, while eccentric
and circular cross sections had the same area constrictions were reduced in area by 50
– 84% relative to the rest of the channel to correspond to patients at very high risk
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for thrombotic stroke [81, 82]. We first used micromilling to construct a mold from
which we cast parts which were subsequently aligned, and bonded to create enclosed
channels with the desired cross sectional areas.
Device dimensions and added downstream resistance elements were chosen such
that each channel would experience identical average shear rates of 7000 s−1, an
amount representative of conditions in patients at high risk for thrombosis and one
which we have verified to cause clot formation in previous experiments. In order
to address such high shear rates for small volumes (less than 5 mL) of blood per
trial, we required a wide range of feature heights and widths from 100 750 µm.
These dimensions were modeled and verified using both an analytical Poiseuillar
flow analysis in conjunction with finite volume characterizations using Navier-Stokes
equations (ANSYS Fluent).
The mold was cut from brass alloy 385 on a vertical milling machine (Haas OM-
1) using square endmills from 1.57 mm to 254 µm in diameter and a 508 µm ball
endmill at spindle speeds from 5,000 - 30000 rpm. For all tools, feed rates were
50.8 mm/minute with depth of cuts set to 1/3 the tool diameter. Surface milled
toolpaths were generated using MasterCAM X3 software. After machining, the mold
was treated for eight hours with a silanizing agent (UCS Chemicals) to facilitate
polymer release during the casting step.
Verification of the molds dimensions was performed using high-resolution (0.762
µm) digital microscopy (Keyence VHX-600), which was used to measure the mold
height over the cross-sectional profile of the stenosis region. Results of metrology
on these areas were characterized by “figure error” [83], which was calculated as the
mean of the absolute value of the difference between the height profile measured using
the Keyence and the desired profile. Results are shown in Table 1. Surface roughness
along the flat face of the channel was sub-micrometer, and provided a sufficiently
smooth surface for bonding castings of PDMS to PDMS along these regions.
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Figure 8: (a) Image of the device mold with four different types of cross-sections. (b)
Images of the milled microchip mold with enlarged images of the constricted regions
of interest of varying cross sectional areas within the mold: elliptical, round, square,
and semicircular. Images captured using digital microscopy. (c) Cross-section of the
fabricated two layer PDMS device. Images taken using a dissection microscope. For
a diagram showing the viewing angle and fabrication process of (c), see Fig. 9.
Table 1: Comparison between designed and fabricated mold dimensions, and their
total calculated figure error within the stenosis region, measured using 3D digital
microscopy. Designed and fabricated total device heights are also included.
Eccentric Circular Square Semicircular
Figure Error (µm) 6.60 2.60 10.2 3.20
Designed mold height (µm) 106 150 150 150
Measured mold height (µm) 106 152 160 151
Designed mold width (µm) 424 300 300 300
Measured mold width (µm) 468 328 303 342
Designed device height (µm) 212 300 300 150
Measured device height (µm) 212 304 320 152
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We have developed a method for achieving a variety of three-dimensional features
unachievable by traditional soft-lithography semiconductor fabrication processes. Em-
ploying this method, we demonstrated the creation of a single device mold containing
four different cross sectional areas, with smoothly transitioning feature sizes ranging
from 100 to 750 µm and aspect ratios ranging from 2:1 to 1:1. Variations in clotting
time reveal the differential behavior of clot formation and nucleation over a range of
cross-sectional areas.
The device fabricated in this work demonstrates the ability of micromilling to
address hereto-unattainable feature dimensions. Analysis of the milled mold showed
a wide range of heights and a surface shapes with “figure error” within 10 µm and
absolute dimensions within 44 µm. Width dimensions showed the largest feature
errors due to artefacts of the metrology method. The limiting factor for the entire
fabrication method occurs in the manual alignment of the two molded parts, which
could be improved through inclusion of specialized techniques such as temporary
methanol bonding and the use of a mechanical stage [84].
Despite the physiological relevance of channels with circular cross-sections, we
decided to use rectangular cross-sections for larger porcine and human studies in
Chapters 4 and 5 due to ease of imaging and current manufacturing capabilities. Also,
the presence of errors in alignment risks unintended local increases in shear rate or flow
streamlines, both factors of great concern in the study of shear induced thrombosis.
However, we did perform limited evaluations of thrombosis in porcine blood in these
different stenosis cross-sections, which are discussed later in this Chapter’s thrombosis
validation section.
2.2.2 Device bonding and interfacing
From this mold, we cast devices using the high fidelity, transparent polymer poly-
dimethylsiloxane (PDMS) (Sylgard 184, Dow Chemical). The poured polymer was
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then placed in a vaccuum chamber at -15-25 psi gauge pressure to eliminate air
bubbles. Degassed polymer was then cured at 70◦C for at least 1.5 hours, and the
polymer gently peeled away from the mold. Devices were cast for thicknesses of 5
mm–a height which allows firm anchoring of fluid interconnects from the device to
attach with resistance tubing.
Next, input and output interfacing holes were punched in PDMS at the inlets
and outlets using a 14 gauge Luer needle with a beveled edge. Use of a non-beveled
needle will result in interfacing holes with small pieces of PDMS debris which may
dislodge and occlude channels during testing. Beveled edges can easily be created by
gentle pressure with a Dremel’s grinding tip. Inlet and outlet tubing was attached
to the device using small (∼1 cm long) sections of PTFE 16 gauge light wall tubing
(Zeus, Orangeberg, SC). This material is preferable to metal due to its exceptional
smoothness and low affinity for cellular adhesion. The 16 gauge PTFE tubing formed
a tight seal with 1/16” inner diameter tygon tubing, while tubing of smaller inner
diameter than the PTFE was attached using an outer “sleeve” cut from 1.5 cm of
Tygon tubing of the next size up, or in some cases sealed with heat shrink. However,
the latter method should be avoided if possible, since the melting point of Tygon is
fairly close to the activation temperature of the heat shrink.
Devices with elliptical, circular, and square cross-sections whose mold fabrica-
tion was previously described were and plasma bonded using high frequency corona
bonding (Electrotechnic, Chicago, IL). Alignment of the layers before bonding was
achieved manually under a stereomicroscope. All channels except the semicircular
channel were bonded to a mirror image. The complete process of milling and align-
ment is shown in Fig. 9.
In contrast to the mirror image alignment and bonding used to create elliptical,
circular, and square cross-sections, normal rectangular cross-section devices were in-
stead bonded it to coverglass (thickness #1.5—0.17 mm). Devices were bonded to
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Figure 9: A comparison between (a) conventional microfluidic channel fabrication,
and (b) our method for forming microfluidic round channels using micromilling and
manual alignment.
coverglass using a PDC-32G plasma cleaner (Harrick Plasma, Ithaca, NY). Bonding
using this machine is mediated through saturating the normally hydrophobic PDMS
surface with oxygen radicals created by high radio frequencies within the cleaner’s
chamber to form a temporarily hydrophilic surfaces able to bond to other similarly
treated surfaces. Scotch tape was used to prevent the adhesion of dust particles to
the device, and/or to remove them prior to bonding. Earlier experiments, such as the
construction of circular cross-sections described later in this Chapter, used a corona
cleaner for surface treatment and subsequent bonding. However, the bond formed
by this method was inconsistent and weak, and we found that the use of the plasma
cleaner produced a much stronger, more consistent bond between the coverglass and
the microfluidic device. In accordance with the plasma cleaner manufacturer, devices
and coverglass were treated with plasma gas for 1.5 minutes on high RF setting with
their bonding faces towards the top of the chamber, then immediately removed and
their surfaces pressed firmly together within the optimal bonding time window of 20
seconds after the plasma RF has been switched off. Bonded devices were then placed
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in a 70◦C oven to assist in the bonding process and to allow unbonded, treated sur-
faces to revert to their original hydrophobic state for a minimum of two hours prior to
filling with collagen solution. This timed step is important, since injection of collagen
into the device directly after plasma treatment can lead to the temporarily hydrophilic
surface pulling the fluid between the PDMS and coverglass, interfering with the bond
between the two. After the requisite two hours in the oven, devices were bonded
firmly enough to inject collagen into the channels. Collagen in a concentration of
100 µg/mL was injected into the channels to fill the entire device [85]. Next, a piece
of Scotch tape was placed over the inlet and outlet holes of the device to prevent
evaporation of the solution. Devices were used for platelet assays a minimum of eight
hours after the bonding process, since plasma surface treatment has been found to
enhance platelet aggregation [86].
The aluminum mold has been used for molding in excess of two hundred times
without notable degradation in performance. Later versions of the device used in
Chapter 5 were cast into acrylic frames and aligned during the molding step with a
customized molding chamber to enable fast, accurate, and repeatable alignment of
the stenosis region to the CCD (x,y = ±46 µm for N=6 trial measurements).
2.2.3 Fluid delivery
Flow control in our device was achieved through gravity pressure head. Many previous
experimental systems for evaluating platelet activity have used syringe pumps to
control volumetric flowrates, and thus shear rates [59, 63]. However, such methods
are problematic for studies of full thrombotic occlusion of flow channels, which would
necessitate the use of high pressures unachievable by the human circulatory system.
Additionally, the use of tubing Thus our system controls flow using gravity pressure
head. In our experiments, we used pressures, P , of 1400 Pa, which were implemented
by elevating the fluid input reservoir – an open, suspended 60-100 mL polypropylene
47
Figure 10: Alignment of the stenosis region to the CCD was enabled by the use of
laser cut acrylic frames. Each frame was aligned to the mold and polymer poured and
set so that the stenosis feature was a known distance from the frame. Next, the cast
devices within the frame were bonded and coated with collagen. The completed de-
vices were then aligned to the CCD through metal posts (”alignment pins”) attached
to the surface of the CCD. The system enabled fast, consistent alignments within
±25 µm of the centerline of the CCD without the need for manual stage adjustment.
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syringe (Monoject, Mansfield, MA) to the height h, calculated as P = ρgh, where g =
9.81 m/s2, and ρ is the average density of blood, 1080 kg/m3 [75]. Thus suspension
height used was thus 132 mm of gravity pressure head. Pressure head was monitored
either manually or using an automated system. Manual monitoring produced average
height differences of approximately 3 mm within the desired height setpoint, while
the automated system was able to maintain heights within sub-millimeter resolution
of the desired setpoint. These errors corresponded with 10-31 Pa of uncertainty.
The automated system operates by detecting the location of the top of the fluid
reservoir. A laser light (Optodiode, Newbury Park, CA) is shone through the trans-
parent syringe reservoir and detected on the other side by a photodiode (US-Lasers,
Baldwin Park, CA). When the light is interrupted by the presence of blood within the
syringe, the signal detected by the photodiode is interrupted, and a linear actuator
(Firgelli, Victoria, Canada) incrementally moves the syringe up by 1 mm increments.
Voltage input from the photodiode and output to the actuator are provided by a
Labview script.
2.3 Experimental validations of flow rate and platelet throm-
bosis
In this section the validation of the computational modelling previously discussed is
shown using experimental flow rate tests. Next we validated the ability of the device
to form platelet-rich aggregates using brightfield microscopy and histological staining.
2.3.1 Flow rate validation
Experimental flow rate tests were used to validate that the device was able to achieve
the desired stenotic shear rates. Flow rate tests were performed using two fluids:
a 43% glycerol/phosphate buffered saline (Sigma Chemical, St. Louis, MO) [87],
viscosity matched at µ=3.85×10−3 Pa· s [75] prior to flowing blood, and porcine blood
anticoagulated with 40 Units/mL of heparin. Interestingly, porcine blood with this
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Table 2: Modeled and experimentally verified steady flow rates in the microfluidic
device. For both glycerol and heparinized blood, flow rates match the model well at
all shear rates well. Measured flow rates are shown as averages ± standard deviation.
Instrument (weighing scale) measurement uncertainty is 0.3 µL/s.
Shear rate γ (s−1) Qmodel (µL/s) Qglycerol (µL/s) Qblood (µL/s)
500 1 0.5±0.4 0.6±0.3
1500 5 3±1 3±1
4000 15 13±1 13±1
7000 19 17±1 17±1
10000 24 27±2 27±2
13000 40 39±7 39±3
level of anti-coagulant did undergo platelet thrombosis in our devices, while human
blood did. This difference may be attributable to the use of acid-soluble collagen to
coat the devices used with these porcine samples.
Volumetric flow rates Q were measured using weighing scales (Ohaus, Parsipanny,
NJ or Adams Equipment, Danbury, CT) with 0.01 g resolution. The open end of
each channel’s outlet tubing was taped into place onto Petri dish, each of which was
placed on an independent scale (four in total, one for each channel). Mass, m, as a
function of time, t, data from the weighing scales was acquired at 1Hz and written
to file using a Labview acquisition program. Mass over time was then converted to
Q according to Q =
∆m
ρ∆t
, where ρ is the density of the fluid (1.11 kg/m3 for 43%
glycerol [88], 1080 kg/m3 for blood [75]), and ∆t is a 10 second window of time.
2.3.2 Thrombus histology
Next we needed to verify that these flow conditions and devices were able to consis-
tently form thrombus. We also needed to confirm that the contents of the thrombus
were platelets, as hypothesized.
To verify the platelet composition of the occlusive thrombus, we used Carstairs
histological staining method. To perform Carstairs staining, we excised the PDMS
layer containing attached thrombi, preserved them with formalin for 48 hours, dehy-
drated them in a series of xylene washes, fixed them in paraffin, microtome sectioned
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Figure 11: Microscopy images (a) of thrombi formed within device stenoses at higher
shear rate, 7000 s−1 (top) and lower shear rate, 4000 s−1 (bottom). Subsequent
histology (b) via Carstairs staining reveals expected platelet thrombi (stained blue)
at high shear rate and red blood cells (stained orange/red) mixed with platelets in
thrombi at the lower shear rate. Images were taken en-face at 4X magnification.
them into 5 µm slices, and stained them. The stain colors platelets blue and red blood
cells orange/red. Thrombus volume within the stenosis was estimated by multiplying
its cross-sectional area by the height of the stenosis.
Thrombus histology results using Carstairs staining method (Fig. 11) indicate
that thrombi formed within the stenosis region of our devices showed high concen-
trations of platelets with low concentrations of fibrin at high shear rates and greater
numbers of red blood cells in thrombi at low shear rates, as expected and consis-
tent with previous reports [15, 89]. Further evidence towards the formation of larger,
more platelet-rich thrombi at high shear rates was shown in optical results detailed in
Chapter 3. Thrombi formed at the higher shear values of 4000 and 10000 s−1 showed
larger changes in SNR of Volumes of thrombi were estimated at 0.0256 µL (N=7),
approximately 55% of the stenosis volume.
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Table 3: Experimental measurements of times for blood flow to occlude microchan-
nels for varying cross-sectional shapes under conditions of identical shear rates (N=3
for all cross-sections).
Eccentric Circular Square Semi-circular
Time to Occlusion µ± σ(s) 78±48 313±55 170±42 66±48
2.3.3 Thrombosis in stenoses of varying cross-sectional shapes
The fabricated devices were used to assess the effects of variations in cross-sectional
area on the formation of clots. Tests were run by flowing blood under specific shear
rate conditions and monitoring the time it takes for clots to form and stop flow
within each microchannel. This quantity is defined as the time to occlusion. Flow
was monitored through the use of video microscopy and mass flow measurements with
10 µL resolution.
Our results showed that the time to occlusion for the circular channel was higher
than within the square channel by almost three standard deviations (Fig. 12). Since
both channels had nearly identical hydraulic diameters and shear rates, we conclude
that this effect may be due to differences in shear effects between square and circular
cross-sectional shapes. One explanation may be due to the larger inner surface area
of the square channel to allow adhesion of platelets (1.3X larger in the square than
the circular). Although this surface area is larger, it is notable that the two still have
similar area:perimeter ratios of 78.5 for circular and 77.5 for square cross sections,
respectively. It may also be possible that platelet margination patterns may vary
between the two cross-sectional shapes, although this topic will require additional
investigation and is beyond the scope of this work. Although these results show large
differences in occlusion times, further investigation should be performed on these test
results due to low number of experimental trials and inherent variability of porcine
blood samples used.
Thus the estimation of hydraulic diameter for square cross-sections, a common
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Figure 12: Channel occlusion was measured by mass flow of blood through the
microchannels of different cross-sectional areas at equal shear rates. The circular
channel required the most blood volume to occlude, followed by the square channel,
while the semi-circular and eccentric channels occluded with nearly the same sample
blood volume.
practice in microfluidics, may not accurately predict fluid behavior for shear-dependent
applications. Additional evidence for the importance of hydraulic diameter is pro-
vided by comparing the circular channels time to that of the eccentric channel with
the same percentage constriction and cross-sectional area. These variations in clotting
time for channels of similar shear rates demonstrate the importance of both cross-
sectional channel shape as well as hydraulic diameter and may provide substantial
differences in thrombosis assays. These initial findings underscore the importance
of developing methods for improved manufacturing techniques in microfluidic assays
and also suggests that the common clinical assessment of arterial constriction by area
may be insufficient to assess patient risk for thrombosis. However, it is again worthy
to note that although these initial results show large differences in occlusion times,
this finding may be due to low number of experimental trials and inherent variability
of porcine blood samples used.
2.4 Conclusions
This chapter describes the design, fabrication, and testing of a microfluidic device for
measurement of in-vitro platelet aggregation for a wide range of different shear rates.
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Figure 13: Images of formed platelet thrombi in channels of varying cross section
morphologies (eccentric, circular, square, and semi-circular) on a single device after
500 seconds.
Analytical and computational modelling have shown the system’s ability to address
specific initial wall shear rates over two orders of magnitude, from 500 to 13000 s−1 a
within a single device trial, simultaneously. Also described is a method for adjusting
this range of shear rates using resistance tubing and input pressure.
We have also discussed novel methods for device fabrication. Unlike other tra-
ditional soft lithography microfluidics which are best for producing simple planar
features of 200 µm or less in height, we have demonstrated the use of micromilling
techniques to produce a variety of complex shapes over feature sizes from 250 to 1000
µm, and channel cross sections of various shapes.
Finally, we demonstrated the ability of these designed and fabricated channel
arrays to experimentally address the correct shear rates and to form platelet thrombi,
and showed that hydraulic diameter alone is insufficient to determine thrombosis times
and dynamics. Although rounded channels provide an interesting prospect for future
work, there are significant problems with achieving these shapes. First, the alignment
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of these shapes to one another could be achieved with maximum accuracy of 31 to
64 µm, which in this case constitutes up to 21% of the width of the channel. This
can also create shape discontinuities that could incur unwanted flow dynamics. In
addition to this level of inaccuracy, the method also requires a high degree of manual
dexterity due to the natural compliance of the PDMS material, short timescale allowed
for optimal PDMS-PDMS bonding (approximately 30 seconds), and difficulty with
visual and manual alignment using a dissection microscope. Findings on the effects of
channel cross-sectional shape on occlusion time suggest that the square approximation
of rounded or eccentric channels may be very inaccurate. Thus it is suggested that
contribution of the latter two shapes to fluid dynamics leading to thrombosis might
outweigh potential errors induced by shape [59], and should thus be pursued in future
device designs provided that the tests shown here can be robustly replicated in similar
studies.
Future development of the device for commercial or clinical applications should
focus on the reduction of sample volume and sample handling required for users,
especially in the area of drug screenings (discussed further in Chapter 5). Although
the volumes used in this study are suitable for research applications such as these,
multiplexing of these tests would require volumes of blood which may prove difficult
for subjects to provide.
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CHAPTER III
OPTICAL DETECTION OF PLATELETS
This chapter describes the development of an optical sensor for label-free, non-contact,
multi-channel, high temporal resolution measurement of platelet-based thrombus for-
mation. First, we describe the theoretical basis for our transmission-based sensing
method. Next, the implementation and capabilities of this system in a variety of wave-
lengths and light sources is discussed. Finally, verification and comparison between
this method and traditional microscopy methods is presented.
3.1 Design and modelling
As previously noted, current methods for measuring platelet aggregation have been
predominantly conducted using microscopy. However, microscopy methods are prob-
lematic due to limitations of small measurement areas, poor depth measurement,
need for image post-processing, and often require sample pre-treatment and/or fluo-
rescence capabilities. Alternative methods have used flow, but such methods can be
bulky and costly. Yet other methods have used electrical impedance, but the use of
electrodes requires the exposure of blood to a non-physiological metal surface.
Thus for our microfluidic system, our goals were to construct an optical sensing
system that was able to detect thrombus kinetics in real time (including clinically rele-
vant measurements of thrombus buildup, occlusion, and detachment events), scalable
to detect thrombosis in many channels, and able to perform such tasks with capabil-
ities similar to conventional microscopy techniques.
The gross differences between large platelet thrombi, a semi-transparent white,
and whole blood, an opaque red cellular suspension are immediately noticeable by eye,
thus measurement of light transmission through the thrombus mass was an attractive
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candidate to measure thrombosis. The transmissive properties of blood’s components
varies widely. Platelets are less scattering and less absorbing to visible light (250-850
nm) than red blood cells due to differences in their index of refraction and lack of
hemoglobin [1, 6]. Therefore, as platelet–rich thrombus accumulates in the stenosis,
otherwise filled with blood, light transmitted through it increases.
To quantify the differences in light transmission through these different tissue
types, we applied a Monte Carlo radiative transport optical model for simulating
large numbers of photon ”packets” propagating through turbid tissues at calculated
trajectories. The simulations are based on macroscopic optical properties of tissues
which extend uniformly over step sizes of 10-1000 µm, and are thus most appropriate
for a tissue-level evaluation, and not one at the cellular level. At each of these step
distances, photon packet trajectory is calculated based on the local tissue’s ability to
scatter it (αs) in a direction determined by its anisotropy of scattering (g), while the
energy which keeps the packet moving is determined by the local ability to absorb
the photons’ energy (αa). The point at which the number of photons which are able
to propagate drops below a certain point due to absorptive energy loss or scattering
to a different direction is the penetration depth of the light source, and the number of
photons able to reach a depth z over the original number incident at the surface of the
tissue is the transmission. Thus these simulations are commonly used in modelling
the capabilities of medical imaging methods such as magnetic resonance imaging
(MRI)[90]. In this work, we seek to use this method to predict the changes in light
transmission as the layers of ”tissue” within the stenosis change their percentages
of composition, from 0% thrombus and 100% whole blood when the stenosis is first
exposed to the sample, to 100% thrombus and 0% blood at full occlusion, as shown
in the schematic of Fig. 14.
The software package which runs these simulations is called the ”Monte Carlo
model of steady-state light transport in multi-layered tissues” (MCML), written by
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Figure 14: Platelets are less scattering and less absorbing to visible light (250-850
nm) than red blood cells due to differences in their index of refraction and lack of
hemoglobin [1, 6]. Therefore, as platelet–rich thrombus accumulates in the stenosis
(otherwise filled with blood, (a)) light transmitted through it increases (b).
Prof. Lihong Wang and Prof. Stephen Jacques [91]. The program’s client input
is provided through the .mci file, which allows the user to specify the properties of
the tissue layers throughout each of the δz depth steps. This input file interfaces
with a command-line based C program called mcml.exe, which uses it to perform the
stochastic simulations, and writes the outputs of the simulations to an output .mco
file.
Notably, the MCML software package also offers additional capabilities beyond
what has been explored in this thesis. In particular, it offers a conv.exe program,
which can account for different beam profiles (Gaussian, ”top hat”, etc.) defined
by the user. Thus for the LED light sources, which may not have as many beams
incident with the surface of the sample as the previous laser sources, use of a custom
beam shape to refine estimates of changing transmission may be beneficial.
In our Monte Carlo optical model input file, we needed to provide inputs for the
bulk optical properties of the scattering coefficient, αs, the absorption coefficient,
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αa, anisotropy of scattering, g, and refractive index, n for the two layers of interest–
platelet thrombus and whole blood (we assumed hematocrit, Hct=0.41). Since all
of these three properties vary over different wavelengths, they are difficult to study
without the use of specialized equipment including an integrating sphere to capture
and characterize the angle of scattered light. However, previous work has measured
and tabulated these parameters in whole blood, as well as in diffuse concentrations
of platelets [1, 92]. However, we sought to characterize the second layer as a layer
of concentrated platelet thrombus, not diffuse platelets. For these more concentrated
layers, we would at least need to know the new scattering coefficient, which is often
nearly two orders of magnitude larger than the absorption coefficient [1]. However,
such measurements on concentrated thrombus optical properties was not available.
Thus we needed a method to determine αs for concentrated platelet-rich thrombus in
order to run these Monte Carlo simulations.
To address this issue, we identified a widely used technique for characterizing
the scattering coefficient at a specific wavelength using rCSLM (reflectance Confocal
Scanning Laser Microscopy) [93, 94]. This method uses experimental measurements
of the intensity of reflected light Ir(z) vs. scanning depth z within the tissue of interest
to calculate αs using the following exponentially decaying function (Equation 6):
Ir(z) = I0exp(−2αs × z) + C (6)
Where I0 is the incident intensity of the confocal light source before entering
the tissue and C is a fitting constant. Reflected light intensity at a specific depth
is determined using image processing, here performed using an automated custom
written Matlab script.
Measurements were performed using a Zeiss LSM Vis microscope using a Plan
Apo 20X objective (NA = 0.75), 71 µm diameter pinhole (1 Airy Unit), 1.61 µs pixel
dwell over a depth range of 44 µm. Acquired images were 450 x 450 4 µm over 16
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line averages. Master gain was set at 867, digital offset to 0.1, digital gain to 1.0.
Our wavelength range of interest for this study was 632.8 - 650 nm (representing the
HeNe laser and the diode laser), thus our reflectance measurements were obtained
using the a 633 nm wavelength (set at 17% power in these experiments).
We verified that the method was successful after confirming its accuracy by using it
to verify the known αs for Intralipid-20% (Sigma-Aldrich, St. Louis, MO). Intralipid-
20% is a fat emulsion clinically used as an intravenous food source in hospitals, but
also commonly used as a substitute for human tissue (also known as an ”imaging
phantom”) for medical imaging since the fat droplets resemble the lipid bilayers of
cellular tissues. Briefly, samples of 1% v/v Intralipid-20% were freshly mixed and
vortexed for 30 seconds before being injected into a microfluidic device. Devices were
bonded to No. 1.0 thickness (0.13-0.16 mm) coverglass to account for the working
distance (1 mm) of the confocal objective. Images were acquired over a depth of 120
µm, with measurements beginning 10 µ into the sample from the coverglass surface,
which was detected by a sudden spike in reflected light intensity. Measurements were
taken at two regions of interest within the stenosis.
Previous work has used this rCSLM method to characterize Intralipid-20 at 1%
v/v concentrations and 633 nm wavelength as 22-48 cm−1 [95]. In our N=2 trials, we
determined values of 22.75 and 23.86 cm−1, thus verifying that we had successfully
executed the rCSLM protocol.
After verifying the rCSLM protocol, we went on to characterize the scattering
coefficient of concentrated occlusive platelet thrombi. Samples of thrombi were formed
within microfluidic devices (again, bonded to No. 1 thickness glass) under shear
conditions of 10000 s−1, and rCSLM experiments were characterized within two hours
of their formation.
To ensure that our measurements of depth vs. reflected intensity were taken in
areas of high platelet density, we labelled platelets were labelled with the fluorophore
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mepacrine for location purposes. This was a necessary step since post-processing of
images was required to obtain the image contrast necessary to determine the location
of a platelet thrombus. Mepacrines 525 nm emission was spectrally excluded from
the platelet aggregation measurement wavelength bandpass through the use of a long
pass 560 nm filter. Mepacrine was not used in any other experiments.
A sample image stack (450 × 450 µm) is shown in Fig. 15. It is notable from
the image that the penetration depth into the stenosis is poor. This is due to the
high degree of scattering from the thrombus and the red blood cells. The image stack
shown was not used for the calculations of thrombus scattering due to its low density.
Empirically we noted penetration depths of only 50 - 100 µm. We had originally
planned to use this method to evaluate the volume of formed thrombi, as employed
by others in literature [96]. However, this was not possible with the 250 µm tall
stenosis used in this work.
Image stacks were then processed by selecting 100 × 100 µm regions of interest,
and summing their pixel values to obtain local intensity as a function of depth z
into the stenosis. This data could then be plotted as depth z vs. reflected light
intensity, Ir(z), and fit to Equation 6, as shown below in Fig. 16. The experimentally
determined scattering coefficient for platelet thrombus is shown along with published
optical properties of whole blood and platelets in Table 4 (αs=184-203, for N=3).
Thus with the determination of the scattering properties of the platelet thrombus,
we were able to provide all of the necessary inputs to the Monte Carlo optical model.
All of the properties used in the model are listen in Table 4.
Using this information, we were then able to run the MCML depth simulations
to calculate expected increase in transmitted light intensity as a function of platelet
thrombus thickness within the channel. The model examined eleven different ”runs”,
each of which were defined as a different thrombus height (and corresponding reduc-
tion in the size of the whole blood layer). Depth step sizes, δz were 10µm, and we
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Figure 15: Fluorescence imaging using confocal microscopy was used to locate the
regions of interest of highest thrombus concentration. As is evident from this image,
the light is not able to penetrate through the entire depth of the stenosis, and reaches
only about 50-100 µm in depth. Image acquisition began 10 µm away from the surface
of the coverglass in order to avoid reflectance artefacts. These measurements were
used to select the region of interest with the highest local thrombus thickness in order
to calculate the scattering coefficient of concentrated platelet thrombus.
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Figure 16: (a),(b) Reflectance measurements as a function of depth within the
platelet thrombus were acquired using confocal microscopy. These values were then
used to calculate the scattering coefficient of platelet thrombus by fitting the data (c)






Blood (Hct 41%) 794* 7.92* 1.42* 0.99*
Platelet thrombus 193 † 1.21* 1.35* 0.96*
Table 4: Cited ([1] (*)) and measured (†) optical properties scattering coefficient
αa, refractive index n, absorption coefficient αa, and anisotropy of scattering g, for
whole blood and platelet thrombus at 633 nm were used to calculate changes in light
transmission during thrombus growth.
Figure 17: A Monte Carlo simulated relationship was calculated using cited and
measured optical properties of blood and platelet thrombus. Values from the simula-
tion were used to calculate of the percentage of 633 nm light transmitted through a
platelet thrombus of varying thicknesses within a 250 µm stenosis filled with blood.
Light transmitted is predicted by the model to increase by 19% from whole blood
(0%) to fully occlusive thrombus (100%).
assumed 1e5 photons of incident light. Varying this number of photons had no effect
on the overall percentages of light transmitted.
Model results returned the percentage of light transmitted through both layers
(blood, thrombus) within the sample (Fig. 17). They predict a nearly linear increase
proportional to thrombus height, up to a 19% change in light transmitted at full
occlusion in which the thrombus thickess equals the full channel stenosis height. These
results are supported by experimental results, which show increases in absolute light
intensity of 24 ± 10.2% (N=68) for a thrombus whose thickness spans the entire
stenosis height.
A significant limitation to our optical model is that it is not able to account
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for changes in bulk optical properties over the course of thrombosis. However, ob-
servation of the thrombosis using brightfield microscopy seems show that thrombus
density appears to change visibly from round to elliptically shaped clumps of non-
contiguous platelet aggregates (10-100 µm in diameter) into a larger, more dense,
semi-transparent mass of combined thrombus. (exceeding 100 µm in diameter) How-
ever this early, diffuse state of independent platelet aggregates is difficult to maintain
for measurement. Often it was observed that even though tests were stopped partway
to attempt to preserve these aggregates in their current state, their appearance would
gradually change to the semi-transparent state seen in more advanced, denser stages.
The observed change in state may be due to platelet shape change, which would cre-
ate a surface that would more easily scatter light and thus appear more white than
semi-transparent.
In fact, the scattering properties of growing aggregates have been used for platelet
detection [97]. This principle provides the output measurements for platelet aggrega-
tion in the technique known as Light Transmission Aggregometry (LTA), one of the
oldest methods for measuring platelet activity and the remaining ”gold-standard” for
such techniques [4, 20, 98]. Such measurements are made possible by the requirement
that the test be run in Platelet Rich Plasma (PRP), a step which requires the slow,
gentle centrifugation of blood to separate its components. Although it remains the
gold standard, it is hampered by the need for this extra sample processing step, as
well as the addition of non-physiological agonists to induce shape change and ag-
gregation in platelets, by the potential activating effects of centrifuging the blood
and the additional sample handling, and finally by the removal of native elements of
whole blood which may play a role in thrombus development. Such scattering effects
in developing thrombi in whole blood may be of interest for future optical studies.
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3.2 Optical system fabrication
The optical system measures platelet aggregation through increases in light trans-
mission comprises a monochromatic (laser) or quasi-monochromatic (light-emitting
diode) light source coupled to a photodiode detector, or charge-coupled device (CCD)
array of such detectors. In this work, we evaluated a variety of light sources including
a 0.95 mW gas HeNe laser at 632.8 nm (SpectraPhysics, Bozerman, MT), a 0.9 mW
diode laser at 650 nm (Melles Griot, Albuquerque, NM), and an adjustable power (up
to 150 mW) LED source at 590 nm (Thorlabs, Newton, NJ). Power levels of all light
sources were more than sufficient to detect thrombus formation–non-adjustable laser
sources required the use of neutral density filters to prevent saturation of the CCD.
When using the laser light sources (at 632.8 and 650 nm), the size of the beam was
typically near 0.75 mm in diameter. Thus it was necessary to expand the beam size to
simultaneously interrogate all of the channels. To do so, we first removed spatial noise
from the beam using a filter comprised of a small objective lens for focusing the beam
into a pinhole of 20 µm in diameter. The resultant filtered beam was expanded in one
direction using a cylindrical lens. The beam covered the width of each stenosis and
the transmission of the light was measured with a 3000 pixel 12-bit linear CCD with
pixel dimensions 7 µm x 200 µm (Thorlabs, Newton NJ) placed beneath the beam.
Optical cross–talk between channels was mitigated with sufficient channel spacing
and the use of an aperture plate, made from laser cut cardstock coated in mylar foil
(Fig. 18).
Due to difficulties with the alignment, the gas laser system above was later re-
placed with a more robust and durable fixturing system which included a variable
Galilean beam expander (Thorlabs, Newton, NJ) and the 650 nm diode laser. The
beam expander created a circular spot size of approximately 25 mm in diameter–wide
enough to cover all stenoses with a variation of 4.5% across the stenosis regions of
the beam. Such differences in initial intensity incident on the stenosis regions did
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Figure 18: (a) The first generation of the optical system comprised a 632.8 nm
HeNe gas laser whose beam was spatially filtered through a 20 µm diameter aperture
and expanded unidirectionally by a cylindrical lens. The resultant linear beam then
encounters a mylar aperture, underneath which the stenoses of the device are aligned
(Device shown in (b)). The beam then shines through each stenosis, and transmitted
light is detected by a linear CCD.
not appear to affect the overall change in transmission due to thrombus formation.
The large spot size was not necessary, but convenient since it did not require special
alignment procedures, and negated the requirement for an additional neutral density
filter. This configuration was used for the experiments described in Chapter 4.
Although our modelling efforts had been focused on laser light in the 632-650
nm range, we had not yet determined whether this wavelength range was optimal.
Furthermore, the use of a LED sources in place of lasers might be able to provide
a lower cost alternative and wider areas of effect. Thus, we next use spectrometry
to determine optimal testing wavelength and constructed the system using an LED
source.
3.3 Wavelength optimization
Previous work has shown the detectable differences in light transmission through
dilute platelet solutions vs. whole blood are greatest at 500-600 nm [1]. In this work,
we experimentally verified these transmission-based differences through concentrated
platelets thrombi formed inside a microdevice vs. whole blood using spectrometry
and two quasi-monochromatic optical systems. Platelet thrombi were formed within
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Figure 19: The microfluidic system comprises the microfluidic device and optical
system. The optical system measures an increase in light transmission (from the
laser to the CCD), Ilaser(t), as the platelet aggregation in the stenotic regions in-
creases during shear-mediated thrombosis. The shear rates in each stenotic region
are controlled by resistance tubing, which terminates in independent weighing scales
to measure flow rates Qn(t). Light transmission Ilaser(t) and flow rates Qn(t) are
acquired automatically in Labview and processed in Matlab.
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PDMS microfluidic devices from whole porcine blood as described Chapter 4. Since
the optical fiber used for spectroscopy (Ocean Optics, Dunedin, FL) is only 300 µm
in diameter, and the thrombus is near the same size, the two needed to be precisely
aligned to obtain accurate spectroscopy readings (Fig. 20). To align the two, a
custom-built base plate made to fit onto a on a microscope stage which held the device
with thrombus inside the stenoses. Next a custom built stage fixture which holds the
optical fiber upright was attached to the microscope base plate. The microscope stage
could be used to align the thrombus sample with the microscope objective. Then the
focus could be switched in the z-direction and the optical fiber positioned directly
above the thrombus using a crosshair overlay avaiable through our Nikon Elements
NIS software. Thus the optical fiber would be precisely aligned to take accurate
spectroscopy images from samples with microscale dimensions.
Using this system, we measured relative changes in light transmission (∆T ) through
platelet thrombi vs. through whole blood (N=18 samples) were measured by over the
visible spectrum (Fig. 22) as:
∆T = [(It − Ib)/Ib)] (7)
Where It is the intensity of light transmitted through platelet thrombi, Ib is the
intensity of light transmitted through whole blood, and λ indicates wavelength. Rel-
ative differences calculated using this method were used instead of absolute differ-
ence due to variations in Ib caused by differences in sample hematocrit. From these
spectrometry experiments, we further verified the optimal wavelength by with quasi-






Where σb represents the standard deviation of the intensity signal of whole blood.
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Figure 20: Precise alignment of the the optical fiber used for spectroscopy (300 µm
in diameter), and the similarly sized thrombus required precisely aligned positioning
in order to obtain accurate spectroscopy readings. To align the two, a custom-built
base plate was made to fit onto a microscope stage, which holds the device with
thrombus inside the stenoses. (b) Next a custom built stage fixture which holds the
optical fiber upright was attached to the microscope base plate. (c) The microscope
stage could be used to align the thrombus sample with the microscope objective. (d)
Then the focus could be switched in the z-direction and the optical fiber positioned
directly above the thrombus using a crosshair overlay avaiable through our Nikon
Elements NIS software. Thus the optical fiber would be precisely aligned to take
accurate spectroscopy images from samples with microscale dimensions.
70
Figure 21: Control samples of plasma (a) and red blood cells (b) validated our
spectroscopy readings by displaying, the 440 nm peak for the bilirubin chromophore
and the 500-600 nm peak for hemoglobin, respectively.
For all tests, σb = 2.4 ± 1.5.
To verify that our method could successfully determine the spectral output for
blood’s components, we first examined the spectral output of isolated components of
the blood–a fraction of concentrated red blood cells, and another of plasma. In these
control samples, we were able to observe the bilirubin chromophore peak at 440 nm
in the plasma sample, as well as the 500-600 nm peak for hemoglobin in the red blood
cell sample (Fig. 21). Thus our controls validated the spectroscopy method used.
Next we applied the validated spectroscopy method to evaluate the spectral prop-
erties of the concentrated platelet thrombus. To our knowledge, this is the first such
characterization of this tissue, since as with the confocal measurements of the scat-
tering coefficient, platelets are most often characterized as dilute cellular suspensions.
Results from spectrometry showed the maximum difference in ∆T to be near 590
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Figure 22: Relative difference in transmission ( ∆T ) between platelet thrombi and
whole blood was measured by spectrometry over the visible spectrum using a high
powered white light source over the 400-700 nm (Sutter Instruments, Novato, CA).
Optimal ∆T occurs at wavelengths near 590 nm in contrast to those at wavelength
of 671 nm. Results shown are averaged readings for N=18 occlusive thrombi samples
vs. whole blood, with error bars indicating standard deviations
nm (13.2±4.04, N=18), with a lower magnitude ∆T at 671 nm at (5.06±2.02, N=18)
(See Figure 1). Consistent with spectrometer predictions, the SNR of the monochro-
matic system at 590 nm (672.72, N=1) were much larger than those measured at 671
nm (87.4±146, N=68).
Standard deviations are largely attributable to natural variations in size and den-
sity of thrombi detected. Signal-to-noise ratio of thrombus detection by light trans-
mission in the 400-700 nm range was optimal at 590 nm from experiments using
Table 5: Spectrometer readings showed a 2.6-fold increase in light transmission be-
tween the 671 nm and 590 nm wavelengths using a white-light source. Similarly, use of
quasi-monochromatic light sources (e.g. light emitting diodes) in place of the broad-
band white-light source showed a similar fold increase in light transmission signal to
noise ratio.
Wavelength (nm) Spectrometer SNR Monochromatic SNR
671 5.1 ± 2.02 (N=18) 87.4 ± 146 (N=68)
590 13.2 ± 4.0 (N=18) 227 ± 135 (N=24)
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broadband spectrometry and two quasi-monochromatic optical systems. The optical
detection described is applicable to current commercial and research methods.
3.4 Brightfield microscopy
In order to validate that our changes in light transmission could be used to mea-
sure platelet aggregation, we sought to create a system able to acquire simultaneous
measurements of flow, CCD intensity at a monochromatic wavelength, and capture
of microscopy images under white light. This was achieved through a custom built
system which used a beamsplitter and two separate multiplexed light sources (Fig.
23). Hardware control and acquisition were sampled at 1 Hz with 20 ms integration
time using Labview (National Instruments, Austin TX) and data was analyzed using
Matlab (Mathworks, Natick, MA). Validations were run on both porcine blood sam-
ples using a 650 nm monochromatic light source (results shown in Chapter 5) as well
as on human blood samples using the optimized 590 nm semi-monochromatic light
source (results shown in Chapter 6).
Brightfield microscopy imaging relies on the interplay of a variety of properties
including material scattering, absorption, and specular/diffuse reflectivity [99]. Thus
brighter areas in microscopy images do not necessarily indicate increases in reflectivity
(and thus decreases in transitivity through the sample), and such results do not
run counter to predictions from our optical model. On the contrary, increases in
brightfield contrast with increasing thrombus volume are expected due to thrombus
related decreases in both scattering and absorption (see Table 4).
Flow rate measurements, Q(t), shown in Fig. 24, also show the occlusion time.
From this flow rate measurement, we were able to calibrate the intensity at which
occlusion occurs in the laser optical system by setting a threshold as a percentage
of maximum intensity. Flow rate is nearly constant while platelets accumulate in
the stenosis because the stenosis is a small fraction of the overall resistance of the
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Figure 23: Schematic showing time multiplexed white-light microscopy and laser sys-
tem optics. White-light microscopy images were acquired with a Zeiss Stemi 2000c mi-
croscope under 5.0X magnification and a Motic 2000 CCD camera. Laser light trans-
mission measurements were obtained using a linear CCD and a laser (or LED) light
source and detected with a linear CCD. Results were normalized as [I(t)− Imin]/Imax
and low-pass filtered to produce relative intensity measurements Imicroscope(t) and
Ilaser(t). Timed switching between the white light and laser sources, in addition to
the acquisition of flow rate data Q(t) were controlled using Labview and results were
post-processed in Matlab.
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microfluidic channel and associated resistance tubing. From our fluid modeling, we
estimate that the resistance of the stenosis reaches the same order of magnitude
as the rest of the system at 28% occlusion, at which point (∼400 s), the flow rate
begins to decay logarithmically while shear rate increases, as confirmed by our fluid
modeling efforts White-light microscopy images were acquired with a Zeiss Stemi
2000c microscope under 5.0X magnification and a Motic 2000 CCD camera in a
detection method used by others [59]. Laser light transmission measurements were
obtained using a linear CCD and a laser (or LED) light source and detected with
a linear CCD. Results were normalized as [I(t) − Imin]/Imax and low-pass filtered to
produce relative intensity measurements Imicroscope(t) and Ilaser(t). Timed switching
between the white light and laser sources, in addition to the acquisition of flow rate
data Q(t) were controlled using Labview and results were post-processed in Matlab.
We first used the microfludic system to form and detect platelet aggregation to full
occlusion of flow at 10000 s−1 initial shear rate with simultaneous optical (microscope
and laser optical system) and flow rate measurements. Results of a typical experiment
are shown in Fig. 24.
From the time series of raw microscope images of platelets aggregating in the steno-
sis, normalized intensity, Imicroscope(t), was computed for comparison with the laser
optical system intensity transmitted, Ilaser(t). Occlusion times between the methods
differ by 3.97%±5.1% (N=6) with Pearson product-moment correlation coefficient,
r=0.94, p<0.01, all measured from porcine blood samples.
Additionally, the system was also able to detect embolism events during which
formed thrombi which had occluded flow would partially fragment or completely
break away from the channel walls, creating a sudden decrease in measuredIlaser(t)
and Imicroscope(t), and a sudden increase in flow rate Q(t).
This build-up and detachment of thrombus is an important area of study due to its
clinical relationship with stroke. In Chapter 5 of this work we discuss the relevance of
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Figure 24: Formation and measurement of porcine platelet aggregation to full occlu-
sion of flow in the microfluidic device using simultaneous measurements of microscope
intensity, Imicroscope(t); light transmission, Ilaser(t); and flow rate, Q(t), at 10000 s
−1
initial shear rate. Microscope images (a) show aggregationbrighter areas of the images
correspond to more platelet mass. The correlation between microscope intensity and
light transmission measurements was calculated as Pearsons r=0.94. All data shown
comes from a single trial.
this metric of thrombus fragmentation/embolism with anti-platelet drug treatment.
Next, we repeated these verifications on human blood samples using the optimized
590 nm quasi-monochromatic light source (Thorlabs, Newton NJ) in the multiplexed
configuration previously shown (Fig. 23). Results showed similarly high Pearson’s
correlation values with microscopy (r=0.92, N=5) to porcine results.
Similar to the previously discussed porcine measurements, we also measured the
use of semi-monochromatic transmitted light intensity with flow rate for human blood
at 590 nm. Again, results showed significantly higher values for change in light
transmission (Table 6).
Thus we have shown that light transmission is an effective endpoint detection for
thrombosis using a variety of light sources and wavelengths.
So we next investigated whether this method could be used for more precise mea-
surements of volumetric growth instead of simple binary detection. In order to assess
the sensitivity of such measurements, we used the simultaneous measurements of
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Figure 25: The microfluidic system detected thrombus detachment (”embolism”)
events, during which formed thrombi which had occluded flow would partially frag-
ment or completely break away from the channel walls. Such events were observable
both through microscopy images (a), as well as through Intensity measurements where
they would cause a sudden decrease in measured ILED(t) and Imicroscope(t), and a sud-
den increase in flow rate Q(t). As noted by the subscript, Intensity readings were
acquired using microscopy and the 590 nm quasi-monochromatic LED light source.
(b)
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flow rate and intensity to plot the relationship between the two for each successful
occlusion trial (Fig. 26)
As with previous experiments in this Chapter, intensity measurements are pre-
sented instead as CCD Signal-to-Noise Ratio (SNR), according to the Equation 8,
(where the standard deviation of the noise due to blood flow was σb = 2.4 ± 1.5).
Volumetric flow rate Q(t) vs. CCD Signal to Noise Ratio SNR measured I(t) for
N=10 trials at 10000 s−1, N=10 trials at 4000 s−1, N=4 trials at 1500 s−1, and N=2
trials at 500 s−1. When trials begin, values of Q(t) are highest, and values of SNR
are low due to the absence of thrombus. Next, there is a nearly linear regime during
which decreases in flow rate are proportional to increases in SNR. Finally, after flow
stops the thrombus continues to become more densely packed and SNR increases,
especially in higher shear thrombi. Although the slopes of Q(t) vs SNR were similar,
their offsets prevent the use of a precise calibrations between these different trials.
While the previous Fig. 26 showed a relationship between Q(t) and SNR as diffi-
cult to calibrate precisely, the relationship between the two can still have great value
as a binary endpoint. To evaluate the utility of the SNR endpoint to detect occlu-
sion, the distributions of SNR values for both non-occluded and occluded channels is
shown in the box and whisker plot of Fig. 27. For each occluded channel, two SNR
measurements, SNRocclusion and SNRfinal. These are defined in Equations 9 and 10,
respectively as:
SNRocclusion =




(I(t = tfinal)− Ib)
σb
(10)
Where I(t = tocclusion) is the measured sensor intensity at the time when flow
Q(t) < 0.001 mL/s, I(t = tfinal) was the measured sensor intensity at the end of the
testing duration (up to 3600 s), Ib) is the intensity at the beginning of the test due
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Figure 26: Volumetric flow rate Q(t) vs. CCD Signal to Noise Ratio SNR measured
according to Equation 8 for N=10 trials at 10000 s−1, N=10 trials at 4000 s−1, N=4
trials at 1500 s−1, and N=2 trials at 500 s−1. When trials begin, values of Q(t) are
highest, and values of SNR are low due to the absense of thrombus. Next, there is a
nearly linear regime during which decreases in flow rate are proportional to increases
in SNR. Finally, after flow stops the thrombus continues to become more densely
packed and SNR increases, especially in higher shear thrombi. Although the slopes
of Q(t) vs SNR were similar, their offsets prevent the use of a precise calibrations
between these different trials. Values of the standard deviation due to the whole
blood sample, σb = 2.4 ± 1.5
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Table 6: Significance p values for Student’s T-test comparisons between calculated
CCD SNR values for channels which did not occlude (SNRNO) vs. those which did
occlude (SNRocclusion and SNRfinal). The former is calculated by Equation 9 at the
time when flow Q(t) < 0.001 mL/s, and the latter by Equation 10 at the end of the
testing duration (up to 3600 s). Results show significant (p<0.05) differences between
SNR values between channels of all tested shear rates with and without occlusions
at both the time of flow occlusion and at the end of the testing period, although
differences with the latter have much greater significance.
p-value 500 s−1 1500 s−1 4000 s−1 10000 s−1
SNRNO vs. SNRocclusion 0.023 0.007 1.5e
−6 6.7e−6
SNRNO vs. SNRfinal 0.032 0.022 0.001 9e
−4
to intensity of the whole blood sample, and σb is the noise level at the beginning
of the test due to the whole blood sample, which averaged 2.4 ± 1.5 over all tests.
(t = tocclusion) and , and the other calculated at the end of the testing duration (up
to 3600 s). Average cutoff values for SNR at the time of [flow] occlusion fall between
50-200 for nearly all shear rates, reflected in the pooled value for SNR at occlusion
time shown on the far right.
Next, significance p values for Student’s T-test comparisons between calculated
CCD SNR values for channels which did not occlude vs. those which did occlude
were calculated. These results show significant (p < 0.05) differences between SNR
values between channels of all tested shear rates with and without occlusions at both
the time of flow occlusion and at the end of the testing period, although differences
with the latter have much greater significance.
After determining that these values were significantly different, we next used the
data to determine an optimal cutoff point for determining binary occlusion/non-
occlusion. Optimal SNR cutoff value was that which maximized the difference in
percentage of SNRocclusion vs. SNRNO. Use of this cutoff would produce a ”false
positive” rate of 9.01% based on the number of non-occluded channels which still
showed a rise in SNR above 90, and a positive detection rate of 96.7% and 74.2% at
the final timepoint of the tests or at the time of occlusion, respectively. Numbers and
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Figure 27: Box and whisker distributions of SNR values for both non-occluded
(SNRNO) and occluded channels (SNRocclusion, SNRfinal). SNRocclusion is calculated
by Equation 9 at the time when flow Q(t) < 0.001 mL/s, and the SNRfinal by Equa-
tion 10 at the end of the testing duration (up to 3600 s). Average cutoff values
for SNR at the time of flow occlusion fall between 50-200 for nearly all shear rates,
reflected in the pooled value for SNR at occlusion time shown on the far right
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Table 7: Utility of the CCD SNR as an occlusion endpoint. Optimal SNR cutoff value
was that which maximized the difference in percentage of SNRocclusion vs. SNRNO.
Use of this cutoff would produce a ”false positive” rate of 9.01% based on the number
of non-occluded channels which still showed a rise in SNR above 90, and a positive
detection rate of 96.7% and 74.2% at the final timepoint of the tests or at the time
of occlusion, respectively.
SNR cutoff = 90 SNRocclusion SNRfinal SNRNO
> SNR cutoff (%) 96.7% 74.2% 9.01%
N Trials 124 124 111
percentages of trials exceeding this cutoff point are shown in Table 7.
3.5 Hematocrit
In addition to the goals of this work discussed at the beginning of this Chapter, we
were also interested in the use of on-chip hematocrit measurement. Hematocrit is
vital metric for thrombosis assays due to its considerable effect on the optical and
biological characteristics of blood. Prior work has found that variation in hematocrit
from 20% to 60% (clinical range) can affect the time to formation of an occlusive
thrombus by 100% [20, 31].
Hematocrit can be measured by light transmittance through blood because other
blood components (e.g., lymphocytes, plasma, and platelets) have comparatively
much lower volumetric concentrations as well as much lower absorption and scat-
tering indices [1] relative to red blood cells at visible wavelengths. This technique
has been used by others in macro-scale cuvettes in spectrophotometers [100], and in
this work we were able to show a nearly linear calibration relationship of hematocrit
vs. transmitted intensity in whole blood samples using our microfluidic device as a
stagnant cuvette. We did not pursue further use and characterization of this method
since our future studies obtained Complete Blood Counts for each sample (a set of
metrics that includes hematocrit, as quantified by a flow cytometer), however this
technique would be valuable in future development as an integrated measurement for
point-of-care applications where flow cytometry is not available. This measurement
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Figure 28: Intensity transmitted vs. hematocrit for unlabeled whole blood measured
through the stenosis region in the microfludic system (N=3). This calibration was
used to exclude samples outside of normal physiologic range (25-60% hematocrit)
from analysis in subsequent platelet aggregation experiments
should be easy to integrate by allowing a small amount of blood to slowly fill the
channels and then temporarily halting flow so that a hematocrit measurement can
be taken and used to exclude patients with abnormal hematocrit or to adjust their
results appropriately. Our calibration data is shown below in Fig. 28.
3.6 Conclusions
In the beginning of this Chapter, the stated goals for the optical sensing method were
to detect thrombus kinetics in real time (including clinically relevant measurements
of thrombus buildup, occlusion, and detachment events), scalable to detect throm-
bosis in many channels, and able to perform such tasks with capabilities similar to
conventional microscopy techniques.
In this chapter we present the experimental characterization of the optical light
scattering properties of platelet thrombus and describe the calculation of the 19 % in-
crease in light intensity which should accompany the formation of an occlusive platelet
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thrombus. We then demonstrate the construction and efficacy of a transmission mea-
surement system using a variety of light sources (633 nm HeNe gas laser, a 650 nm
diode laser, and a 590 nm LED array) and an 11 bit depth linear CCD. Additional
experiments adding a multiplexed white light source and microscope camera showed
that intensity measurements from microscopy image processing were nearly identical
(Pearson’s r=0.93) to measurements using our light transmission method. Charac-
terizations of the relationship between flow rate and increases in light transmission
showed that endpoint detection of flow occlusion could be reliably detected by light
transmission measurements to detect 96.7% of fully occluded trials at a CCD SNR
cutoff point of 90, although use of this method for finer measurements of thrombus
volume will require further methodological improvements. The method is also able
to detect thrombus detachment, verified by simultaneous flow rate measurements.
The system built and characterized in this work shows excellent correspondence
with white light microscopy intensity readings. Thus the method provides a low cost,
small-footprint alternative with similar potential capabilities. Due to methodological
difficulties in measuring volume of thrombus during testing, it is currently difficult to
use this method to precisely determine volume of thrombus formed. However, such
capabilities may not be necessary for simple bedside tests for whom endpoints such as
occlusion of SNR are easier and more clinically important. Thus this method shows
great promise for future development for point-of-care devices.
Future work on optical thrombus detection might include the use of larger detec-
tors which would avoid errors associated with thrombi migrating downstream of the
stenosis. Another important aspect is the characterization of the thrombus prior to
compaction–a better understanding of these changes might improve the precision of
the transmission measurements to enable volume measurements of thrombi.
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CHAPTER IV
EFFECTS OF SHEAR RATE ON PLATELET ACTIVITY
IN PORCINE BLOOD
This chapter describes the application of the multi-shear microfluidic system in label-
free, porcine whole blood samples. The data provides a survey on the effects of shear
rate on untreated whole blood within a test population for an animal model and
a proof-of-concept for the device and optics discussed in Chapters 2 and 3. These
results form the foundation for the investigation of the simultaneous effects of shear
rates and anti-platelet agents in this Chapter.
4.1 Methods
The purpose of these experiments was to first validate the ability of the system to
form and measure the dynamic process of thrombosis and to establish an appropriate
protocol for sample handling. Next, we desired to characterize the variability due to
our experimental setup as well as in our samples. Finally, we applied the microfluidic
system to whole porcine blood for shear rates spanning physiological to pathological
flow conditions.
Porcine blood samples obtained fresh from a local abattoir (Holifield Farms, Cov-
ington, GA). Samples were gathered in quantities of 1 L from porcine carotids vessels
and gently inverted in polystyrene bottles containing 3.5 Units/mL of unfractionated
porcine heparin (Elkins-Sinn Inc., Cherry Hill, NJ). This concentration of heparin has
been used by others to prevent clotting in storage reservoirs while allowing thrombus
formation under flowing conditions [59, 101]. Although citrate is one of the most
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often used anticoagulants by platelet researchers, it is a calcium chelator that re-
quires the addition of ADP to re-activate platelets after its addition [89, 102]. In
contrast, heparin does not require agonist addition to re-activate platelets, hence our
preference. Early experiments examining the effects of altering added heparin con-
centrations showed no significant differences in platelet behavior after the addition of
heparin within the window of concentrations from 2 to 10 Units/mL. However, at con-
centrations below 2 Units/mL, samples coagulated within ten minutes of collection,
and at concentrations above 10 Units/mL, thrombosis was no longer observed in these
porcine samples when exposed to acid-soluble collagen. In contrast, human samples
retained platelet activity at higher concentrations of heparin (up to 40 Units/mL)
when exposed to fibrillar collagen (see Chapter 5).
Samples were transported back immediately, but were not available for use until
1.5 to 2 hours after collection due to transit time. After transit, samples were placed
on an orbital shaker at about 60 rpm.
Samples were used within five hours of collection, as longer times have been re-
ported to reduce the efficacy of the low concentration of the added heparin. Samples
older than five hours were noted to have larger deviations for occlusion times, and
previous researchers have reported increased observations of emboli after this time.
Due to the non-sterile conditions of sample acquisition, and/or large circulating lipid
aggregates, artefact particles as long as 1 mm and as short as 20 µm were common.
Thus, prior to experiments, the blood was filtered by flowing it slowly through a 200
µm pore polypropylene mesh (Smallparts, Seattle WA) to remove platelet or lipid
aggregates that could cause embolic occlusion.
The collagen used to coat the interior surface of the device is a crucial initiator of
platelet activity and adhesive substrate. Prior studies by others have shown that the
choice of collagen type has a dramatic effect on subsequent thrombosis [85].
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In initial studies of porcine blood, we used acid-soluble collagen I (Sigma Chem-
icals, St. Louis, MO) similar to others in the field [63]. While this collagen was
suitable for initiation of occlusive thrombosis in porcine blood, it was not effective at
initiating thrombus formation in human blood samples, a finding supported by inves-
tigations by Bernardo, et al., who suggested that acid-soluble collagen was unlike the
fibrillar collagen found physiologically due to its significantly reduced ability to bind
the vWF adhesion protein [85]. Thus in human experiments, acid-insoluble collagen
from equine tendon (Chronolog Corporation, Haverton, PA) recommended from the
aforementioned group’s publication was used (see Chapter 5).
For each porcine blood sample, four shear rates were run simultaneously in a single
trial while platelet aggregation to occlusion was measured by the laser optical system
only and flow rates were measured by the weighing scales. A trial is defined as a
single experiment with one new microfluidic device comprising four channel runs. Up
to three trials were run with each sample. An example of the output from one such
multi-channel assay is shown in Fig. 30.
An example of the raw data from a trial (a single experiment with one new mi-
crofluidic device comprising four channel runs) is shown in Fig. 30, pictured next
to the schematic of the system for context. Intensity measured by the CCD (top) is
separated into four regions of interest according to the location of the stenoses and
the intensity data is filtered to remove the high intensity white light time periods
when microscopy images are being acquired (middle). Both microscopy images and
CCD intensity information was acquired at 1Hz, and periods between white light and
laser/LED source switching was 15 seconds. Flow rate data Q(t) was simultaneously
acquired through the weighing scales. Data was acquired in Labview and filtered and
analyzed in Matlab.
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Figure 29: (a) The implementation of the experimental apparatus described previ-
ously by schematics in Fig. 19 and Fig. 23 which produces the output shown in Fig.
24. The system uses two light sources (white light and laser/LED), two sensors (CCD
and microscope camera), and weighing scales in our assay measurements. Fluid de-
livery is achieved with an automated system which maintains gravity pressure head
within 10-31 Pa of the target. Flow rate Q(t) is measured using weighing scales.
A beamsplitter positioned over the microfluidic device allows acquisition of images
through the microscope lens to the microscope camera (b)
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Figure 30: An example of the raw data from a trial (a single experiment with one
new microfluidic device comprising four channel runs) is shown in Fig. 30, pictured
next to the schematic of the system for context. Intensity measured by the CCD (a) is
separated into four regions of interest according to the location of the stenoses and the
intensity data is filtered to remove the high intensity white light time periods when
microscopy images are being acquired (b). Flow rate data Q(t) was simultaneously
acquired through the weighing scales, and shown here in units of mL/s (c). Data was
acquired using Labview and later filtered and analyzed in Matlab.
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4.2 Results and discussion
In total, 14 porcine blood samples were run on a total of 27 trials resulting in N=4
channels/device × 27 trials=108 channel runs. Of these samples, 5/14 (36%) showed
no occlusion at any shear rate or showed emboli at all shear rates, so these were
excluded after a single trial. Embolus was defined as decrease in flow rate to less
than 50% of initial within 30 s [59]. Of the remaining 9 samples run in 22 trials
(N=88 channel runs), none of the channels with initial shear rate of 500 s−1 and 1500
s−1 formed occlusive thrombi over 2000 s (N=18). This finding is consistent with
previous work which has shown that rapid platelet accumulation is absent with low
shear rates (<2000 s−1) [59].
The other N=70 channels were run at a variety of higher shear rates. Only two
high-shear experiments did not clot (one at 4000 s−1, one at 7000 s−1), while in
the other rest, occlusive thrombi formed at times less than 1200 s (N=68). This
finding is consistent with reports from others that the platelet protein vWF begin
to show significantly adhesive action at shear rates of 4000 s−1 [13]. The times to
occlusion for the N=68 channel runs described are shown in Fig. 31, along with the
corresponding standard deviations. The average difference between the optical and
flow rate measurement of time to occlusion was 8.4%; the standard deviations of the
time to occlusion measurements ranged from 50-212 s. For this range of pathological
shear rates (4000-13000 s−1), we did not observe a statistically significant (p<0.05)
difference in the time to occlusion versus shear rate. Our findings with N=86 channel
runs suggest that thrombosis is binary, present above 4000 s−1 and not present below
1500 s−1. We have not studied this transition regime at higher resolution in this work.
Observable thrombus growth was only visible within the stenosis, although oc-
casional aggregates were captured upstream of the stenosis entry. Thrombus growth
typically began at the entrance of the stenosis, where previous fluid modeling (Fig. 4)
has shown peak shear rates. These small (∼50 µm in diameter), uniformly dispersed
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Figure 31: (a) Shear rates vs. occlusion times for six initial shear rates measured
using the optical system and flow rate. Error bars indicate one standard deviation.
For the range of pathologically relevant shear rates (4000-13000 s−1), we did not
observe a statistically significant (p<0.05) difference in the time to occlusion versus
shear rate. (b) Shear rate vs. volume of blood (V) required to occlude flow. Error
bars indicate one standard deviation. We observed statistically significant (p<0.05)
differences in the volume to occlusion versus shear rate, save the 7000 s−1 to 10000
s−1 comparison.
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Figure 32: Observable thrombus formation typically begins after an initial lag time
with small aggregates at the entrance of the stenosis. These aggregates rapidly grow in
size and unite with later-forming downstream aggregates to create occlusive thrombi.
platelet aggregates would appear, enlarge, and unite with later-forming downstream
aggregates to form larger aggregates (Fig. 32). The unified larger mass would often
undergo significant remodeling, losing and gaining mass over time until the occlusion
of flow. Despite the lack of flow, the thrombus often continued to develop by com-
pacting into a dense, semi-transparent mass. This continued development was evident
in measured intensity increases in both Imicroscope(t) and Ilaser(t). Occasionally the
thrombus would shift downstream or embolize completely, resulting in decreases in
Imicroscope(t) and Ilaser(t) although flow was still occluded.
To examine the intra-trial variability of blood clotting behavior, we measured how
the blood clotting behavior varies between adjacent channels in the same trial with
the same blood on the same device at the same shear rate. In 14 trials with duplicate
shear rates channel runs (D=14 sets), we measured the average standard deviation
of the clotting time, σ, for the sets. The average across all shear rates (D=14) was σ
= 75 s. The average at specific shear rates was, for γ = 4000 s−1, σ = 30 s (D=2);
for γ = 7000 s−1, σ = 99 s (D=9); and for γ = 10000 s−1, σ = 34 s (D=3)).
To study the inter-trial variability, we measured how the blood clotting behavior
varies between successive trials with the same blood at the same shear rate, we ran 9
triplicate channel runs (T=9 sets) and computed the average standard deviation of
the clotting times for the sets. The average across all shear rates (T=9) was σ = 106
s. The average at specific shear rates was, for γ = 7000 s−1, σ = 155 s (T=3); for γ
= 10000 s−1, σ = 61 s (T=2); and for γ = 13000 s−1, σ = 91 s (T=4)). Since the
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intra- and inter-trial variability measured were similar, occlusion time measurements
across different trials and channels at common shear rates were comparable.
4.3 Conclusions
High shear rate platelet aggregation is central to the study of thrombosis. To study
the effects of shear rate, we developed a multi-channel optical in-vitro method to
simultaneously characterize changes in the times and volumes to platelet-based oc-
clusive thrombus formation in whole, label-free blood samples across multiple shear
rates over both the physiological to pathological range. The use of a laser to quantify
thrombosis in whole, label-free blood is faster and simpler than fractionation and mi-
croscopy techniques[60, 64, 103]. For example, mepacrine staining requires low shear
mixing and fluorescence imaging.
Our findings suggest that shear-dependent occlusion time from thrombosis is bi-
nary in untreated porcine blood samples, present above 4000 s−1 and not present
below 1500 s−1. We did not observe a statistically significant (p<0.05) difference in
the time to occlusion versus shear rate. Intra- and inter-trial variability were similar,
so occlusion time measurements across different trials and channels at common shear
rates are comparable. In contrast, the blood volumes required for flow to full occlusion
are significantly different (p<0.05), save the 7000 s−1 to 10000 s−1 comparison.
The laser optical system described should be scalable to tens to hundreds of chan-
nels whereas the conventional microscope and flow rate measurements, which yield
similar occlusion times are typically limited to single channels. Measurements of
occlusion from our optical system showed high correlation (r=0.94) compared with
more expensive and bulky white light microscopy methods, and it is potentially more
easily miniaturized.
Although the dimensions of the stenoses and channels used in the tests allowed
for thrombus to form via rapid platelet-platelet accumulation (vs. smaller channels
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which allow only small aggregates to form via a separate set of bonding events), there
were some design tradeoffs. One issue with the system noted during this study was
the large volume of blood required to occlude the channels (2-8 mL per channel, in
contrast to the 0.8 mL used by alternative methods [20]). However, such expenditure
of sample is specifically necessary for this set of studies, which requires not only
sufficient channel heights to observe rapid platelet accumulation, but also high flow
rates in order to obtain high shear rates.
Regarding a potential compliance mismatch between our PDMS flow channels and
arteries, several groups have previously shown that vessel compliance has a minor
effect on wall shear stress that would be dwarfed by the shear effect of thrombosis
narrowing the lumen [10, 104, 105, 106, 107]. Further, reported Youngs Moduli are
comparable (e.g., PDMS elasticity at pressures tested in this work = 0.38-0.75 MPa ,
human vessels elasticity at physiological blood pressure = 0.5-2 MPa [108, 109, 110]).
Endpoint detection of thrombosis using time to occlusion could be addressed using
either optical or flow-rate based detection methods, and results of time to occlusion
vs. shear rate were supported by previous research. Thus, it appears to be a useful
metric well suited for these studies. However, the correlation of this method with
microscopy data provides a fertile area for the addition of other metrics including
thrombus detachment, mentioned in Chapter 1 as an important testing criteria for
the ISTH, and is covered in experiments detailed in Chapter 5.
Future work will apply this microfluidic device and laser optical system to the clin-
ical characterization of patient blood clotting with and without anti-platelet agents at
varying shear rates, since these agents efficacy is suspected to be shear rate dependent.
We have presented a proof of concept for applying clinically derived pathological flow
conditions to whole blood samples in a microscope-free, high throughput, microscale
system. In contrast to current clinical platelet diagnostics including parallel plate
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assays and commercial devices [4], our system is able to examine platelet activity un-
der multiple, well-defined shear flow conditions simultaneously at volumes consistent
with typical clinical blood draws.
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CHAPTER V
EFFECTS OF SHEAR RATE AND ANTI-PLATELET
THERAPIES ON HUMAN BLOOD
This chapter describes the application of the multi-shear microfluidic system in label-
free, human whole blood samples treated with varying dosages and types of anti-
platelet agents. We first discuss the mechanism of anti-platelet agents and their
applications. Next, a survey of the effect of shear rate on untreated human blood is
presented and compared with the previously discussed porcine model. We then apply
the system to examine the simultaneous effects of shear rate and anti-platelet dosing
on human blood.
5.1 Experimental design
The pathology of myocardial infarction (heart attack) and cardiovascular accident
(stroke) is thrombosis, the formation of platelet aggregates, in the coronary or cerebral
vasculature. The mainstay of prevention for these events is the use of anti-platelet
drugs to block the mechanisms underlying platelet aggregation. However, providing
optimal drugs and dosages for patients therapy has been challenging, with estimates of
5-45% of patients misdiagnosed for the incorrect drug or dosage [20, 7]. Furthermore,
the process of platelet aggregation is complex, involving multiple overlapping chemical
mechanisms that are highly dependent upon blood flow conditions. Thus both local
flow conditions and choice of anti-platelet therapy have inter-related effects which can
dramatically affect patient outcomes, but has not been thoroughly characterized for
clinically relevant conditions.
Specifically, previous work has described three specific shear flow regimes and their
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associated mechanisms: “venous flow found in venules and veins (500-1000 s−1), pri-
marily governed by fibrinogen, coagulation factors, and the GPIIb/IIIa (also known
as integrin αIIbβ3); “arterial flow found in healthy arteries (1000 - 4000 s
−1), primarily
governed by GPIb, GPIIb/IIIa, and soluble agonists such as ADP; and “higher patho-
logic shear found in stenotic or obstructed arteries (4000 s−1 and above), primarily
governed vWF and GPIb [4, 13, 12]. Anti-platelet drug therapies have been developed
to disable specific targets of each of these aforementioned three mechanisms including:
GPIIb/IIIa inhibitors (eptifibatide, abciximab), soluble agonist inhibitors (clopido-
grel, acetylsalicylic acid), and anti-coagulants (heparin, citrate) [4]. A multi-shear
approach to screening anti-platelet efficacy could thus provide salient information on
shear-dependence to guide clinicians to choose appropriate drugs and dosages for pa-
tients with potential arterial pathologies, or to aid in the process of industrial drug
candidate screenings [4].
Recent work by Hosokawa et al. [111] has examined changes in platelet accu-
mulation due to both dosage and low shear rates (240, 600 s−1) within non-stenotic
channel geometries. While this work did examine changes in efficacy due to shear
rate and drug dosage, the shear range and channel geometries used were not relevant
to the intended therapeutic target of higher pathological shear rates in stenotic vas-
cular geometries. Commercial systems for platelet evaluation have shown the ability
to detect drug activity in-vitro. However, these systems operate at undefined shear
rates and non-physiological flow conditions including closed-volume mixing using a
stir bar or beads, flow through a membrane, or cone-and-plate mixing [20].
Thus most current methods for evaluating platelet thrombosis have not been ad-
dressed salient features including pathologically relevant stenotic flow [20, 112, 57], a
wide range of shear rates from venous to pathological [60, 113], continuous monitor-
ing of thrombus formation and detachment dynamics [4], and evaluation of advanced
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stages of thrombus development. As a result, multi-shear, patient-specific charac-
terization of drug efficacy has not yet been fully addressed. In previous work we
characterized our microfluidic system and demonstrated its efficacy on thrombus de-
tection in porcine blood samples [114]. In this work we report on the application of a
microfluidic system to evaluate and quantify the influences of both clinically relevant
drug dosage levels and a range of shear rates from venous to pathological levels on
platelet aggregation within stenotic single-pass flow channels.
We began this study by validating the coating of the inner channel surfaces with
fibrillar collagen to initiate thrombus formation. Next, we applied the system to eval-
uate the shear-induced effects of two different drug models, GPIIb/IIIa inhibitors and
soluble agonists, in preventing advanced stages of platelet aggregation. Consistent
with literature, effects of GPIIb/IIIa inhibitors were greatly reduced at pathologically
high shear rates [115]. Experiments with acetyl-salicylic acid (ASA) show that ther-
apy is most effective at inhibiting platelet function under physiological levels of shear
500 and 1500 s−1. In contrast, at high shear rates there were no significant changes
in occlusion times, in agreement with findings by clinicians and other researchers.
Although thrombi grew as normal, the main effect of ASA appeared to be a destabi-
lizing one since ASA-treated blood showed nearly 70 % more fragmenting or embolic
effects at after treatment vs. untreated controls.
5.2 Methods
The design and construction of the microfluidic chips and associated hardware used
to characterize thrombosis have been described previously [114]. Briefly, devices were
designed and validated to simultaneously address shear rates of 500, 1500, 4000,
and 10000 s−1 using finite volume fluid modelling and experimental flow rate test-
ing. Device molds were fabricated from micromilled aluminum, and molded using
poly-dimethylsiloxane (PDMS) and bonded to coverglass via surface plasma bonding
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(Harrick Plasma) to form enclosed flow channels.
5.2.1 Collagen surface adsorption
The use of fibrillar equine collagen (in contrast to the acid-soluble collagen used
in Chapter 4 on porcine blood) had a pronounced effect on promoting thrombotic
occlusion. In initial tests using devices with acid-soluble collagen, 14% of trials at
1500 s−1, 41% of trials at 4000 s−1, and 48% of trials at 10000 s−1 reached occlusion
with 60 mL of sample (N=55 trials runs for each shear rate). Channel runs which did
occlude required volumes of 11, 17, and 19 mL (respectively), on average (Fig. 33).
In order to initiate platelet adhesion, these enclosed channels were filled with fibrillar
equine collagen (Chronolog Corp) at a concentration of approximately 100 µg/mL.
In contrast, using devices with fibrillar equine collagen yielded 68% of trials
(N=20) at 500 s−1, 71% of trials (N=29) at 1500 s−1, 95% of trials (N=29) at 4000
s−1, and 96% of trials (N=29) at 10000 s−1 reaching occlusion with the same 60 mL
of sample. Requisite sample volume was also reduced, with occluded channel runs
requiring 2.4, 4.4, 5.1, and 5.4 mL, respectively.
To determine whether this discrepancy in the percent of channel runs occluded un-
der varying types of collagen was due to a deficiency in the adsorption of each collagen
type (fibrillar or acid-soluble) to the device’s surfaces, or whether it was due to the
structure of the collagen itself, we examined the structure of each collagen type and
its surface adsorption properties. Surfaces were characterized using both histological
staining with Picrosirius Red and brightfield microscopy and collagen structures more
closely examined using atomic force microscopy (AFM), both common methods for
collagen characterization [116, 85, 63, 117, 118]. We characterized adsorption of both
types of collagen onto coverglass by incubating glass slides with 30 µL of collagen
solution in a humidified, covered petri dish overnight, after which they were gently
rinsed with 1 mL of irrigated saline solution to remove excess collagen and to emulate
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Figure 33: The use of fibrillar equine collagen (a) in contrast to the acid-soluble
collagen (b) used in Chapter 4 showed a significantly higher percentage of occluded
samples from human subjects at both high and low shear rates (57% increase at 1500
s−1, 54% increase at 4000 s−1, and 47% increase at 10000 s−1). In contrast to human
subjects’ relative insensitivity to acid-soluble collagen, porcine blood (c) showed a
high percentage of occlusion, suggesting comparatively enhanced sensitivity to shear
induced platelet activity.
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the priming process used in our devices.
We first characterized acid-soluble collagen. Staining and brightfield microscopy
results showed that acid-soluble collagen had indeed adhered in a dense layer to
the glass substrate of the device. Images and analysis from AFM data showed the
structure of these collagen molecules were rounded globules of approximately 500 nm
in diameter and 6-10 nm in height (Fig. 34).
Next, we characterized the fibrillar collagen, this time examining its adsorption
onto two different types of substrates, glass and PDMS. Although collagen adsorption
to glass has been well documented by other groups, adsorption to PDMS has not been
well characterized. To examine the adsorption of collagen on each of these surfaces,
slides were prepared by pipetting 30 µL of collagen solution onto a glass coated slide
and a glass slide spin-coated in PDMS (200 µL of freshly mixed 1:10 PDMS spun
at 1500 rpm for 60 seconds) and cured as normal. Afterwards, they were incubated
overnight with collagen, after which they were rinsed with saline in the same process
as the coverglass described previously.
Results from staining and brightfield microscopy revealed that fibrillar collagen
did absorb to the surface of the coverglass, although the resultant layer was not as
dense as that of the acid-soluble collagen (Fig. 35). We observed that while collagen
did absorb in noticeable amounts to the inner PDMS surfaces of the device, the
concentration was qualitatively much less than that of the glass surface (Fig. 35).
The structure of the fibrillar collagen was also much different, with fibrils varying
widely in length (20-50 µm), and diameter (0.025-1 µm).
In comparison to the surface imaging of the acid-soluble collagen shown in Fig.
34, it was clear that although the latter formed a denser layer of molecules on the
surface, they were still unable to capture more platelets. Thus it appeared to be
the structure and/or composition fundamental to the collagen type which made the
fibrillar collagen a more adhesive molecule for platelets. Thus the order of surface
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Figure 34: Surface adsorbed acid-soluble collagen onto glass surfaces. Brightfield
microscopy of Picrosirius Red staining shows dense adsorption of acid-soluble colla-
gen to coverglass. Individual acid soluble monomers are visible under Atomic Force
Microscopy (AFM) in x-y place imaging, and surface traces along the red line in the
middle image reveal rounded globular structures of approximately 500 nm in diameter
and 6-10 nm in height (bottom). This step confirmed that our surfaces were coated
with collagen, despite the lack of consistent platelet adhesion to these surfaces.
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Figure 35: Surface adsorbed fibrillar collagen onto glass (a) and poly-dimethyl silox-
ane (PDMS) (b) surfaces. Brightfield microscopy of Picrosirius Red staining shows
dense adhesion of collagen molecules on glass in comparison to PDMS surfaces. Im-
ages and analysis from AFM data shows Collagen fibrils visible in the x-y planes of
both PDMS and glass surfaces under AFM and were probed along the red line of
each sample to examine fibril heights. Height data show much shorter fibrils present
on PDMS surfaces, as well as its surface imperfections. Glass shows superior collagen
adhesion to PDMS, although an appreciable amount does appear on the latter.
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adhesive properties from most adhesive to least adhesive for platelet binding can be
ranked as: fibrillar collagen on glass, fibrillar collagen on PDMS, acid-soluble collagen
on glass, acid-soluble collagen on PDMS.
This finding has been supported by recent work by Bernardo et. al, who provides
evidence that this may be due to the presence of substantial amounts of vWF in the
equine collagen, but not in acid soluble collagen [85]. Despite this report, it is notable
that other recent research in this area has been conducting using microfluidic surfaces
coated with the acid-soluble form of collagen used in Chapter 4 of this study after a
similar AFM-based structural characterization [63].
Due to the increased efficiency of thrombosis and the wide commercial use of
fibrillar collagen in contrast to acid-soluble collagen, the remainder of this work will
show and discuss results using a fibrillar collagen model.
5.2.2 Device preparation and sample handling
Before use, each device was primed with a saline solution to prevent non-specific
adsorption and to remove air bubbles. Blood samples were collected from N=9
healthy adults (6 males, 3 females; mean age 24 ± 5 years) who self-reported no
anti-thrombotic or anti-coagulant drug use at the time of testing. Samples were
collected in accordance with protocol H10090 approved by the Georgia institute of
Technology Institutional Review Board. Blood was drawn through a 21 gauge needle
into 60 mL syringes pre-filled with 3 Units/mL of un-fractionated heparin (Elkins-
Sinn Inc, Cherry Hill, NJ) and used within five hours of collection. A small additional
2 mL aliquot was drawn to perform a cell count (Cell-Dyn Ruby, Abbott Diagnos-
tics, Abbott Park, IL), which provided data on the number of platelets, platelet
volume, hematocrit, white blood cell count, hemoglobin concentration, red blood cell
count, and mean corpuscular volume. Samples with abnormally low platelet count
(<150×10e3/µL) or hematocrit (< 30 %) were excluded from the study. In contrast
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Figure 36: Flowchart for experimental method of anti-platelet agent testing on hu-
man blood. Blood samples were drawn into 60 mL aliquots and anti-coagulated with
3 Units/mL of heparin. An additional 2mL aliquot of blood was used for a complete
blood count, and samples were checked for abnormal platelet count, platelet volume,
or hematocrit. Experimental aliquots were treated with varying concentrations of
anti-platelet agents (eptifibatide, ASA, or additional heparin), while control aliquots
were treated with equal volumes of saline solution. Control and experimental samples
were evaluated using a commercial platelet analyzer and our microfluidic system)
to citrate, the use of heparin does not require the addition of non-physiological adeno-
sine diphosphate (ADP) to activate platelets in order to form white thrombus, both
of which have been found by others to interfere with the function of eptifibatide.
Eptifibatide (Integrilin, Millennium Pharmaceuticals, South San Francisco, CA),
unfractionated heparin, or ASA (MP Biomedical, Santa Ana, CA) were added within
twenty minutes of sample collection into 60 mL sample aliquots. Eptifibatide was
added in concentrations of 0, 0.24, 0.48, 0.72, and 2.4 µM. These concentrations
were chosen such that the highest concentration corresponded to the clinically rec-
ommended dose for an adult human (a 250 µg/kg body mass bolus dose, assuming
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average body mass of 70 kg and blood volume of 5 L), ASA (0.36, 1, 2mM), and
heparin (3.5, 8, 20 Unit/mL). Due to the short life of ASA in solution, aliquots were
prepared immediately before addition to the sample by dissolving 100 mg/mL into
dimethyl-sulfoxide (DMSO) (Sigma Chemical, St. Louis, MO) and then diluted into
saline to the appropriate concentrations before addition into blood samples, a tech-
nique employed by others [119]. Drug concentrations were chosen to reflect clinical
recommendations and practice. Saline was added to control aliquots in equivalent
volumes to drug dosages (0.526 mL). Each added dosage constituted less than 1% of
the total aliquot volume to limit reductions in viscosity and hematocrit to 1.23% and
1.67%, respectively.
Flow was driven by pressure head of 1400 Pa and kept constant by a custom-built
automated system consisting of a laser diode and photo-diode for detection of the
fluid level and a linear actuator to keep the syringe at the correct height. For both
eptifibatide and ASA, we applied our microfluidic system to evaluate thrombosis for
shear rates from venous to pathological flow conditions. For each treated or untreated
60 mL sample aliquot, four shear rates were run simultaneously within a single trial
while platelet aggregation to occlusion was measured by the four weighing scales at
the outlet of each channel (Ohaus, Parsipanny, NJ) and acquired and processed using
Labview (National Instruments, Austin, TX) and Matlab (Mathworks, Natick, MA),
respectively.
A trial is defined as a single experiment with one new microfluidic device com-
prising four channel runs, each of a different shear rate. Our previous studies have
shown good agreement on thrombosis detection between these flow rate measures and
microscopy [114]. Occlusion times, tocclusion, were measured as the time at which the
flow rate as a function of time, Q(t), fell below 0.001 mL/s as measured over a 10
second time window. Tests were considered non-occluded if the 60 mL sample was
exhausted during the course of the test or if occlusion did not occur in less than one
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hour. Embolization events were defined by the occlusion of flow (Q<0.001 mL/s),
followed by a resumption of flow (Q>0.001 mL/s) measured over a 10 second time
window (see Fig.25).
Parallel measurements of platelet activity was measured using the commercially
available Whole Blood Analyzer (Chronolog Corporation, Havertown, PA) according
to manufacturer instructions. As described in Chapter 1, the machine is composed
of a pair of electrodes, a stirring element, and a heating element. A 500 µL blood
sample is added to an equal amount of saline, an electrode, and a small stir bar in
a cuvette, and warmed for approximately five minutes at 37◦C. The sample is then
ready to be placed in the testing chamber, which has a rotating magnet that will spin
the stir bar in the cuvette. The test will be able to begin when the electrode has
been able to establish a consistent baseline. At that point, a chosen agonist is added
to the cuvette, and the stir bar both distributes the agonist throughout the sample,
and also provides a local shearing force on the blood. Activated platelets then adhere
to the electrode, and the impedance will rise in accordance with the coverage of the
electrode by platelets in the sample. The machine has three primary outputs used to
describe its measurements of impedance due to platelet adhesion over time: lag time
(the time period before impedance passes 2 Ohms), amplitude (the maximum change
in impedance over the timecourse of the trial), and area under the curve (the integral
of the impedance over time) also called the ”AUC”. In this work, sample activity was
induced using 4 µL of collagen and/or Arachidonic Acid and a stirring rate of 1200
rpm, after which they were evaluated over six minutes.
5.2.3 Analysis
In order to depict both the frequency of occlusion and occlusion times, data is rep-
resented by 1/tocclusion. Thus as occlusion times are prolonged, 1/tocclusion decreases
until reaching zero, which represents a non-occlusion event. Error bars in this chapter
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Figure 37: Experimental data obtained from the Whole Blood Analyzer (Chronolog
Corporation). A 500 µL blood sample is added to an equal amount of saline, an elec-
trode, and a small stir bar in a cuvette, and warmed for approximately five minutes
at 37◦C. Agonist activated platelets adhere to the electrode, and the impedance will
rise in accordance with the coverage of the electrode by platelets in the sample. The
machine has three primary outputs used to describe its measurements of impedance
due to platelet adhesion over time: lag time (the time period before impedance passes
2 Ohms), amplitude (the maximum change in impedance over the timecourse of the
trial), and area under the curve (the integral of the impedance over time) also called
the ”AUC”. Here data is shown for a subject with untreated blood where the cal-
culated lag time is 53 seconds, the amplitude is 16 Ohms, and the Area Under the
Curve is 54.
108
is indicated as standard error of the mean since these measurements are intended to
describe the variation of population values, not of individuals from each-other. Sta-
tistical analysis of results was performed using the SAS software package and Matlab.
Matlab was used to calculate basic comparative statistics including student’s t-test
and standard error/standard deviation values.
SAS was used to construct and analyze a Cox proportional hazards model, which
was performed for both drug models. This analysis format was chosen for its ability
to analyze the weights of multiple, continuous variables (shear rate, dosage, donor)
to predict the probability of an event (thrombotic occlusion) and its time to reach
the event. The model is described by Equation 11, where β is the relative weight of
each of the multiple variables, ”clot” is the binary event describing whether occlusion
occurs (1) or not (0), and tocclusion is a continuous numerical value. The format
was also chosen due to its similarity to the Kaplan-Meier analysis method used in the
GRAVITAS clinical study, which evaluated the VerifyNow Platelet Function Analyzer
[38], and was the intended method in early phases of the study prior to its release [120].
Within the Cox survival model, independent variables were identified as significant
by Chi-square statistics were used to calculate p-values under a predetermined alpha
level of significance α = 0.05, which was then used to calculate independent variable
significance where p<0.05 was considered significant.
tocclusion ∗ clot = β1 + β2 ∗ shear + β3 ∗ dosage (11)
Lag time and Rapid Platelet Accumulation (RPA) growth were calculated using
the following method. Flow rate data was used to estimate the thrombus volume,
where 48% of the initial flow rate at each given shear rate as calculated in Chapter 2
was used as the point at which the thrombus reached 48% the volume of the stenosis
region, for comparison and consistency with Para et. al. [73]. Lag time was measured
as the time at which thrombus reached this same 48% (Equations 13, 12). While this
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calculated lag time occurs later than the 19% shown in the same work by Para, it was
consistent and easily detectable for these experiments, although such post-analysis
would be possible with more attention to data filtering algorithms.
0.48 ∗Q(t = 0) = Q(t = tlag time) (12)
RPA growth = 0.48 ∗ (Vstenosis)/(tfinal − tlag time) (13)
Lower shear rates 500 and 1500 s−1 were difficult to study due to the resolution
limit ( 0.3 µL/s) of the scales at such low flow rates (0.5 to 5 µL/s). Further studies
might be able to approximate thrombus growth rates similar to previous findings in
units of volume/surface*time using more advanced image processing including surface
area and edge detection methods which could be applied to microscopy images or
intensity readings.
5.3 Results and discussion
To study the effects of these anti-platelet agents on platelet activity at varying shear
rates, we first examined the effects of shear rate on untreated human blood on intra-
subject and inter-subject occlusion times and volumes in our microfluidic system.
These results were compared with porcine results previously discussed in Chapter
4. Next, we examined the dose-response of anti-platelet agents on clotting times
and volumes at varying shear rates. Our results with varying shear rates were then
compared with results from a commercial platelet function analyzer.
5.3.1 Effects of shear rate on untreated human blood
We first characterized the variations in our assay by examining intra-sample variation
in human samples. Intra-patient 1/tocclusion (mean ± SEM) were (5.1± 1.2)× 10−4 at
500 s−1, (4.1±1.4)×10−4 at 1500 s−1, (16±0.1)×10−4 at 4000 s−1, and (24±2.1)×10−4
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Figure 38: Intra-subject variation in 1/tocclusion responses were evaluated in N=5 tri-
als of a single subject over different days and blood draws in control trials. 1/tocclusion
varied from 0.9 to 2.1 ×10−4 for the tested shear rates of 500, 1500, 4000, and 10000
s−1.
at 10000 s−1 (N=5 for all shear rates). The average SEM for all tested shear rates
was 1.36 × 10−4. Due to the nature of previous porcine sample acquisition data for
intra-sample variation was not available for comparison.
Next, we examined shear-induced variations in 1/tocclusion within samples from
multiple subjects (N=9) tested at varying shear rates. Results pooled from this
subject group showed 1/tocclusion (mean ± SEM) of (4.8 ± 1.6) × 10−4 at 500 s−1,
(3.9± 0.1)× 10−4 at 1500 s−1, (16± 2.4)× 10−4 at 4000 s−1, and (24± 1.9)× 10−4 at
10000 s−1 (N=9 for all shear rates). The average SEM for all tested shear rates was
1.7×10−4, 25% greater than the measured intra-patient variation.
Similar to results from the porcine model, occlusion times at physiological shear
rates tested (500, 1500 s−1) did not differ significantly from eachother (p>0.1). Re-
sults from the previous porcine data (Chapter 4) quantified using 1/tocclusion (mean
± SEM) showed (25± 3.0)× 10−4 at 4000 s−1 (N=8), (24± 2.5)× 10−4 at 7000 s−1
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Figure 39: Comparison of 1/tocclusion in human vs. porcine blood samples. For both
sample types, occlusion times at physiological shear rates tested (500, 1500 s−1) did
not differ significantly from eachother (p>0.1). In contrast to the porcine model,
higher shear rates did show significantly different
(N=26), (28±2.2)×10−4 at 10000 s−1 (N=14), (28±2.0)×10−4 at 13000 s−1 (N=20).
The average SEM for all tested shear rates in porcine samples was 2.5 ×10−4.
While porcine samples showed no significant differences between its high and low
shear occlusion times, higher shear rates did show significantly faster occlusion times
(p>0.05) in human samples. Values for ratio of occluded channels (Fig. 33) were
nearly identical at 0.95 for 4000 and 10000 s−1. However, platelet activity was higher
in porcine samples at high shear rates (4000 and 10000 s−1) than in human samples,
reflected elevated 1/tocclusion values. Additionally, values for SEM in 1/tocclusion val-
ues were 1.5 fold higher in porcine blood than human, showing greater variation in
occlusion for porcine samples than human samples.
We next examined RPA growth and lag time. This work estimates rapid platelet
accumulation (RPA) growth from 0.47 to 50 (cm3 ∗ 10−6/s), mean value of 14±1.1
(cm3∗10−6/s) for N=72 samples over all tested initial wall shear rates 500, 1500, 4000,
10000 s−1. These values are similar to the range of RPA growth values determined in
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Figure 40: RPA growth and lag time measurements for untreated human blood
samples. This work estimates rapid platelet accumulation (RPA) growth from 0.47
to 50 (cm3 ∗ 10−6/s), mean value of 14±1.1 (cm3 ∗ 10−6/s) for N=72 samples over
all tested initial wall shear rates 500, 1500, 4000, 10000 s−1. These values are similar
to the range of RPA growth values determined in previous work by Para and Bark
as 20±4.5. Lag times ranged from 144 to 2668 seconds, mean value of 803±77 for
N=72. Higher shear rates (4000, 10000 s−1) were 365±37 s (N=36).
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previous work by Para and Bark as 20±4.5 (cm3 ∗ 10−6/s) within stenoses of 70-83
% and initial wall shear rate values near 5000 s−1 [73, 59, 5]. Lower shear rates 500
and 1500 s−1 showed larger standard deviations in lag time and RPA growth results
due to the resolution limit ( 0.3 µL/s) of the scales at such low flow rates (0.5 to 5
µL/s).
Lag time values determined at the higher shear rates (4000, 10000 s−1) were
365±37 s (N=36), similar to the activation time of near 100 s determined by Hellums,
and the 100-200 s range determined by Bark and Para [5]. Since these lag times are
calculated in a different method than both authors, such levels of error are expected.
Also, our lag time measured growth until 48% volumetric growth, which may be
considered beyond initial lag by some definitions which define it as 20% [73].
Also similar to the results of Bark and Para, this work notes lag times inversely
proportional to shear rate, shown in Fig 40 measurements of shear vs. lag time.
Statistical analysis showed significant (p<0.001) differences between lag times at all
shear rates except for the lowest shear rates (500, 1500 s−1).
After characterizing intra-patient and inter-patient variation of untreated human
samples, and comparing our results with previous porcine data, we next examined
the effects of treating human samples with anti-platelet agents.
5.3.2 Effects of eptifibatide and shear rate on human blood
We first characterized the effects of the anti-platelet injectable drug eptifibatide (Inte-
grilin). The drug was added in-vitro at concentrations of 0.24, 0.48, 0.72, and 2.4 µM
to construct dose-response curves for N=5 different subjects’ blood samples, shown
in Fig. 41.
Dose-response behavior varied throughout patients, with maximum response val-
ues for 1/tocclusion at the highest shear rate (10000 s
−1 ) ranging from 0.0013 to 0.0032
s−1. Drug sensitivity varied as well with subjects showing non-occlusion at a dosage
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range of 0.72 to 1.2µM, half the manufacturer recommended clinical dosage of 180
µg/kg per patient (or 2.4 µM in whole blood).
Notably, each of these tested subjects show reduced drug sensitivity at the highest
shear rate of 10000 s−1 in comparison to lower shear rates 500, 1500, and 4000 s−1,
although their individual thresholds for loss of activity vary.
Results from dose-response curves pooled from all N=5 subjects showed decreases
in platelet activity with increasing doses of eptifibatide, reflected in the decreasing
values of 1/tocclusion and increasing error values due to differences in inter-subject drug
sensitivity shown in Fig. 41.
While samples subjected to physiological shear rates of 500 and 1500 s−1 ceased
to show platelet activity at drug dosages of 0.48 and 0.72 µM , respectively, higher
shear rates of 4000 and 10000 s−1 required dosages of 1.2 µM or higher to completely
inhibit platelet activity. As with the results from untreated human subjects, all shear
rates were shown to be statistically different (p<0.001) from each other using Cox
survival analysis, save for 500 s−1 and 1500 s−1.
In addition to dose-response curves of constant shear rate, the data can also be
visualized by shear-response curves of constant dosage (Fig. 43). Here we can see that
shear-response decreases proportionally with increasing dosages until the application
of dosages above 0.72 µM.
We next examined RPA growth and lag times vs. eptifibatide dosage. Lag times
at mid range shear 4000 s−1 increased significantly (p<0.01) in lag time by 4.15X,
although this result is confounded by non-occluded trials. In contrast, high shear
10000 s−1 lag times were not significantly different (p>0.1) with increasing dosages
in trials which did occlude, until occlusion was lost in all trials at 1.2 µM. A possible
explanation for sudden transition is that the initial binding of platelets at high shear
is mediated primarily by vWF-GPIb, not the GPIIb/IIIa platelet cohesion mechanism
affected by eptifibatide [17], which could slow or inhibit occlusion but not delay the
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Figure 41: Eptifibatide dose-response curves of varying shear rates in N=5 human
subjects. Platelet response is defined by 1/tocclusion, where tocclusion is the time at which
platelet thrombus occludes the stenosis. All subjects show reduced drug sensitivity
at the highest shear rate of 10000 s−1 in comparison to lower shear rates 500, 1500,
and 4000 s−1
116
Figure 42: Eptifibatide dose-response curves of varying shear rates pooled from N=5
human subjects. Platelet response is defined by 1/tocclusion, where tocclusion is the time
at which platelet thrombus occludes the stenosis. At physiological shear rates of 500
and 1500 s−1, occlusion is eliminated at dosages of 0.48 and 0.72, respectively, while
dosages of 1.2 µM or higher are required to eliminate occlusion at high shear rates
of 4000 and 10000 s−1. As with the results from untreated human subjects, all shear
rates were shown to be statistically different (p<0.001) from each other using Cox
survival analysis, save for 500s−1 and 1500 s−1.
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Figure 43: Eptifibatide shear-response curves for varying dosage concentrations
pooled from N=5 human subjects. Increasing dosages appears to reduce the 1/tocclusion
by similar proportional amounts at all tested shear rates until approaching the effec-
tive concentration range of 0.96 to 1.2 µM.
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Figure 44: Raw occlusion times, tocclusion, for varying shear rates and concentrations
of eptifibatide. Unlike the 1/tocclusion metric used in the previous Fig 50, this metric is
more intuitively understandable for the reader. However, it does not account for non-
occlusion events and thus shows very small sampling N for some points, in contrast
to the previous figure which is able to provide means and standard error amounts for
five samples per point. No occlusion times are available at dosages greater than 1.2
µM, since channels did not occlude.
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onset of thrombosis. RPA growth decreased consistently over increasing dosages in
channels which did occlude for all shear rates.
We next determined the volume of sample required to produce occlusion. Unlike
occlusion times, occlusion volumes Vocclusion were not significantly different at higher
shear rates of 4000 and 10000 s−1, although higher eptifibatide dosages required pro-
gressively higher sample volumes at all tested shear rates. These results contrast with
our previous findings on porcine blood, whose occlusion times did not vary signifi-
cantly at high shear rates, but did show increasing occlusion volumes with increasing
shear rates (Fig. 31). Occlusion times for samples which did occlude are shown in Fig.
44, although it should be noted that this method does not account for non-occluded
samples.
Thrombus detachment events provide a measure for the stability of platelet ag-
gregates formed. Under increasing dosages of eptifibatide, thrombi formed at high
shear rates did embolize by more than 20 % when compared with controls, indicating
that the thrombi which were able to form were weakened by the inactivation of the
GPIIb/IIIa receptor.
Thus we characterized platelet activity in our microfluidic system using metrics
of 1/tocclusion, 1/Vocclusion, and the ratio of thrombus detachment events. Next, we
compared these performance metrics with a commercial system, the Chronolog Whole
Blood Analyzer (WBA).
The WBA measures platelet activity by the changes in electrical impedance in-
duced by platelets adhering to the surface of an electrode. The electrode is submerged
in a sample of constantly stirred whole blood and measures changes of impedance over
time after the addition of agonist. Thus, resulting metrics of platelet activity dur-
ing a standard (6 minute duration) test are the amplitude (the maximum change in
impedance), area under the curve (integral of area under the change in impedance
curve), and the lag time (time until impedance begins to rise above the initial zero
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Figure 45: Lag times and RPA growth vs. eptifibatide dosage in human blood. Lag
times at mid range shear 4000 s was significantly (p<0.01) affected by increases in
eptifibatide dosage, until occlusion ceased at 1.2 µM. In contrast, high shear 10000
s−1 lag times were not significantly different (p>0.1) with increasing dosages in tri-
als which did occlude, until occlusion was lost in all trials at 1.2 µM. RPA growth
decreased consistently over increasing dosages in channels which did occlude for all
shear rates.
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Figure 46: Eptifibatide dose-response curves for varying dosage concentrations
pooled from N=5 human subjects. Unlike occlusion times, occlusion volumes Vocclusion
were not significantly different at higher shear rates of 4000 and 10000 s−1, although
higher eptifibatide dosages required progressively higher sample volumes at all tested
shear rates.
Figure 47: Effects of eptifibatide on the stability of occlusive thrombi. Under in-
creasing dosages of eptifibatide, occlusive thrombi which were able to form at high
shear rates did detach (embolize) by more than 20 % when compared with controls
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Figure 48: Dose-response measurements using the Chronolog Whole Blood Analyzer
showed detectable differences in Amplitude, Area Under the Curve (AUC), and lag
time until reaching a concentration of 0.5 µM, after which response did not change
significantly for increased dosages. Both methods showed significant differences in re-
spective thrombosis metrics (1/V occlusion and Area Under the Curve) at the clinical
dosage of 0.24 µM.
baseline). Results showed similar dose-response capabilities between these three met-
rics which detected eptifibatide concentrations up to 0.5 µM until responses did not
change significantly.
Comparison of the WBA performance with the shear curves produced in our
system showed significant (p<0.05) reductions in platelet function metrics after the
addition of eptifibatide, although the thresholds for dosage sensitivity were different.
The commercial WBA did not show significant differences in successive readings
following 0.5 µM, thus this was determined as its sensitivity threshold. In contrast,
our microfluidic method ceased to show significant differences after 1.2 µM at the
higher shear rates (4000, 10000 s−1), and 0.72 µM at the lower shear rates (500,
1500 s−1). Both methods showed significant differences in respective thrombosis
metrics (1/Vocclusion and Area Under the Curve) at the clinical dosage of 0.24 µM, a
capability which has been validated in clinical trials of the WBA [20]. While we did
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not anticipate identical results to the WBA, this procedure confirmed that we were
able to show significant differences due to the application of the drug within a similar
order of magnitude for dosage. Since the clinical utility of the WBA for determining
dosage efficacy has not yet been determined, we cannot yet assess the importance of
this difference in threshold [20, 25].
Clinical implications : Results from this study showed statistically significant dif-
ferences (p<0.001) between all shear rates (save the lower shear rates 500, 1500 s−1),
as well as between eptifibatide dosages. Our system also provides clinical implications
that higher dosages of this therapeutic may be necessary in patients with existing car-
diovascular pathologies such as atherosclerosis, which induce high local shear rates
similar to the 10000 s−1 condition shown in this work. These findings that both dosage
and shear have significant effects on our occlusive thrombosis are important because
dosage is usually thought of as the main determinant of efficacy, while this model
shows that both have significant effects for a large range of values. The system thus
shows potential for creating more precise models for dosing patients with eptifibatide
and other GPIIb/IIIa inhibitors. Such a prospect is particularly compelling due to
the serious bleeding complications inherent in overdosing with this class of platelet
therapies.
Comparison with the WBA show that our device performs at least to the standard
of current commercial devices, as our device has shown both detection of clinically
recommended dosages, and a similar sensitivity limit. The latter is expected, since
clinically relevant sensitivity limits and their implications for treatment have not yet
been defined.
5.3.3 Effects of acetylsalicylic acid and shear rate on human blood
After characterizing the direct GPIIb/IIIa receptor inhibitor anti-platelet agent, epti-
fibatide, we next examined a the effects of acetylsalicylic Acid (ASA) a class of drugs
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which prevents the release of soluble factors.
We characterized the effects of in-vitro addition of ASA at concentrations of 0,
0.36, 1.0, and 2.0 µM to construct dose-response curves for N=5 different subjects’
blood samples (Fig. 49). The pool of human subjects in this study used 3/5 of the
same subjects from the previous eptifibatide trials, while 2/5 subjects were different.
Dose-response behavior varied throughout subjects, with maximum response val-
ues for 1/tocclusion at the highest shear rate (10000 s
−1 ) ranging from 48 ×10−4 in Sub-
ject 4 to 28×10−4 in Subject 1, representing an overall difference of 16×10−4, more
than one standard deviation above other subjects. Drug sensitivity varied slightly
with subjects showing loss of occlusive thrombus formation only at lower shear rates
(500 and 1500 s−1) for dosage concentrations of 0.36 to 1 mM. Unlike eptifibatide ex-
periments, no dosage tested was able to completely eliminate occlusion at high shear
rates, despite the use of much higher ASA concentrations than clinically prescribed
(1 and 2 mM concentrations are 10-20X the recommended daily dosage of aspirin,
respectively).
Results from dose-response curves pooled from these N=5 subjects showed similar
SEM values in subjects’ responses at all tested concentrations of ASA, in contrast to
increasing SEM values with increasing dosages of eptifibatide shown in the previous
subsection (Fig. 42). High shear rates 4000 and 10000 s−1 showed non-significant
(p>0.05) decreases in 1/tocclusion responses with increasing doses of eptifibatide using
a student’s t-test.
Similar to untreated human tests and eptifibatide tests, there was no signifi-
cant difference in response values between the two lower shear rates at all measured
dosages, although all other combinations of shear rates were significant (p<0.001)
according to Cox survival analysis.
We next examined RPA growth and lag times vs. ASA dosage. Measurements
of both Lag time and RPA growth at mid-to-high shear rates 4000 and 10000 s−1
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Figure 49: ASA dose-response curves of varying shear rates in N=5 human subjects.
Platelet response is defined by 1/tocclusion, where tocclusion is the time at which platelet
thrombus occludes the stenosis. Addition of ASA appeared to eliminate occlusive
thrombosis only at physiological shear rates of 500 and 1500 s−1, but was unable to
prevent occlusion at high shear rates of 4000 and 10000 s−1 despite the use of high
concentrations of up to 20X recommended daily values.
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Figure 50: ASA dose-response curves of varying shear rates pooled from N=5 human
subjects. Platelet response is defined by 1/tocclusion, where tocclusion is the time at which
platelet thrombus occludes the stenosis. At physiological shear rates of 500 and 1500
s−1, occlusion is eliminated at dosages between 0.36 and 1 mM. In contrast, none of
the tested dosages were able to prevent or even significantly (p>0.05) affect 1/tocclusion
at high shear rates of 4000 and 10000 s−1. Similar to eptifibatide results, Cox survival
analysis showed all shear rate curves were significantly (p<0.001) different from one-
another, save for the 500 to 1500 s−1 comparison.
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Figure 51: Raw occlusion times, tocclusion, for varying shear rates and concentrations
of ASA. Unlike the 1/tocclusion metric used in the previous Fig 50, this metric is more
intuitively understandable for the reader. However, it does not account for non-
occlusion events and thus shows very small sampling N for some points, in contrast
to the previous figure which is able to provide means and standard error amounts for
five samples per point.
were not significantly (p>0.1) different in either lag time or in RPA growth. Again,
apparent changes in RPA growth and Lag time were confounded by reduced numbers
of occluded trials, and thus fewer data points. Although the timescale of activation
is similar to lag times found in this work (as with Hellums and Bark) [121, 5], the
addition of ASA, an anti-platelet agent which should block platelet activation, did
not appear to significantly affect lag times at high shear rates 4000 and 10000 s−1,
indicating that platelet activation might not be the operative mechanism as such high
shear levels. This finding is in agreement with theories on high shear platelet binding
from others [17].
As with eptifibatide, we also measured platelet response by 1/Vocclusion, where
Vocclusion is the sample blood volume required to occlude flow (Fig. 53). Unlike
eptifibatide results, occlusion volumes, 1/Vocclusion at higher shear rates of 4000 and
10000 s−1 were not significantly different (p>0.05), nor did their values change over
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Figure 52: We next examined RPA growth and lag times vs. ASA dosage. Mea-
surements of both Lag time (a) and RPA growth (b) at mid-to-high shear rates 4000
and 10000 s−1 were not significantly (p>0.1) different in either lag time or in RPA
growth. Again, apparent changes in RPA growth and lag time were confounded by
reduced numbers of occluded trials, and thus fewer data points.
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Figure 53: ASA dose-response curves for varying dosage concentrations pooled
from N=5 human subjects. Platelet response here is measured by 1/Vocclusion, where
Vocclusion is the sample blood volume required to occlude flow. At high shear rates
of 4000 and 10000 s−1, 1/Vocclusion values did not differ from eachother nor change in
value significantly for all tested ASA concentrations of 0 to 2 mM
all concentrations. Similar to eptifibatide, the lowest tested venous shear rate of
500−1 showed the largest variation in 1/Vocclusion values. Also similar to eptifibatide
results, Cox survival analysis showed all shear rate curves were significantly (p<0.001)
different from one-another, save the 500 to 1500 s−1 comparison.
Thus ASA did not appear to affect the formation of occlusive thrombi. However,
did it affect the formed occlusive thrombus? To answer this question, we again exam-
ined the Ratio of Embolization, defined as (# trials with thrombus detachment)/(#
total trials). (Fig. 54).
Controls in both the previous eptifibatide study and this ASA study showed em-
bolization of 13% and 14%, respectively. However, as ASA concentrations increased,
embolization increased dramatically and nearly all samples embolized. Furthermore,
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Figure 54: Ratio of Embolization, defined by (# trials with at least one thrombus
detachment)/(# total trials). Controls in both the previous eptifibatide study and
this ASA study showed embolization of 13% and 14%, respectively. However, as ASA
concentrations increased, embolization increased dramatically and nearly all samples
embolized.
all of the 3/5 subjects from the previous eptifibatide study showed the same or in-
creased numbers of emboli formed in this study (0-5 additional embolic events over
all trials with added concentrations of added ASA or eptifibatide).
Thus from our microfluidic system, we found non-significant (p>0.05) decreases
in platelet activity at high shear rates 4000 and 10000 s−1, and a significant (p>0.05)
loss of activity between 0.36 and 1 mM for lower shear rates 500 and 1500 s−1. Unlike
with eptifibatide, we were not able to detect a drug concentration threshold at which
platelet activity ceased for all shear rates.
Comparison of the WBA performance with the shear curves produced in our
system provided a similar sensitivity limit to our findings at low shear rates 500 and
1500 s−1 of 0.36 mM ASA. (Fig. 55). As with eptifibatide, this limit was defined by
the dosage concentration at which the 1/tocclusion values did not change significantly
for increasing concentrations.
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Figure 55: Dose-response measurements using the Chronolog Whole Blood Analyzer
with 4 µL collagen agonist shows detectable differences in Amplitude, Area Under
the Curve (AUC), and lag time until reaching a concentration of 0.72 µM, after which
responses did not change significantly for increased dosages.
To exclude the possibility the ASA used was properly prepared and affecting
platelet function, we used an agonist called arachidonic acid. ASA affects platelets
through inhibition of the enzymes cyclo-oxygenase-1 and -2 (COX-1, COX-2), which
use Arachidonic acid to form the pro-aggregation soluble factor TXA2 [122], and is
employed in commercial platelet function tests including the VerifyNow, Light Trans-
mission Aggregometry, the PFA-100, and impedance aggregometry [25]. Thus adding
Arachidonic acid to platelets and observing loss of platelet aggregation indicates that
ASA is properly affecting platelet function.
Use of Arachidonic acid as an agonist in the WBA did indeed showed a complete
loss of platelet response at all of the ASA concentrations tested in this work (Fig.
56). Thus we verified that these tested concentrations were properly able to inhibit
the production of the soluble factors which promote platelet aggregation.
Clinical implications : Results in this section are supported by both clinical trials
and by previous research groups.
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Figure 56: Dose-response measurements using the Chronolog Whole Blood Analyzer
with 10 µL of Arachidonic Acid showed complete inhibition of platelet activity at all
tested concentrations of ASA.
Clinical trials have reported ”no antithrombotic benefit...in patients with severe
atherosclerosis and stenoses...however anti-thrombotic protection...in patients with
less severe lesions is reported”, and that high dosage ASA therapy is ineffective at
preventing re-occlusion in high shear stenosis (i.e. greater than 90%) in angiographic
studies [123]. Such reports are supported by our results, which showed elimination of
low shear platelet activity at 500 and 1500 s−1, and insensitivity to platelet activity
to aspirin at 4000 and 10000 s−1.
Researchers have reported similar results using ex-vivo flow models. One group
testing ASA efficacy when ingested and metabolized in-vivo reported that ASA sensi-
tivity is lost in eccentric stenoses of shear rates at 10500 s−1 [124]. In contrast, at low
shear rates of 2600 s−1, platelet binding is more dependent on shape change, fibrin
deposition, and fibrinogen bonds [15]. It is notable that these results are controver-
sial, with other researchers have reporting that both in-vivo and in-vitro (as in this
study) models of ASA had no significant effect at 800-3000 s−1 [125]. Such studies
may be reconciled with findings in this study if there is a distinct change in platelet
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bonding in the 3000-4000 s−1 range, as predicted by some [13].
Multiple justifications are available to describe this phenomenon. First, ASA
loses efficacy when shear-enhances transport of soluble factors such as TXA2 (one
of the main targets of ASA) away from the growing platelet thrombus [126, 115].
Additionally, platelet shape changes induced by soluble factors is not necessary to
form thrombi at high shear [12].
The primary clinical applications of our findings are twofold. First, that high
dosages of aspirin does affect thrombus embolization and stability provides evidence
that a system such as our may be useful in detection of stroke risk in patients.
Currently, ASA is a commonly used prevention measure for ischemic stroke, but
resistance to such treatment is common and effectiveness has been found to vary over
time [127]. Thus the high shear thrombus formation and embolization seen in this
study may be one possible mechanism for the observed resistance to treatment.
Second, it provides strong evidence that the poorly characterized phenomenon
of ”aspirin resistance” may in fact be primarily mechanically related. Thus, this
work advises that future clinical tests for characterizing causes for aspirin resistance
consider angiographic data in addition to previously considered genetic testing and
dose-response data.
While the microfluidic system in its current state may not be directly applicable
to determining patient dosages, it does provide valuable information on potential
improvements in preventing or predicting bleeding and stroke. For example, future
work may create a system which is able to calculate thrombosis risks based on shear
rate and dosage using the Cox survival method employed in our analysis methods.
Patients angiograms would be assessed for percent stenosis, which could then be used
to correlate with a shear rate range. Using the relative risk table, physicians could
then use this shear rate to ”look up” the closest dosage corresponding to a low risk
of thrombosis to reduce the risk of overdose/bleeding.
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The system may also be used for predicting bleeding or thrombosis tendency in a
similar way to current commercial methods by using a ”cut-off value” for untreated
samples [20, 25], with pre-determined low values hitting a cut-off for ”likely to undergo
thrombosis” and pre-determined high values hitting a cutoff for ”likely to bleed/low
baseline platelet activity”. However, as with current commercial tests, such results
will require significant clinical validation to determine suitable cut-off points.
5.4 Conclusions
This Chapter has shown the application of the multi-shear microfluidic system in
label-free, human whole blood samples treated with dosages of eptifibatide (0 to 2.4
µM) and acetyl-salicylic acid (0 to 2 mM), representatives of two popular types of
anti-platelet therapies.
Both porcine and human samples showed significant elevations in platelet throm-
bosis prior to the administration of therapy, with the former showing nearly binary
shear-dependent occlusion time (present above 4000 s−1 and not present below 1500
s−1), and the latter showing a more graded response with increasing shear rate. Ad-
ministration of increasing dosages of eptifibatide in human samples showed that the
drug was effective at all shear rates, with increasing dosages showing significantly
(p<0.01) different 1/tocclusion dose-response curves for all shear rates save the lowest
physiological shear rates 500 and 1500 s−1. At all shear rates, increased dosages of
eptifibatide decreased response until thrombosis was not detectable. Notably, increas-
ing shear rates required similarly increasing concentrations of eptifibatide to eliminate
thrombosis, indicating that optimized patient dosages are indeed shear dependent.
Similar to eptifibatide, all dosages of ASA showed significantly (p<0.001) different
1/tocclusion dose-response curves for all shear rates save the lowest physiological shear
rates 500 and 1500 s−1. In contrast to eptifibatide, addition of increasing dosages
of ASA did not show significant alterations in platelet thrombosis at high shear, but
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was eliminated at clinically relevant dosages at physiological shear rates 500 and 1500
s−1. Findings from both drug models agree well with published clinical observations
and research studies. Thus the microfluidic system and its applied studies show
the effects of pathologically high shear rates on increasing platelet thrombosis and
demonstrate the widely varied shear-dependent efficacy of two types of therapies.
This study lays the foundation for the future development of a medical diagnostic for
optimizing the type and dosage of patient platelet therapy and to better understand
their mechanisms of action.
Thus we have shown that ASA therapy is most effective at inhibiting platelet func-
tion under physiological levels of shear 500 and 1500 s−1. In contrast, at high shear
rates only moderate reductions in platelet activity can be measured, in agreement
with findings by clinicians and other researchers. Although thrombi grew as normal,
the main effect of ASA appeared to be a destabilizing one since ASA-treated blood
showed nearly 70% more fragmenting or embolic effects after treatment vs. untreated
controls. We theorize that this may be due to the enhanced transport of soluble
factors away from the site of thrombus growth at high shear regions, a concept well
supported in current literature [57, 63, 115, 125, 124].
Findings of this Chapter can be generally stated as follows:
Shear rate is a significant determinant of occlusion time
• In eptifibatide, both dosage and shear create significant differences in occlusion
times
• In ASA, dosage is significant for low shear only. Shear rate has significant effects
at all dosages
• Results supported by previous clinical and research finding
Commercial comparison
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• Our device is able to measure changes in thrombus embolization, commercial
device cannot.
• Commercial device has similar results to single shear curve from our multi-shear
system
• Our device is able to measure changes in thrombus embolization, commercial
device cannot.
5.4.1 Endpoint Recommendations
This study examined a variety of different endpoints to characterize thrombosis under
varying drug dosages and shear rates, including 1/tocclusion, tocclusion, occlusion volume,
thrombus detachment, RPA growth, and lag time. The ability to extract data from all
of these methods presents a significant advancement in the field and great potential
for enhanced point of care readouts (although the clinical correlates of such metrics
still need to be confirmed through clinical studies). The preferred metrics from this
list were 1/tocclusion or tocclusion, and thrombus detachment. 1/tocclusion data was an
excellent method for visualizing data due to its ability to display non-occlusion events
as zero. However, such estimates can provide small distortions in data, since the
assumption that the channel would ”never occlude” may be an exaggeration.
Metrics of tocclusion were useful in Cox survival analysis, which does not require
processing of all trials into 1/tocclusion format. tocclusion is also more intuitive to un-
derstand, although it is can be misleading in data plots due to changing N which
compose its average and standard deviation at each shear/dosage point.
The thrombus detachment endpoint provided relevant information for future clin-
ical recommendations in the case of ASA, and consistent with the recommendations
of the ISTH, would be an excellent addition to current devices which do not include
it.
Control values for RPA growth and lag time measurements provided valuable
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points of comparison with previous work, despite their methodological flaws men-
tioned in the Methods: Analysis subsection [5, 121, 59]. In this study we found
control lag times and RPA values similar to theirs, and a similar trend of decreased
lag times for increased shear rates. Although the timescale of activation is similar to
lag times found in this work (as with Hellums and Bark), the addition of ASA, an
anti-platelet agent which should block platelet activation, did not appear to signifi-
cantly affect lag times at high shear rates 4000 and 10000 s−1, indicating that platelet
activation might not be the operative mechanism as such high shear levels. This find-
ing is in agreement with theories on high shear platelet binding from others [17].
Thus these measurements provided interesting insights into dose-response behavior
in eptifibatide, showing significantly (p<0.05) reduced RPA growth and increased lag
times over the same shear rates, and between different shear rates.
However, one major difference between this work and the previously cited authors
is the use of a constant flow system and extensive work on edge detection in order to
make predictions of shear rate, since these metrics were extracted in a post-analysis
fashion and not explicitly planned for. This study employed the use of initial wall
shear rates only. Thus the measurement of the shear rate at which lag time and
RPA occur and how these varies with shear rate is presently unknown for this study.
Furthermore, results for RPA growth should be approached with caution since non-
optimal, low resolution flow-rate measurements were poorly suited to measuring RPA
growth at low shear rates. Finally, measurements of RPA growth and lag time were
difficult to extract meaning from since subjects who did not form occlusive thrombus
had none of these metrics, and thus the N of trial data varied widely across conditions.
Further studies might be able to approximate thrombus growth rates similar to pre-
vious findings in units of volume/surface*time using more advanced image processing
from microscopy or intensity readings.
Lag time and RPA growth are potentially interesting areas of study for thrombosis
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studies. Future recommendations for those who would like to use this system to study
these metrics would be first to develop a method for more thoroughly characterizing
changes in shear rate over time within these trials, especially for changing flow rate
values. Next, studies should be repeated with higher N subjects to allow a sufficient
number of readings to be made at each shear rate and dosage point to verify the find-
ings described in the previous paragraph. Intensity measurements using our existing
optical sensing method could also provide improved metrics for RPA growth and lag




CONCLUSIONS AND FUTURE DEVELOPMENT
6.1 Conclusions
Thrombosis is the pathological formation of platelet aggregates which occlude blood
flow causing stroke and heart attack—the leading causes of death in developed nations
and the largest domestic healthcare expenditure. The mainstay for prevention and
post-operative treatment of these events is the use of platelet therapies. Determin-
ing dosage for platelet therapies (e.g. aspirin, Integrilin, and Plavix) is a persistent
medical challenge, and studies estimate up to 45% of patients exhibit insufficient
responses to them. Recent studies have shown that this loss in anti-platelet ther-
apy efficacy may be dependent on local flow conditions including high shear rates
and stenosis morphology. In Chapter 1 of this thesis, current thrombosis evaluation
methods were reviewed and demonstrated to be limited by one or more of the fol-
lowing parameters: non-pathologically relevant flow conditions, need for external cell
labeling and/or centrifugation, low throughput, high costs, channel sizes insufficient
to observe later stages of occlusive thrombosis, and the need for large volumes of
blood. There is presently no instrumentation able to simultaneously examine thera-
peutic efficacy for a wide range of fluid shear rates from physiological to pathological
levels. Thus the creation and application of such high throughput instruments could
enable essential, large scale, comprehensive studies which would inform research on
cardiovascular pathologies and their appropriate anti-platelet therapies.
In this work, a microfluidic device and associated optical system were designed and
fabricated for simultaneous measurement of platelet aggregation at multiple initial
wall shear rates within multiple stenotic channels in label-free whole blood and used
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to characterize thrombosis under varying dosages of platelet therapies. In Chapter 2,
we demonstrate a device for inducing platelet aggregation to full thrombotic occlusion
within four microfluidic stenotic channels in label-free whole blood at initial wall
shear rates from 500 to 13000 s−1, as confirmed by finite volume modelling and by
flow rate experiments. Next, in Chapter 3, we discussed the development of an
optical system that allows label-free microscope-free, multi-channel, real-time, non-
contact, high temporal resolution measurements of platelet-based thrombosis and
showed excellent agreement with results from traditional brightfield microscopy, flow
rate, and histology measurements.
In Chapters 4 and 5, the microfluidic system was applied to characterize thrombo-
sis at multiple initial wall shear rates and at varying dosages of two platelet therapies:
acetyl-salicylic acid (aspirin) and eptifibatide (Integrilin). Both porcine and human
samples showed significant elevations in platelet thrombosis prior to the administra-
tion of therapy, with the former showing nearly binary shear-dependent occlusion
time (present above 4000 s−1 and not present below 1500 s−1), and the latter show-
ing a more graded response with increasing shear rate. Administration of increasing
dosages of eptifibatide in human samples showed that the drug was effective at all
shear rates, with increasing dosages showing significantly (p<0.01) different 1/tocclusion
dose-response curves for all shear rates save the lowest physiological shear rates 500
and 1500 s−1. At all shear rates, increased dosages of eptifibatide decreased response
until thrombosis was not detectable. Notably, increasing shear rates required simi-
larly increasing concentrations of eptifibatide to eliminate thrombosis, indicating that
optimized patient dosages are indeed shear dependent.
Similar to eptifibatide, all dosages of ASA showed significantly (p<0.01) different
1/tocclusion dose-response curves for all shear rates save the lowest physiological shear
rates 500 and 1500 s−1. In contrast to eptifibatide, addition of increasing dosages
of ASA did not show significant alterations in platelet thrombosis at high shear, but
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was eliminated at clinically relevant dosages at physiological shear rates 500 and 1500
s−1. Findings from both drug models agree well with published clinical observations
and research studies. Thus the microfluidic system and its applied studies show
the effects of pathologically high shear rates on increasing platelet thrombosis and
demonstrate the widely varied shear-dependent efficacy of two types of therapies.
This study lays the foundation for the future development of a medical diagnostic for
optimizing the type and dosage of patient platelet therapy and to better understand
their mechanisms of action.
Thus we have shown that ASA therapy is most effective at inhibiting platelet func-
tion under physiological levels of shear 500 and 1500 s−1. In contrast, at high shear
rates only moderate reductions in platelet activity can be measured, in agreement
with findings by clinicians and other researchers. Although thrombi grew as normal,
the main effect of ASA appeared to be a destabilizing one since ASA-treated blood
showed nearly 70% more fragmenting or embolic effects after treatment vs. untreated
controls. We theorize that this may be due to the enhanced transport of soluble
factors away from the site of thrombus growth at high shear regions, a concept well
supported in current literature [57, 63, 115, 125, 124].
6.2 Original contributions
In summary, this system presents the first systematic, in-vitro characterization of the
effects of a spectrum of physiological to pathological shear rates and platelet therapy
doses on occlusive platelet thrombosis and embolus. The system, developed accord-
ing to best practices recommendations of ISTH, simultaneously measures thrombosis
by changes in flow rate, transmitted light intensity, and microscopy in an in-vitro
diagnostic. Results from studies using this instrument lay the groundwork for more
accurate platelet therapy treatment models by identifying shear rate as a significant
factor in thrombosis. The work showed that pathological vs. physiological shear
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rates have significant effects on thrombosis dose-response curves. For eptifibatide
(Integrilin), both dosage and shear create significant differences in occlusion times
while ASA (Aspirin) dosage is significant for low shear only. Finally, the system also
presents the first characterization of the bulk optical properties of platelet thrombus,
useful for future instrument development.
We have shown that the system can indicate decreased platelet thrombosis after
addition of drugs in an in-vitro model and verified them through a commercial method
(which has shown efficacy in predicting MACE events in clinical trials) although
the in − vivo correlate effects (e.g. induction/cessation of MACE events, excessive
bleeding) of such treatments in our studies must still be assessed.
6.3 Future Development
Currently the primary deficiency of platelet analysis systems is their questionable
clinical relevance. We hope to have eliminated some of these concerns through the
developments discussed in the previous section. However, the focus of this work is a
scientific quantification of how shear rate changes anti-platelet efficacy, not as a com-
mercial platelet function diagnostic. Development of this work as a clinical diagnostic
will require a new set of criteria, including reduced testing volumes, extended clinical
validations, and simplified design.
6.3.1 Instrumentation development
The dimensions of the current microfluidic device were chosen to ensure the obser-
vation of platelet-platelet cohesion present in late stage thrombosis, in contrast to
many prior microfluidic studies which focused on platelet adhesion. Furthermore, the
dimensions were also chosen to prevent early occlusion by the emboli present in many
porcine blood samples. However, recent geometric analysis (Casa, unpublished), have
theorized that platelet-platelet bonding dominates platelet-substrate binding by an
order of magnitude at dimensions as small as 100 µm in diameter, in contrast to
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the smallest dimension in our device, 250 µm. In addition, studies described in this
work have found that human blood lacks the large emboli present in human blood.
Furthermore, the same study estimates that the reduced size of each assay channel
should require significantly reduced trial times and sample volumes. Reduced sample
volumes would greatly benefit future clinical studies by decreasing the time between
sample blood draws (due to volumetric limits), time required to draw blood (approx-
imately 15 minutes per 60 mL aliquot), and reduce safety risks. Our very limited
study on the shape effects of channels implies that circular channels show signifi-
cantly different occlusion time results in some porcine samples, but further tests of
this principle using human blood should be examined before further action is taken
on the significant task of repeatably and easily creating circular cross section devices.
Although flow was used in Chapter 5 as the primary metric for occlusion, optical
metrics have much greater potential for future development due to lower complexity
and greater scalability and affordability. This work thus recommends future devel-
opment of optical metrics to replace flow. Efficacy of the optical measurement of
occlusion endpoint in Chapter 3, and this can potentially be improved upon with
some of the instrumentation recommendations listed in the following part of this
Chapter as well as in Chapter 3.
Recent collaborative work with the Capstone undergraduate Mechanical Engi-
neering class has seen the development of a point-of-care benchtop prototype able
to replicate the salient features of our detection and data acquisition methods in a
compact and user-friendly format. The prototype measures 30 cm x 16 cm x 15 cm
(11.8”×6.3”× 5.9”) in size including fluidic handling and optics that takes an av-
erage of 30 minutes per test. The system takes advantage of the optical methods
described in this work to rapidly and inexpensively screen platelet activity without
the use of added fluorophores, labelled beads, or microscopy involved with alternative
methods. The reader unit shown in Fig. 57 uses the same disposable microfluidic
144
chip developed in Chapter 2 of this project to form thrombus. Similar to the method
described in Chapter 2, blood is flowed into the device using automated gravity pres-
sure head control from a syringe on a motorized actuator. Blood is delivered to the
stenoses from the syringe, and collected in disposable blood bags downstream in this
prototpe. Hardware control, data acquisition, data processing, and even the printing
of results is made possible by two onboard Arduino micro-controllers and a small
receipt printer. The light source in the device is a set of four green laser diodes which
deliver light through fiberoptic cables incident on the surface of the chip, which is
then collected by four independent photodiodes situation underneath the stenoses of
the microfluidic device opposite the fiberoptic cables. The device was able to detect
thrombus formation in porcine blood samples. The system’s small footprint, low cost
components, and relative ease of use are promising for future development.
6.3.2 Clinical applications
Future clinical studies are required to determine the relationship of these results to
clinical MACE endpoints, similar to those described in Chapter 1. If provided with
unlimited resources, an ideal study would examine tocclusion (or predicted risk for
occlusion calculated by Cox-analysis), RPA/lag time, thrombus detachment, vWF
titers, known genetic fingerprints of drug non-responders, platelet count, and mean
platelet volume in a population of patients with varying degrees of stenosis being
treated with aspirin and/or a GPIIb/IIIa inhibitor. Angiographic data from patients
would provide information on internal shear rates of 500-1500, 2000-4000, and 10000
s−1 and higher. Initial patient number targets would be N=40 per shear rate for a
total of N=120 subjects. Numbers are estimates for achieving statistical significance
in RPA and lag time, which required more subjects than the present results shown
in this work. Blood samples would be run with no, low, and high and dosages of the
given drug and corresponding tocclusion and thrombus detachment metrics recorded.
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Figure 57: Collaboration with a team of students in Georgia Tech’s Mechanical
Engineering Capstone program saw the creation of a promising point-of-care benchtop
prototype able to replicate the salient features of our detection and data acquisition
methods in a compact and user-friendly format. The prototype measures 30 cm ×
16 cm × 15 cm (11.8”×6.3”× 5.9”). Similar to the method described in Chapter
2, blood is added to the system using automated gravity pressure head control from
a syringe on a motorized actuator (a). A touchscreen interface on the cover of the
reader unit (b) allows the user to begin the test. When testing has begun, blood will
flow from the syringe to the to the microfluidic device, which sits beneath the hinged
touchscreen cover (c). Hardware control, data acquisition, data processing, and even
the printing of results is made possible by two onboard Arduino microcontrollers and
a small receipt printer housed inside the device’s acrylic body. The light source in the
device is a set of four green laser diodes which deliver light through fiberoptic cables
incident on the surface of the chip (c).
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Half of each patient/shear population would be treated with the high dosage, and
the other with the low dosage, and patient outcomes tracked for 10 years, with any
MACE events recorded.
Obvious challenges with reaching this clinical goal are the aforementioned instru-
mentation challenges, and the financial challenges of such a large, long-term test.
However, it may be able to ”piggy-back” off the many pre-existing angiographic co-
hort studies which appear to be common in cardiovascular research.
The technology also prompts additional interesting future clinical investigations.
While the studies presented in Chapter 5 presented an interesting proof of concept
in-vitro characterization of thrombosis in healthy individuals, additional studies will
be required to define the utility of this instrument for diagnosing more diverse patient
populations with pre-existing pathologies. There are to could also be used to probe a
number of interesting hematological pathologies including von Willebrand’s disease,
thrombocytopenia, sickle-cell anemia, and coronary artery disease. Successful detec-
tion of von Willebrand’s disease has been shown by other high shear platelet function
tests such as Siemens’ PFA-100, a system with similar capabilities to the system de-
scribed in this work. Sickle-cell anemia presents specific scientific interest due to the
large number of children with the condition affected by strokes. The application of
this model system to studies of that pathology might reveal novel pro-thrombotic
interactions between red blood cells and platelets.
Additional future clinical studies should also examine other popular drug models,
especially clopidogrel, which remains one of the most popular anti-platelet drugs on
the market. Other popular drug models of interest include abciximab, prausgrel, and
ticlopidine. With the need for platelet therapeutics only increasing, we anticipate
applications of this system to experimental drug screenings. In fact, recent work has
shown pharmaceutical firms such as Portola (the developer of Integrilin) publishing
on the use of a traditional parallel plate flow chamber to screen known drugs [54],
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proving that there is an immediate need and application for a flow system such as
ours with significantly improved throughput and scientific relevance.
It is also notable that the study presented in Chapter 5 examines the effects of anti-
platelet agents added in-vitro. While this model may recapitulate the initial behavior
of injectable drug bolus (relevant for heparin and Integrilin), it may not accurately
describe the long-term effects, nor the behavior of orally administered drugs such as
aspirin and Plavix due to metabolic or otherwise genetically linked efficacy factors
[22]. Thus it is recommended that future studies examine blood from two separate
blood draws before and after patient use to determine how this system may be used to
optimize anti-platelet therapy. Additional long term studies of patient outcomes will
be necessary to determine the long term benefits of such therapies and their efficacy
at preventing re-stenosis, stroke, or heart attack.
6.3.3 Translational development
In order to achieve significant clinical impact, this system will also need to transition
to a more streamlined and user-friendly design. While current devices on the market
such as the VerifyNow have not achieved strong clinical results, they have demon-
strated the commercial potential of a platelet function analyzer in the point-of-care
market. Over the course of this project, we have made some progress towards this
goal. Collaboration with a team of students in Georgia Tech’s Mechanical Engineering
Capstone program saw the creation of a promising point-of-care benchtop prototype
30 cm × 16 cm × 15 cm (11.8”× 6.3”× 5.9”) in size including fluidic handling and
optics that takes an average of 30 minutes per test.
Translational development of this project will require steps towards FDA clear-
ance. This path begins with the FDAs 510(k), which requires that our device show
equivalency to another category of device currently on the market, such as the
21CFR864.5700 ”automated platelet aggregation system”. However, while 510(k)
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approval would allow the legal marketing of such a product, we anticipate that it
would require significant clinical validation, certification from Clinical Laboratory Im-
provement Amendments (CLIA), and/or a Current Procedural Terminology (CPT)
code from the American Medical Association before it is well-received in the medical
community.
This thesis has described the motivations for platelet research as well as current
methods for measurement and analysis, and set forth goals for advancing our meth-
ods and knowledge in the field. Specifically, it has developed a microfluidic device
and associated light transmission optical measurement method for studying the si-
multaneous effects of shear rate and platelet therapy dosage on platelet thrombosis.
Finally it has demonstrated the utility of this method using two different drug mod-
els at a range of shear rates from physiological to pathological, to determine two
different activity profiles. It is my hope that the findings of this work will be of use





This section summarizes the primary thrombosis metrics used in this work, and sum-
marizes their advantages, disadvantages, and relationships to one-another.
A.1 Measurements using flow
• Flow rate: Q(t)
Advantages: Flow rate measurements provide direct feedback on channel oc-
clusion with little data processing in comparison to optical methods. Flow rate
can also be used to detect thrombus detachment events.
Disadvantage: Cannot directly measure number of platelets or thrombus mor-
phology, unlike optical methods.
Related metrics: tocclusion, Vocclusion
• Occlusion time: tocclusion
Advantages: Flow occlusion also provides a clinical analog to cerebral or my-
ocardial infarct. Also, measurements of flow cessation are comparable to those
of the commercial platelet function analyzer, the PFA-100 [20]. In the PFA-100,
the equivalent metric for tocclusion, found in this work, is known as the closure
time, (CT), which occurs when a collagen-coated cellulose membrane hole is
filled with platelets during pressure driven flow of whole blood at 4000 s−1.
For rough comparison, tocclusion of whole, human blood at 4000 s
−1 in our device
with a minimum cross-sectional area of 9.3∗10-2 mm2 (cross sectional area) oc-
curs at 521 ± 128 seconds, vs. the PFA-100s closure times of 137-300 s−1 in a
2.25∗10-2 mm2 (cross sectional area) orifice.
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Disadvantages: Requires significant extra instrumentation bulk for measure-
ments in comparison to non-contact optical methods such as LED and laser light
transmission. Additionally, this method is hindered by high costs and limited
resolution at low flow rates (<1 µL/s). As a final metric, use of raw tocclusion
values do not reflect non-occluded trials, a problem which can be circumvented
through the use of 1/tocclusion (see below).
• Inverse occlusion time: 1/tocclusion
Advantages: This metric is valuable for statistical analysis including para-
metric and pairwise comparison analysis (e.g. logistic and MANOVA models,
corresponding Tukey post-hoc methods) due to its ability to assign endpoint
values to both occluded and non-occluded channel runs.
Disadvantages: The estimate of non-occluded events as 0 assumes infinite
occlusion time, which adds distortion to data.
Related metrics: tocclusion,Vocclusion
• Occlusion volume: Vocclusion Total volume of blood required to occlude the chan-
nel.
Advantages: This value is useful for determining required sample volumes
during testing, and can provide an estimate of the total number of platelets
that would have passed through the stenosis in order to cause occlusion.
Disadvantages: This metric has large variations in data and not often used
by other commercial methods.
Related metrics:tocclusion, Q(t)
• Rate of Platelet Accumulation growth: RPA growth
Advantages: RPA growth provides an estimate of platelet behavior during
its accumulation phase, which prior research has indicated as a defining event
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distinct from adhesion and early aggregation. RPA values were 14 ± 1.1 (cm3 ∗
10−6/s) for N=72 samples, similar overall to the average value determined by
Para, 20(cm3∗10−6/s). However, unlike that study we did not observe increases
in RPA growth for increasing initial shear rate, perhaps due to the pressure-
controlled (vs. flow rate controlled) flow.
Disadvantages: RPA growth is difficult to study for low shear rates due to
the low resolution of weighing scales. Results were also confounded by changing
experimental N due to non-occluded trials, which did not have a measurable
tfinal.
• Lag time: tlagtime
Advantages: tlagtime gives an indication of the time required for platelets to
complete the adhesion phase, nominally dependent on the GPIb-vWF high shear
bond, a separate measurement from overall occlusion time. As expected, we
observed decreasing lag times with increasing shear rates, a result reported by
many others [59, 17, 128].
Disadvantages: Like RPA growth, tlagtime is also not easy to measure for
low flow rates (shear rates). This is reflected in decreasing SEM values with
increasing shear rates.
Related metrics: RPA growth, Q(t)
A.2 Optical measurements
• Intensity of microscopy imaging : Imicroscope(t) Changes in total intensity values
at each CCD element corresponding to the stenosis ROI. Values were normalized
by subtracting baseline noise due to changes in ambient light and/or changes
in the angle of the light source.
Advantages: Excellent for determining thrombus morphology and relative
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platelet (vs. fibrin/RBC) content. Although this method is difficult to cor-
relate to volumes without the use of confocal methods or thin adhesion layers,
it remains a standard method for many researchers [128, 3, 59, 129], and can
be used for rough estimates of numbers/concentrations of platelets, unlike flow-
based methods. Like Q(t), also able to detect thrombus detachment.
Disadvantages: This method determines overall intensity of the entire image,
thus morphology data is lost. Due to small observation areas, requires the use
of an expensive automated stage to observe multiple channels, which can slow
the acquisition times.
Related metrics:Ilaser(t), ILED(t)
• Intensity of laser transmission: :Ilaser(t), ILED(t) Both raw values are on a 0 to
211 (2048) scale due to the sensitivity of the CCD sensor. Values are captured
and averaged over the width of the stenosis, for an approximate ROI size of 200
× 700 µm region of interest.
Advantages: Large sensor area negates the need for automated stage (allows
faster acquisition times and is more suitable to point-of-care applications), while
retaining the advantages of optical measurements similar to above (standard
method, non-contact). Threshold values can be related to Q(t). Dynamic mea-
surements are similar to more expensive and less convenient microscopy methods
(R correlation value of 0.94 with Imicroscope(t)). Similar to microscopy, can
be used for rough estimates of numbers/concentrations of platelets.Like Q(t)
andImicroscope(t), also able to detect thrombus detachment.
Disadvantages: Cannot determine thrombus morphology or relative platelet
(vs. fibrin/RBC) content.
Related metrics:Imicroscope(t)
Signal to Noise Ratio: SNRocclusion,SNRNO, SNRfinal
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Advantages: Takes into account small variations in baseline noise due to dif-
ferences in sample hematocrit, and can be used for a cut-off value for when
channels occlude within 8.4% accuracy.
Disadvantages: Use of SNR to determine occlusion resulted in some false
positives (non-occluded channels whose intensity rose but did not fully occlude)
of 9%
Related metrics:Ilaser(t), ILED(t)
A.0.4 Summary and opinions
The preferred metrics in this study are tocclusion and 1/tocclusion (based on flow rate
Q(t)) for their ability to be compared with current commercial platelet function tests
(i.e. the PFA-100) and use in statistical analysis methods, respectively.
In this study, tlag time and RPA growth were difficult to study due to low resolution
data from flow rate measurements, and thus were not preferable metrics. Optical
methods based on Ilaser(t), ILED(t) are promising for measurements of overall platelet
concentrations within the stenosis, but are less accurate than flow rate Q(t) based
measurements for tocclusion and 1/tocclusion. Thus, although these methods and metrics
show promise for future use, they were not used in the majority of Aim 3 of this thesis
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